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From the plethora of possible microbial hosts, Escherichia coli remains the most widely used 
“microbial factory” for recombinant protein production (RPP). However, despite the numerous 
advances, RPP in E. coli is still a significant challenge. Strong promoters to achieve high expression 
and protein production levels are often used, however, the underlying effects on the host 
physiology are often unseen. 
This thesis reports the development of “stress-minimisation” approaches for the production of 
recombinant proteins, either targeting the cytoplasm or the periplasmic space. First, the 
fermentation conditions for the production of TNFα in the cytoplasm were optimised. The 
expression vector, culture medium, temperature, inducer concentration and induction point were 
optimised, yielding 5.35 g ∙ L-1 of rhTNFα, 70% being accumulated as a soluble product. 
Second, different approaches for the production of recombinant proteins targeting the periplasm 
were evaluated, using an antibody fragment, scFv163R4, as a model protein. The effect of different 
growth conditions and signal peptides on the production of the scFv163R4 were evaluated. 
However, the selection of the optimal signal peptide was proven to be challenging, establishing 
the requirement of a high-throughput screening assay. This resulted in the development of a 
screening assay using β-lactamase as a reporter protein, for the evaluation of mutant signal 
peptide libraries with improved translocation activity. Initial evaluations resulted in the selection 
of two mutant signal peptides with enhanced translocation of scFv163R4-A, yielding almost 1 g ∙ 
L-1 of periplasmic scFv163R4-A. The generation of mutant signal peptide libraries in combination 
with the β-lactamase screening assay represents an important advance for the production of 
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1.1 Industrial recombinant protein production: an overview 
1.1.1 The rise of the biotechnology industry 
From ancient times, living organisms have been widely exploited for the development or 
production of different bioproducts. Early biotechnology dates back to 6,000 BC, as evidence has 
been found that beer was already being produced by the Sumerians. In the brewing process, 
malting grains converts starch into sugars, which are broken down into alcohols by yeast to 
produce beer. In 3,500 BC, other fermentation processes were developed in China, such as wine 
and soya fermentations. Soon after, the development of lactic fermentation allowed the 
production of other forms of food, such as cheese and yogurt (Buchholz and Collins, 2013).  
In the 1800s, mainly beer, but also wine, acetic (e.g. vinegar) and lactic acid fermentations 
significantly contributed to the economy of the United Kingdom and other European countries. 
However, the nature of the fermentation was attributed to “secret living forces” emerging from 
spontaneous generation and the concept of the fermentation process is often found associated to 
mystic concepts. In 1830s, Schwann and Cogniard-Latour were the first to describe little globular 
bodies, the yeast of the beer, as responsible of alcoholic fermentation. Two decades later, Louis 
Pasteur developed the initial theories about fermentation, settling the scientific debate on the 
nature of fermentation in favour of the role of living organisms. Pasteur’s work not only included 
the development of the first fermentation theories, but also a sterilisation process, pasteurisation, 
which is still used today by the dairy industry (Buchholz and Collins, 2013). 
In 1928, Alexander Fleming discovered the mould Penicillum, and his work led to the purification 
of the antibiotic compound that we today known as penicillin. The large demand for this antibiotic 
during the Second World War facilitated the development of the penicillin manufacturing process. 
Penicillin initiated the era of antibiotics, being among the first medications to be effective against 
bacterial infections caused by Staphylococci and Streptococci (Buchholz and Collins, 2013).  
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The turning point in genetics arose from the establishment of a model for the molecular structure 
of deoxyribonucleic acid (DNA) by Watson and Crick, supported by the work carried out by 
Rosalind Franklin at Wilkins’ laboratory (Buchholz and Collins, 2013). Only 20 years later, Boyer 
and Cohen developed the recombinant DNA technology, showing that genetically engineered DNA 
molecules can be cloned into foreign cells, laying the foundations of gene cloning (Buchholz, 2007; 
Buchholz and Collins, 2013). In 1975, Milstein and Köhler developed the hybridoma technology 
enabling the production of monoclonal antibodies, which led to a new era of therapeutic biologics 
(Weiner et al., 2010). In 1976, Boyer in collaboration with Robert Swanson founded Genentech, 
which only a few years later developed the production of the recombinant human insulin. In 1982, 
the Food and Drugs Agency (FDA) approved the commercialisation of Humulin®, the recombinant 
human insulin produced in Escherichia coli, for the treatment of type I diabetes, being the first 
recombinant protein drug to reach the market. The precedent of its approval favoured the 
production of other recombinant proteins, such as human growth hormone, β-interferon and the 
hepatitis B vaccine. Nowadays, recombinant proteins, including hormones, growth factors, 
cytokines and monoclonal antibodies, represent a significant part of total revenue obtained by the 
pharmaceutical industry (Buchholz and Collins, 2013). 
In 1997, an important announcement revolutionised public opinion when Wilmut and Campbell 
proclaimed the birth of the sheep “Dolly”, the first mammal cloned from an adult somatic cell by 
nuclear transfer. A long public debate concerning the possible outcomes of animal cloning and its 
potential application to humans arose from this announcement. 
Genetic engineering had not only transformed the pharmaceutical industry, but also had a great 
impact in other types of industries, such as agriculture, environmental technology, and small 
chemicals production. Plant biotechnology led to a new "green revolution" with the development 
of genetically modified (GM) crops, which can provide higher yields, minimising the use of 
herbicides and pesticides. The first transgenic product, Flavr Savr® tomato, was approved in 1994, 
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and since then, GM crops have been massively cultivated in the United States, Canada, Brazil and 
Argentina (Buchholz and Collins, 2013). Nonetheless, controversy still exist with respect to ethical 
and biosafety implications of GM products, with a still growing negative public opinion in Europe. 
A detailed timeline of the history of biotechnology can be found in Figure 1.1. 
 
1.1.2 Economic impact of the biotechnology industry 
Since the advent of recombinant DNA technology in the 70s, the biotechnology market has grown 
to reach an average compound annual growth rate (CAGR) of 11.6% from 2012 to 2017, and it is 
expected to reach a value worth $414.5 billion by the end of 2017.  Industrial biotechnology has 
global annual sales of over $250 billion with products varying from pharmaceuticals, chemicals, 
industrial enzymes, cosmetics, food or dietary supplements (Meyer and Schmidhalter, 2014). Just 
the market value of the biopharmaceuticals has reached a total cumulative sales value of $140 
billion in 2013, which exceeds the reported gross domestic product (GDP) of three-quarters of the 
economies in the world (Walsh, 2014). 
A list detailing the top 10 best-selling pharmaceutical products in 2015 can be found in Table 1.1, 
showing the penetration and economic impact of biotechnology, which accounted for 40% of the 
total sales of the pharmaceutical industry in 2013 (Spadiut et al., 2014). The market is led by 
Humira®, the first full human monoclonal antibody drug approved by the FDA in 2002, and still 
today ranks first among the best-selling pharmaceutical products, accounting for $14 billion of 
sales in 2015. Other monoclonal antibody-derived products, included among the best-selling 
biopharmaceuticals, are Remicade, MabThera/Rituxan, Avastin and Herceptin. Humira® is closely 
followed in sales by Enbrel®, a chimeric protein generated by the fusion of the TNFα receptor to 
the constant end of the IgG1 antibody. Monoclonal antibodies, including Fc-fusions, generated 











Table 1.1. The top worldwide 10 best-selling pharmaceuticals in 2015 (PharmaCompass, 2016). 
 
Rank Trading name Generic name Type of molecule Company Disease/Medical use Total sales 
1 Humira® Adalimumab Monoclonal antibody AbbVie Rheumatoid arthritis $14 billion 
2 Harvoni® Ledipasvir/ 
Sofosbuvir 
Small molecule Gilead Sciences Hepatitis C $13.8 billion 
3 Enbrel® Etanercept TNFα-receptor fusion 
protein 
Amgen / Pfizer Rheumatoid arthritis $8.7 billion 





5 MabThera®/Rituxan® Rituximab Monoclonal antibody Roche Lymphoma, Leukaemia 
Autoimmune disorders 
$7.1 billion 
6 Lantus® Insulin glargine Recombinant protein Sanofi-Aventis Diabetes mellitus $7 billion 
7 Avastin® Bevacizumab Monoclonal antibody Roche Metastatic cancers $6.8 billion 
8 Herceptin® Trastuzumab Monoclonal antibody Roche Breast cancer $5.8 billion 





10 Sovaldi® Sofosbuvir Small molecule Gilead Sciences Hepatitis C $5.3 billion 
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Among non-antibody based products, insulins are the most lucrative product class, collectively 
generating sales of $21.5 billion in 2013. Lantus®, Levemir®, Novolog® and Humalog®, all insulin-
derived products, are included between the 50 largest selling pharmaceutical products, 
constituting the bulk of products manufactured using microbial platforms (Walsh, 2014). 
 
1.1.3 The next generation of biopharmaceuticals 
Recombinant proteins, interferon and growth factors 
Recombinant proteins constitute a significant portion of the biopharmaceutical market, including 
a broad range of products, such as growth factors, hormones, cytokines and anticoagulants. As 
depicted in Figure 1.2, among cytokines, interferon products (IFNα, IFNβ and IFNγ) represent 
2% of the biologicals in preclinical or early phase clinical development. Growth factors, such as 
erythropoietin-stimulating agents (ESAs), colony-stimulating factors (CSFs), and anticoagulants, 
such as recombinant tissue-plasminogen activator (rt-PA), have been extensively commercialised 
by the pharmaceutical industry (Aggarwal, 2014). 
 
Monoclonal antibodies, antibody fragments and derivatives 
Today, over 200 recombinant proteins have reached the market, leading the number of new 
biological entities (NBE) approved during the last years (Walsh, 2006; Walsh, 2010). This 
exceptional market success is largely derived from the commercialisation of monoclonal 
antibodies, the fastest growing class of biopharmaceutical product (Carter, 2011; Spadiut et al., 
2014). Monoclonal antibody-based products accounted for 33% of the biological products in early 
phases of development in 2012 (Figure 1.2).  
Since the approval of the first monoclonal antibody in 1986, known as muromonab-CD3 (OKT3), 
for acute allograft rejection, monoclonal antibodies have been engineered to optimise their 
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properties and reduce undesired effects. However, limitations are often associated with the 
development of monoclonal antibodies, such as cost-intensive manufacturing processes, low 
tissue penetration and rapid renal clearance (Carter, 2011). Small antibody fragments, such as 
antigen-binding (Fab) and single-chain variable (scFv) fragments and other engineered variants 
are emerging as credible product candidates, representing respectively the 6% and 4% of the 




Recombinant vaccines represent 33% of the products in preclinical and clinical development 
(Figure 1.2). This sector has experienced a high growth mainly driven by the blockbuster vaccine 
Gardasil®, used to protect against certain strains of human papillomavirus (Aggarwal, 2014). 
 
Gene-based therapies: antisense, RNA interference and gene therapy 
Gene therapy can be defined as the therapeutic delivery of nucleic acids into a patient’s cell with 
the aim of altering gene expression to treat a pathological process by the addition of DNA or RNA 
oligonucleotides or by the use of viral vectors (Kay, 2011). 
Antisense oligonucleotides are single-stranded DNA molecules designed to be complementary to 
a specific gene’s mRNA, inhibiting the expression of a target gene (Gleave and Monia, 2005). RNA 
interference (RNAi) are double-stranded RNA oligonucleotides used for sequence-specific gene 
silencing, using the cell’s natural machinery to target specific mRNA within the cell, inducing its 
degradation and resulting in gene suppression (Kay, 2011).  Both antisense and RNAi technologies 
are still facing numerous obstacles; however, an increasing number of these molecules are 

































Vaccines Antisense Cell therapy Gene therapy
Growth factors Interferons Recombinant proteins Other
RNA interference Mabs Fabs ScFv
Others
Figure 1.2. Biopharmaceuticals in preclinical or clinical development in 2012 (Adapted 
from Nelson and Reichert, 2009; PhRMA, 2013). 
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Viral platforms are the most credited DNA delivery method. So far, 70% of the gene therapy 
products in clinical trials have used virus as method of delivery, such as retrovirus, lentivirus, 
adenovirus or adeno-associated virus (Yin et al., 2014). After the death of a patient in 1999 
following a high dose of an adenoviral product, today gene therapy is facing a renaissance. In 2012, 
the lipase lipoprotein deficiency therapy Glybera® got approval by the European Medicine Agency 
(EMA), leading to the resurgence of gene therapy (Walsh, 2014). 
 
Cell therapy 
Cell therapy is based on the injection of cellular material, meaning intact living cells, into a patient. 
Several cell therapies have been recently approved, such as tissue-engineered skin, cartilage 
repair products and the first personalised cellular immunotherapy for cancer treatment. Cell 
therapy is still in early phases of development and facing numerous obstacles associated with the 
manufacturing process, such as the high cost of goods, the process variability and complexity of 
scale-up (Brandenberger et al., 2011). 
 
1.2 Recombinant protein production 
1.2.1 Production hosts for recombinant protein production 
E. coli as a host for recombinant protein production 
Escherichia coli is a Gram-negative, rod-shaped bacterium, commonly found in the lower intestine 
of warm-blooded organisms. E. coli is the most widely studied prokaryotic model organism, 
playing a major role in bioengineering and industrial microbiology due to its fast growth, well-
known genetics, physiology and biochemistry (Chou, 2007). E. coli is considered the main 
workhorse for the production of non-glycosylated recombinant proteins, being one third of the 
approved protein therapeutics produced using this host organism (Terpe, 2006). 
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Nevertheless, there are some important disadvantages of E. coli as an expression host for 
recombinant protein production (RPP), such as the high level of endotoxin production. 
Lipopolysaccharides, also known as endotoxin, the major component of the outer membrane of 
Gram-negative bacteria are pyrogenic for humans, so their removal from the final product is an 
essential requirement (Petsch and Anspach, 2000). In addition, E. coli lacks the machinery 
required to perform certain post-translational modifications, such as glycosylation (Terpe, 2006). 
Escherichia coli K-12 and its derivatives are the most widely used strains in the biotechnology 
industry and classified in risk group 1 in biosafety guidelines. Commonly used K-12 strains include 
E. coli strains MG1655, DH1, DH5α and W3110 (Huang et al., 2012).  
Alternatively, E. coli B strains are also widely used for RPP due to their low acetate accumulation, 
even when high concentrations of glucose are used as carbon source (Huang et al., 2012). Among 
others, E. coli BL21 is one of the most commonly used strains and has a proven track record for 
protein expression studies (Sørensen and Mortensen, 2005). E. coli BL21, and its parental strain 
B834, are deficient in lon and ompT proteases, associated to proteolytic degradation of 
recombinant proteins. Other strains, such as Origami (Novagen) are deficient in trxB/gor genes, 
which facilitate cytoplasmic disulphide bond formation; Tuner strains (Novagen) are lacY mutants 
which allows precise control of gene expression by fine tuning of the inducer concentration; or 
C41 and C43 strains, also known as Walker strains, for improved production of membrane 
proteins (Shadev et al., 2008; Miroux and Walker, 1996). Further details regarding E. coli strains 
commonly used for RPP can be found in Table 1.2. 
 
Other prokaryotic hosts for recombinant protein production 
Pseudomonas spp., another Gram-negative host used for RPP, are widely known for their rapid 
growth and secretion ability, considered as a promising alternative to E. coli (Krzeslak et al., 2009).  
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Table 1.2. E. coli strains frequently used for recombinant protein production (Adapted from 
Terpe, 2006). 
 
Strain Key features 
K-12 strains 
W3110 One of the oldest laboratory strains of E. coli K-12, cured of lambda and F 
HMS174 recA mutant, Rif resistance 
JM 83 Usable for secretion of recombinant proteins into the periplasm 
AD494 trxB mutant, facilitates cytoplasmic disulphide bond formation 
Origami trxB/gor mutant, facilitates cytoplasmic disulphide bond formation 
B strains 
B834 Parental strain of BL21, methionine auxotroph, 35S-met labelling 
BL21 Deficient in lon and ompT proteases 
BLR recA mutant, stabilises tandem repeats, deficient in lon and ompT proteases 
C41 and C43 Mutants selected for expression of membrane proteins 
Origami B trxB/gor mutant, facilitates cytoplasmic disulphide bond formation, deficient in 
lon and ompT proteases 
Rosetta Enhances the expression of eukaryotic proteins that contain codons rarely used 






Bacillus subtilis is a Gram-positive rod-shaped bacterium known for its great secretion ability for 
host enzymes or enzymes obtained from related strains. Nowadays, 60% of enzymes on the 
market are produced in Bacillus spp., mainly alkaline proteases for detergents and amylases for 
baking and starch production (Demain and Vaishnav, 2009). However, secretion of heterologous 
proteins is often hampered in this host organism (Westers et al., 2004). Other Gram-positive hosts, 
as Streptomyces or Lactoccocus have been also used for RPP. 
 
Eukaryotic hosts for recombinant protein production 
Yeast has been used extensively by the biotechnology industry, Saccharomyces cerevisiae and 
Pichia pastoris being the preferential host choices for RPP. Yeast, as bacteria, can grow in non-
expensive culture media to high cell densities, but can produce complex post-translational 
modifications (PTMs), such as glycosylation (Schmidt, 2004). However, the glycosylation pattern 
generated by yeast is not the same as those found in human proteins, as yeast produces N-linked 
oligosaccharides containing mainly mannose residues (hyperglycosylation). Hyperglycosylated 
proteins have a reduced half-life and can be immunogenic (Demain and Vaishnav, 2009). 
Filamentous fungi, such as Aspergillus niger, are also used for the biotechnology industry mainly 
for the production of acids, antibiotics or enzymes, e.g. celullases and amylases (Schmidt, 2004). 
 
Mammalian cells as a host for recombinant protein production 
Mammalian cells have become the dominant option for RPP, and almost 70% of the recombinant 
proteins produced by the pharmaceutical industry are produced using mammalian cell lines 
(Demain and Vaishnav, 2009; Schmidt, 2004). Mammalian cultures are used mainly for the 
production of monoclonal antibodies due to their ability to correctly fold and assemble complex 
proteins and make post-translational modifications with a high similarity to human cells 
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(Schmidt, 2004). Numerous mammalian cell lines are available, widely used examples being 
Chinese Hamster Ovary (CHO), Baby Hamster Kidney (BHK), mouse myeloma derived-cells (NS0) 
and Human Embryo Kidney (HEK-293) cell lines (Wurm, 2004). 
The optimisation of culture conditions for mammalian fermentation is the results of years of 
research and development of vectors, cell lines and medium composition. Mammalian cell 
cultures can grow adhered to the walls of culture containers, usually roller bottles filled with 10 - 
30% of culture media, or in suspension in stirred tank reactors (STRs) or wave bioreactors, the 
last ones being the preferential choice for RPP (Wurm, 2004). 
 
1.2.2 Expression systems for RPP in E. coli 
 
Gene expression efficiency and recombinant protein production is highly dependent on the 
expression vector design, including genetic elements such as the origin of replication, antibiotic 
resistance markers, promoters and translation initiation regions (Figure 1.3) (Sørensen and 
Mortensen, 2005). The gene dosage, promoter strength, mRNA stability and the efficiency of 
translation often have a great impact on the final rate of protein synthesis, and therefore, in the 
recombinant protein yield (Huang et al., 2012). 
 
Gene dosage 
The origin of replication (ori) is the sequence where replication is initiated in the vector, which 
determines the copy number and consequently, the gene dosage. Both high copy (e.g. pUC vectors, 
500 to 700 copies) and medium copy (e.g. pBR322, 15 to 20 copies) number vectors have been 
used for RPP, however, medium copy vectors are recommended to avoid segregational instability 





Figure 1.3. Diagram of a model expression vector. Artificially constructed vectors contain 
essential components including: the origin of replication (ori); the promoter upstream of the 
ribosome-binding site (RBS); the multiple cloning site (MCS) where the gene of interest will be 
inserted; transcriptional terminator sequences; the antibiotic resistance gene; and some vectors 









































Resistance markers conferring resistance to antibiotics are regularly present in the plasmid 
backbone to ensure plasmid maintenance. Commonly used antibiotic resistance genes are 
ampicillin, which inhibits the formation of peptidoglycan cross-linking in the bacterial cell wall; 
and kanamycin, chloramphenicol or tetracycline, which bind to ribosomes interfering with 
protein synthesis (Sørensen and Mortensen, 2005). 
 
Transcriptional regulation 
Promoters are DNA sequences, localised 10 to 100 bp upstream of the ribosome-binding site. The 
RNA polymerase recognises two major sequence elements localised in the promoter sequence, -
35 and -10 (Pribnow box) bases upstream of the transcriptional initiation (Figure 1.3). Initiation 
of transcription by the RNA polymerase is regulated by the sequence of the promoter, and 
interaction with transcription factors (TFs), which respond to external stimuli such as changes in 
the culture media or the addition of chemical compounds, such as sugars. A more detailed 
description of commonly used promoters for RPP can be found in Section 1.2.2.2.  
The ribosome-binding site (RBS) is a sequence of nucleotides upstream of the start codon, which 
interacts with the 16S subunit, responsible for the recruitment of the ribosome during translation 
initiation. The RBS is located between 5 to 13 bp upstream of the start codon and contains a 6-
base consensus sequence, AGGAGG, known as the Shine-Dalgarno sequence (Figure 1.3). 
Transcription terminators, inverted repeats prone to form a stem-loop structure, are often located 







Translation efficiency is determined by the sequence and structure of the translation initiation 
region (TIR), which comprises the Shine-Dalgarno (SD) sequence, the start codon (AUG), the 
spacing between the SD and the start codon and translation enhancers. The modulation of TIR 
sequences is known to have a great impact on recombinant protein expression, as poor 
transcription efficiency often results in low recombinant protein yields (Huang et al., 2012). 
There are three start codons, AUG, GUG and UGG, the most commonly used is AUG, which is 
present in 91% of E. coli’s genes. There are three stop codons, UAA, UGA and UAG but translational 
termination is preferably mediated by UAA. If desired, more than one stop codon can be included 
at the end of the coding sequence to avoid ribosome skipping (Huang et al., 2012). 
 
Codon usage 
The codon usage in E. coli and other organisms vary affecting protein translation. Expression of 
genes containing rare codons can lead to premature translation termination, growth arrest or 
amino acid missincorporation. Codon optimisation may help to overcome this problem, 
substituting rare codons for those preferentially used by E. coli (Sahdev et al., 2008). Another 
approach is the overexpression of tRNAs coding for rare codons from a vector, as E. coli Rosetta 
(DE3) which carries the pRARE plasmid (Sørensen and Mortensen, 2005; Huang et al., 2012). 
 
Lactose expression system and derivatives 
The lactose operon contains the sequence coding for the genes required for the transport and 
catabolism of lactose in E. coli.  In the absence of lactose, the synthesis of mRNA is repressed to 
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avoid the waste of energy used in the synthesis of proteins when not required. If lactose is not 
present in the media, the Lac repressor (LacI), binds to the operator sequence, blocking the 
transcription of the lacZYA genes located downstream of the promoter (Figure 1.4 A). In contrast, 
when lactose is present in the medium, the lactose molecules bind to the Lac repressor, inducing 
a conformational change, which triggers its dissociation from the operator sequence (Figure 1.4 
B). The transcription of the lacZYA genes is higher when glucose is not present, as the cAMP levels 
increase binding to the catabolite activator protein (CAP). The cAMP-CAP complex interacts with 
the RNA polymerase stimulating the synthesis of mRNA (Figure 1.4 C) (Lodish et al., 2011). 
The lactose operon is the most studied regulatory mechanism in E. coli, and several promoters 
have been constructed from lac-derived regulatory elements (Terpe, 2006). The lac expression 
system is based on the lac operon, where the genes coding for the enzymes required for lactose 
metabolism have been substituted for a gene of interest. In addition, the inducer lactose is 
commonly substituted for isopropyl-β-D-thiogalactopyranoside (IPTG), a sugar analogue, whose 
uptake is not dependent on permeases. IPTG diffuses freely through the cytoplasmic membrane, 
so the level of induction depends on the concentration of the inducer present in the medium. In 
addition, IPTG cannot be cleaved by the β-galactosidase, and therefore is not metabolised 
(Schumann and Ferreira, 2004).  
Several mutations of lac promoter have been identified, such as the lacUV5, which presents two 
point mutations within the -10 region of the promoter and one in the -66 region of the CAP binding 
site. This mutated version showed a 2.5-fold activity increase over the wild type promoter and a 
lower sensitivity to catabolite repression, allowing maximal expression in rich culture media 
(Terpe, 2006). As the level of the wild-type LacI repressor is not sufficient to completely repress 
the expression of the genes located downstream of the lac promoter, mutant variants have been 
isolated, such as LacIq, allowing a lower basal expression when compared with the wild type 
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Figure 1.4. Regulation of the transcription of the lac operon. The transcription-control 
region of the lac operon includes three protein-binding regions: the CAP binding site, the lac 
promoter and the lac operator (O). When lactose is not present in the culture media, low 
amounts of mRNA are produced since the lac repressor is bound to the operator sequence, 
inhibiting the initiation of transcription by the RNA Polymerase (RNAP) (A). When lactose and 
glucose are present in the culture medium, the lac repressor binds lactose, dissociating from the 
operator sequence, allowing transcription at low rates (B). When only lactose is present in the 
culture medium, the level of cAMP increases as a consequence of the low intracellular levels of 
glucose, constituting the CAP-cAMP complex, which binds to the CAP binding site, interacting 
with the RNA polymerase, allowing gene transcription at high rates (C) (Adapted from Lodish et 
al., 2013)  
lacY lacA 
lacY lacA lacZ 
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20 
  
Synthetic promoters were created with the desire to further improve the strength of the lac 
promoter by constructing a trp/lac hybrid promoter combining the -35 and -10 regions of the 
tryptophan and lactose promoters, respectively. The increase in the spacing between the −35 and 
−10 consensus sequences 1 bp or 2 bp resulted in an improvement of the promoter efficiency, 
leading to the development of the tac and trc promoters (Terpe, 2006). 
Nonetheless, even when hybrid promoters, such as tac and trc, allowed the production of proteins 
up to 15 to 30% of the total cell protein, its high basal expression under non-induced conditions 
represents an important drawback (Terpe, 2006). Stronger and more tightly regulated expression 
systems have been developed, as leaky expression of certain recombinant proteins may result 
toxic for the host organism. 
T7 expression system 
Podoviral polymerases are widely used by the biotechnology industry, especially the RNA 
polymerase (RNAP) derived from the bacteriophage T7. The T7 RNA polymerase is known for its 
high specificity for its cognate promoter, which cannot be efficiently recognised by the E. coli RNA 
polymerase. In addition, it is five times more active than E. coli’s RNA polymerase (Fernandez and 
Hoeffler, 1999). The characterisation of the T7 RNA polymerase led to the development of a series 
of expression systems, known as plasmids for expression by T7 RNA polymerase or pET vectors, 
developed by Studier and collaborators (Studier, 1990; Rosenberg et al., 1987; Studier and 
Moffart, 1986). 
The most common strategy for the T7 polymerase delivery in E. coli makes use of BL21 (λDE3), 
whose chromosome contains a prophage (λDE3), encoding the T7 RNA polymerase 
(bacteriophage T7 gene 1) under the control of the lacUV5 promoter (Sørensen and Mortensen, 
2005). Since the T7 promoter is not completely repressed by LacI, some molecules of T7 RNA 
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polymerase are continuously expressed, generating considerable amounts of target mRNA even 
in the absence of inducer. Mutant versions of LacI repressor, such as LacIq, or the co-expression of 
the T7 lysozyme, the natural inhibitor of the T7 polymerase, can be used to achieve a lower basal 
expression (Fernandez and Hoeffler, 1999). 
The expression of the gene of interest is directed by the T7 RNA polymerase, with the gene coding 
for the T7 polymerase expressed from E. coli’s chromosome under the control of the Lac promoter. 
When the inducer, either lactose or IPTG, is present in the media, the T7 RNA polymerase is 
expressed and recognises the T7 promoter present in the plasmid, allowing the transcription of 
the gene of interest (Fernandez and Hoeffler, 1999). Another possible alternative is to place the 
gene coding for the T7 polymerase under the control of the araBAD promoter, which allows a 
tighter regulation of the T7 expression system (Figure 1.5) (Wycuff and Matthews, 2000). 
 
Arabinose expression system 
E. coli can use other carbon sources apart from glucose or glycerol, such as arabinose. Expression 
of the enzymes required to metabolise arabinose into a suitable sugar form, which can be used in 
the pentose phosphate metabolic pathway, is positively regulated by the AraC protein. AraC is a 
transcription factor, which acts inducing the synthesis of enzymes required for the arabinose 
uptake (araE, araF and araG) and catabolism (araB, araA and araD). When arabinose is not 
present in the system, AraC binds simultaneously to two DNA half sites, O1 and O2, located 210 bp 
apart on the araBAD promoter (Figure 1.6). This binding is formed through a DNA loop which 
restricts the access of the RNA polymerase to the Pc and PBAD promoters. When arabinose is 
present in the medium, arabinose binds AraC, inducing a conformational change which allows 
AraC to bind to the adjacent half-sites O1 and I. Since AraC no longer constitutes a loop between 
the two DNA sequences, the RNA polymerase is able to transcribe the genes located downstream 
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Figure 1.5. The mechanism of action of arabinose-inducible T7 expression system. In the T7 expression system, the addition of arabinose 
allows the expression of the T7 RNA polymerase from the host chromosome. The T7 RNA polymerase recognises the T7 promoter present on 
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Figure 1.6. The mechanism of action of arabinose expression system. The arabinose operon is regulated positively by AraC. When 
arabinose is not present in the culture medium, AraC forms a loop between the O1 and O2 sites, restricting the access of the host RNA polymerase. 
When arabinose is added to the culture medium, AraC binds to the O1 and I sites, allowing the transcription of the gene of interest (Adapted 




AraC also regulates the transcription of the arabinose transporters (araE and araFGH) which 
results in an all-or-nothing response under induction conditions. A more homogenous cell 
induction can be achieved in strains deficient in arabinose transport genes, where arabinose 
uptake is catalysed by arabinose independent transporters supplied from a constitutive promoter 
or an arabinose-independent inducible promoter (Sørensen and Mortensen, 2005; Khlebnikov et 
al., 2000). 
Guzman et al. (1995) extensively described the arabinose expression system, well known for its 
tight regulation. Low basal expression can be achieved with the araBAD promoter, highly 
desirable when “toxic proteins” need to be produced (Terpe, 2006). 
 
Other expression systems 
lac-derived expression systems are the most widely used by the biotechnology industry, however, 
a broad range of different expression systems are nowadays available for RPP (Terpe, 2006). The 
selection of the expression system will depend on the characteristics of the recombinant protein, 
expression level, intracellular and extracellular protein production level and cell growth 
characteristics. A detailed list of commonly used promoters for RPP can be found in Table 1.3. 
λ pR/pL is a thermoregulated expression system derived from bacteriophage lambda (λ), 
commonly used for the production of protein therapeutics. The gene of interest is commonly 
inserted between the major leftward (pL) and/or the rightward (pR) promoters, which in nature 
controls the early lytic genes of the λ phage. The pR/pL promoters are induced shifting the culture 
temperature from 30 °C to 42 °C, as a result of the presence of a temperature-sensitive repressor 
cI857, a mutant cI repressor which is highly unstable at high temperatures (Valdez-Cruz et al., 




Table 1.3. Commonly used expression systems for protein production in E. coli (Adapted 
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expression when anhydrotetracycline (aTc) is added to the culture medium (Terpe, 2006). No 
specific strains are required (pASK75 vector), and the tet promoter is tightly regulated and not 
dependent of the metabolic state or the E. coli strain used (Samuelson, 2011). As with the 
arabinose expression system, the rhamnose (PrhaBAD) system is also known to be a tightly 
regulated system (Egan and Schleif, 1993). 
Other promoters, such as the alkaline phosphatase promoter (PhoA), are active when a nutrient 
(phosphate) is depleted from the culture medium (Huang et al., 2012). Also, as the T7 expression 
system has shown a high popularity as the first choice for RPP, other phage-derived expression 
systems, like the T5 (Qiagen), have been developed. In contrast with T7, the T5 promoter is 
recognised by the host RNA polymerase (Samuelson, 2011). 
 
1.3 Routes of production of recombinant proteins in E. coli 
E. coli cells, like other Gram-negative bacteria, are constituted of an inner and outer membrane, 
which divides the organism in three compartments: the cytoplasm, the periplasm and the 
extracellular space. Recombinant proteins can be produced targeting any of these compartments. 
Advantages and disadvantages of targeting the production of recombinant proteins to each 
cellular compartment can be found listed in Table 1.4. 
 
1.3.1 Cytoplasmic recombinant protein production 
Accumulation of recombinant protein in the soluble fraction 
The production of recombinant proteins in the cytoplasm is often the most common choice, as 
successful production often leads to high titres of correctly folded (and likely to be active) protein 
products. Nevertheless, the production of proteins in a soluble form will depends on the host cell’s 
capability and the total metabolic load imposed on the cells during RPP (Shadev et al., 2008).  
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Table 1.4. Advantages and disadvantages of the production of recombinant proteins in the 
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High-level protein production often leads to the accumulation of misfolded or unfolded proteins 
in inclusion bodies (IBs). Several expression strategies have been developed to avoid this 
outcome, as the co-expression of chaperones, the reduction of the protein synthesis rate by using 
low cultivation temperatures and/or low inducer concentration, or the use of a highly soluble 
fusion partner (Fahner et al., 2004). However, there is no general rule for the selection of an 
optimal strategy and different conditions need to be evaluated in a trial-and-error approach. In 
addition, the success of the different strategies seems to be protein-specific (Choi et al., 2006). A 
more detailed description of factors affecting protein folding during the production of 
recombinant proteins in the cytoplasm can be found in Section 1.5.2. 
In addition, purification of recombinant proteins from the cytoplasm is a relatively difficult 
process, since this compartment contains the majority of cellular proteins (Baneyx and Mujacic, 
2004). Downstream processes often require extensive development and optimisation, being often 
time-consuming and costly. 
 
Accumulation of recombinant proteins in the insoluble fraction 
As transcription and translation are fast and coupled process in E. coli, some eukaryotic proteins 
requiring longer time and/or folding chaperones assistance often fail to reach their native 
conformation, accumulating as misfolded proteins in the cytoplasm, where they tend to aggregate, 
forming inclusion bodies (Huang et al., 2012). Inclusion bodies (IBs) are intracellular deposits of 
insoluble aggregates of unfolded or partially misfolded proteins (Alfasi, 2011; Gasser et al., 2008), 
which can be founded in the cytoplasm or the periplasm depending on the presence of a secretory 
signal peptide (Baneyx and Mujacic, 2004). 
Despite the fact that unfolded proteins accumulated in IBs can be biologically inactive, several 
commercial products, including interferon, interleukins and Fc-fusion proteins have been 
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produced and purified from IBs (Huang et al., 2012). Under recombinant protein production 
conditions, inclusion bodies are mainly constituted by misfolded protein, accounting for 80% - 
95% of the inclusion body content. Chaperones, as DnaK and GroEL, and co-chaperones, as DnaJ-
GrpE and GroES, are also accumulated with the unfolded protein (Valdez-Cruz et al., 2010). 
Recombinant proteins accumulated in the inclusion bodies can be easy to recover and purify, since 
IBs can be easily isolated after cell disruption due to their high density. In addition, as a result of 
the host proteins concentration being lower when compared to the cytoplasmic soluble fraction, 
they are highly pure. Refolding of IBs to active proteins is often complex, requiring considerable 
optimisation for each target protein. In addition, chaotropic agents used during protein refolding 
can affect the integrity of refolded proteins (Huang et al., 2012). In general, protein refolding can 
be unsuccessful and associated with high yield losses during processing. However, when 
successfully optimised, recombinant protein production in IBs and protein refolding has been 
proven a suitable production route for protein therapeutics. 
Since most recombinant proteins for pharmaceutical purposes are human originated, they often 
lack the N-terminal methionine required for cytoplasmic production in E. coli, which can be a 
problem for recombinant proteins intended for human therapeutics (Choi et al., 2006). When this 
is required, periplasmic protein production is the optimal choice, since upon translocation to the 
periplasm, the cleavage of the signal peptide generates an authentic N-terminus.  
 
1.3.2 Periplasmic recombinant protein production 
 
Periplasmic and outer membrane proteins are initially synthesised in the cytoplasm as larger 
precursor proteins containing an amino-terminal signal peptide consisting of 20 to 40 amino 
acids, which following translocation to the periplasmic space is cleaved. Signal peptides are highly 
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conserved sequences containing three well-differentiated regions: an amino-terminus, a 
hydrophobic domain and the cleavage site (Choi and Lee, 2004; Oliver, 1985). SEC, SRP and TAT 
signal peptides share the same basic structure which can be found depicted in Figure 1.7. 
 
The basic amino-terminus (N-region) 
The basic amino-terminus consists of a stretch of two to ten amino acids, positively charged, which 
enables the precursor protein to insert itself into the inner membrane. A basic amino acid residue 
is often found after the start codon, frequently a lysine, coded by the codon AAA, which seems to 
favour the translocation of the precursor protein (Low et al., 2013). 
 
The hydrophobic core (H-region) 
The hydrophobic core region has a variable length, being composed of 10 to 20 neutral 
hydrophobic amino acids residues, preferably leucine, alanine and valine, but phenylalanine, 
isoleucine, methionine and tyrosine can also be found at this region. Although it seems there is no 
strong preference for a specific amino acid to be located at a particular position, its distribution 
does not seem to be completely random (Choi and Lee, 2004; Oliver, 1985). 
 
The processing site (C-region) 
The processing site is a consensus sequence which contains the cleavage site recognised by the 
signal peptidase I. Alanine is the most frequent amino acid at positions -1 and -3, forming the so-
called Ala-X-Ala box; however, other amino acid residues can be found at these positions (Choi 
and Lee, 2004). Amino acid residues located at -1 must have a small neutral side-chain, such as 








xxAxA M   K 
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Figure 1.7. Structure of the signal peptide. Signal peptide sequences are constituted by three 
differentiated regions: a basic amino-terminus or N-region; the hydrophobic core or H-region; 
and the cleavage site or C-region. The N-region is constituted by positively charged amino acid 
residues. A lysine residue, coded by codon AAA, is commonly found at the second position of the 
amino acid sequence. The H-region is constituted by hydrophobic amino acids, preferably 
leucine, alanine and valine. A helix-breaker residue, such as glycine or proline, can often be found 
in this region. The C-region is constituted by small negatively charged amino acid residues. 
Alanine is the most frequent residue at the cleavage site, forming the so-called Ala-X-Ala box (A). 
Comparison of the structure of signal peptides targeting the SEC, SRP and TAT translocation 
pathways (B) (Adapted from Low et al., 2013; Palmer and Berks, 2012). 
+ hydrophobic AXA 
+ ↑ hydrophobicity AXA 
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leucine, isoleucine and valine. Any amino acid residue seems to be tolerated at position -2 and -4 
(Oliver, 1985). The secondary structure at the processing site of precursor protein also plays a 
key role determining the exact cleavage site (Choi and Lee, 2004). 
In addition, the export initiation domain, also known as the pro-region, is a stretch of 
approximately up to 30 amino acids long located downstream the processing site, which may 
influence the ejection of the precursor protein through the inner membrane. Mutations in this 
region may hamper or reduce protein export, altering the cleavage site, since a net negative charge 
in this region is required for efficient protein translocation (Low et al., 2013). 
 
Periplasmic translocation is a two-stage process required for the transport of proteins to the 
periplasmic space, the outer membrane and the extracellular environment. There are three main 
pathways used for protein translocation in Gram-negative bacteria: the SecB-dependent, the SRP-
mediated and the twin-arginine translocation pathways, which can be found depicted in Figure 
1.8 (Mergulhao et al., 2005). 
 
SecB-dependent translocation pathway 
In E. coli, 50% of the cellular proteins are exported to the periplasmic space, the outer membrane 
or to the extracellular environment, with more than 90% being translocated through the SEC 
translocation pathway (Low et al., 2013). The translocation of a precursor proteins involves a 
cascade of interactions initiated from translation of the mRNA by the ribosome to the 
translocation of the protein to the periplasm by the SEC machinery (Mergulhao et al., 2005; Low 








Figure 1.8. Periplasmic protein translocation pathways. SecB-dependent translocation pathway (A). The majority of the protein intended 
to be translocated to the periplasm is directed to the SecB-dependent pathway. The trigger factor (TF) binds to nascent chains as they emerge 
from the ribosome. Subsequently, polypeptides are transferred to DnaK or SecB, which prevents its premature folding. SecB delivers the 
precursor protein to SecA, which initiates its translocation through the SecYEG translocon complex. SRP-mediated pathway (B). The majority 
of the proteins with highly hydrophobic signal peptides (green) or transmembrane segments are recognised by SRP, which delivers the nascent 
chains to FtsY and to the SecYEG complex. TAT translocation pathway (C). Fully folded or partially folded precursor proteins with signal 
peptides bearing the twin-arginine motif (yellow) are translocated by the TAT pathway, through the TatABC complex. DSB oxidative pathway 
(1). Cysteine residues present in disulphide-bonded proteins are introduced by DsbA, while DsbB helps to main DsbA in an oxidised form. DSB 
isomerization pathway (2). DsbC catalyses the isomerisation of incorrectly formed disulphide bonds. DsbC is maintained in a reduced form by 











































During protein translocation, SecB binds the precursor protein or preprotein, preventing its 
premature folding (Figure 1.8 A). Unlike other chaperones, SecB binding does not require ATP 
hydrolysis, maintaining the precursor protein in a translocation-competent state (Danese and 
Silhavy, 1998). Once SecB is bound to a precursor protein, it will bind SecA, releasing it from SecB 
and transferring the preprotein to SecA. SecA targets the precursor protein to the membrane-
bound translocation apparatus, the SecYEG complex (Sec61αγβ complex in eukaryotes) 
(Papanikou, 2007). SecA binds the SecYEG complex, and acting as an ATPase, causes the release 
of SecB from the membrane. SecE and SecY form a conducting channel, where SecG stimulates the 
translocation activity. Binding of the precursor protein to the membrane-bound SecA, results in 
the translocation of approximately 20 amino acids. Subsequently after the binding of ATP to SecA, 
another 15 to 20 amino acids are translocated. After the hydrolysis of ATP, the precursor protein 
is transferred from SecA into the translocation channel; SecA is then released from the membrane 
and exchanged for the cytosolic SecA. After several rounds of insertion and release of the SecA 
from the precursor protein, it is then translocated through the channel, process that can be 
facilitated by the proton motive force (Mergulhao et al., 2005). Once the signal peptidase I cleaves 
the signal peptide, the now mature protein is released from the membrane by SecD (Low et al., 
2013). 
Although the SEC translocation pathway has been extensively used for RPP, it is not able to 
translocate fully folded proteins. Therefore, proteins that fold rapidly in the cytoplasm, are often 
produced targeting the SRP or the TAT translocation pathways (Mergulhao et al., 2005). 
 
SRP-mediated translocation pathway 
The signal recognition pathway targets primarily membrane proteins which directs, co-
translationally, to the SecYEG translocon (Low et al., 2013). This translocation pathway is also 
present in eukaryotic cells, where the signal recognition particle (SRP), a complex of six proteins 
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and 7S RNA mediates protein translocation across the endoplasmic reticulum (ER). In eukaryotes, 
SRP docks the precursor protein to the ER membrane by interaction with SRα, a subunit of the 
membrane-associated receptor for SRP, which favours the co-translational translocation of 
proteins (Danese and Silhavy, 1998). 
In prokaryotes, the signal recognition particle (SRP), composed by Ffh protein and the 4.5S RNA 
subunit, homologous to two eukaryotic SRP constituents, the SRP54 and 7S RNA, binds to the 
nascent preprotein (Danese and Silhavy, 1998). Depending on the hydrophobicity of the signal 
peptide and the characteristics of the precursor protein, such as the presence of a transmembrane 
segments, SRP will bind to the nascent chain with high affinity, which interacts with the FtsY 
receptor, homologous to the eukaryotic SRα, displacing the trigger factor (TF) and initiating the 
translocation processes (Figure 1.8 B) (Luirinka and Sinning, 2004; Mergulhao et al., 2005). The 
signal recognition particle shares a common attachment site and the binding of one or the other 
will determine whether the protein will be translocated co-translationally through the SRP-
mediated pathway, or post-translationally by the SecB-dependent pathway. FtsY interacts with 
the protein-SRP complex and, in combination with Ffh, release the nascent chain to the SecYEG 
translocon (Baneyx and Mujacic, 2004). 
For RPP, the SRP translocation pathway is targeted particularly for proteins that fold too quickly 
in the cytoplasm, as nascent protein chains are bound to SRP as they exit the ribosome tunnel, 
avoiding premature folding or protein aggregation (Lee and Jeong, 2013). The use of the SRP-
mediated translocation pathway for phage display has been reported (Steiner et al., 2006). 
 
TAT pathway 
The twin-arginine translocation, also known as TAT pathway, receives its name due to the 
presence of two consecutive and highly conserved arginine residues (RR) present in signal 
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peptides targeting this pathway. In contrast with SEC and SRP-dependent pathways, the TAT 
pathway mediates the translocation of fully folded or partially folded proteins by using the proton 
motive force (PTM). The average size of TAT signal peptides is 37 amino acids, containing an 
extended polar region with the consensus motif S/T-R-R-X-F-L-K and generally are less 
hydrophobic than SEC signal peptides (Figure 1.7 B) (Patel et al., 2014; Palmer and Berks, 2012). 
The main components of TAT pathway are the proteins TatA, TatB, TatC, TatD and TatE, however, 
their specific functions have not yet been completely elucidated (Figure 1.8 C). It has been 
proposed the involvement of TatA constituting a channel and TatB and TatC providing the initial 
binding site for the precursor protein, constituting the TatABC complex. Briefly, the twin-arginine 
motif of the signal peptide is recognised by TatC, the folded protein is then translocated through 
TatA. Once the precursor protein reaches the other side of the membrane, the signal peptide is 
cleaved, and TatA dissociates from the TatBC complex (Palmer and Berks, 2012; Mergulhao et al., 
2005).  
The TAT pathway has been considered less efficient and slower than the SecB-dependent 
pathway, as it can be easily saturated. In consequence, the co-expression of the TatABC operon is 
required when this pathway is being targeted for RPP (Mergulhao et al., 2005). 
 
 
Disulphide bond formation is limited in the reductive environment of the cytoplasm, and 
disulphide bonded proteins are often targeted to the periplasm, which allows the formation of 
disulphide bonds due to its oxidising nature and the presence of the disulphide bond (DSB) 
generation machinery (Choi and Lee, 2004). The presence of disulphide bonds is a common post-
translational modification which requires the participation of two cysteine residues, often crucial 
for the stability and activity of numerous proteins, and its absence may induce degradation and 
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proteolysis (Baneyx and Mujacic, 2004). The DSB machinery is involved in the formation of 
disulphide bonds by either introducing disulphide bonds in newly synthesised proteins, also 
known as the DSB oxidative pathway, or by rearranging the existing disulphide bonds, known as 
the DSB isomerization pathway (Heras et al., 2009). 
 
DSB oxidative pathway 
The DSB oxidative pathway is responsible for the introduction of disulphide bonds into newly 
synthesised proteins that have been recently translocated to the periplasm. It involves two 
proteins: DsbA, a highly oxidising protein, and DsbB, which helps to maintain DsbA in an oxidised 
form. DsbA comprises a thioredoxin (TRX) domain which contains a pair of redox-active cysteines 
as part of the CXXC motif (Figure 1.8 1). During the formation of disulphide bonds, the two 
cysteines presents in the CXXC motif of DsbA become reduced, catalysing the oxidation of the 
cysteines present in the substrate protein. Subsequently, DsbA is regenerated to its original 
oxidised form by DsbB, ready to catalyse the formation of disulphide bonds in another protein 
(Heras et al., 2009). 
 
DSB isomerization pathway 
The DSB oxidative pathway introduces disulphides bonds indiscriminately in any protein 
substrate containing more than two cysteine residues, therefore, a proofreading system that can 
correct the formation on non-native disulphide bonds is needed (Figure 1.8 2). The proofreading 
and shuffling activity is carried out by DsbC, a disulphide isomerase that catalyses the 
isomerization of disulphide bonds when incorrectly introduced by DsbA. As DsbA, DsbC contains 
a TRX domain with a CXXC motif, however this domain is linked to DsbG by amino-terminal 
dimerization, creating a hydrophobic cavity. This hydrophobic cavity allows the binding of 
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substrate proteins, and prevents the interaction with DsbB, separating the oxidative and 
isomerization pathways. DsbC and DsbG are maintained in its reduced form by DsbD, an integral 
membrane protein (Heras et al., 2009). 
 
 
For the production of recombinant proteins containing disulphide bonds, targeting the 
periplasmic space is often the preferred option (Choi and Lee, 2004). The three translocation 
pathways can be used for RPP and the selection among them is generally driven by the 
characteristics of target protein. Whereas the SEC translocation pathway only allows the 
translocation of unfolded proteins, TAT allows the transport of fully folded protein products. As 
the SRP pathway allows co-translational protein translocation, is generally being targeted for 
proteins that fold too quickly, hampering its translocation through SEC (Mergulhao et al., 2005). 
An advantage of periplasmic protein production is the lower concentration of host proteins in the 
periplasm when compared to the cytoplasm, which often allows an easier purification of the 
protein product. However, the limited space of the periplasm does not allow the accumulation of 
high amounts of recombinant protein, and yields are usually lower when compared to cytoplasmic 
protein production (Jonasson et al., 2002). Leakage to the extracellular medium can be observed 
when the protein is accumulated to high titres, caused by the osmotic pressure build-up 
(Mergulhao et al., 2005). 
Nevertheless, several bottlenecks are often faced when the periplasmic space is targeted for RPP: 
the secretion efficiency is protein-dependent which can lead to low amounts of recombinant 
protein being secreted to the periplasm; misfolded proteins can be accumulated in IBs within the 
periplasm; and translocation of the protein to the periplasm does not always guarantee the correct 
formation of disulphide bonds. The selection of the optimal signal peptide and the overexpression 
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of chaperones may help to address some of the problems; however, different methods need to be 
evaluated (Choi and Lee, 2004). 
 
1.3.3 Extracellular recombinant protein production 
The secretion of proteins to the culture medium has been highlighted as an alternative route to 
reduce the cell stress induced during RPP, as recombinant proteins are no longer accumulated 
inside the cell. Six secretion mechanisms are known to mediate protein secretion to the 
extracellular environment in Gram-negative bacteria, recombinant proteins being generally 
secreted by the type I or by a second step of the type II secretion system (Ni and Chen, 2009).  
The type I secretion system is the most frequently used for RPP, being capable of transporting 
proteins up to 800 kDa across the outer membrane (e.g. haemolysis (Hly) system). In contrast 
with the type I secretion system, the type II is a two-step process, which initially involves the 
translocation of the protein to the periplasm by SEC, SRP or TAT pathways, where it folds. In the 
second step, the protein is transported across the outer membrane. The use of other secretion 
systems, such as type III and V, have been reported but have not been widely used for RPP (Ni and 
Chen, 2009).  
Recombinant proteins can also be released to the extracellular environment by non-specific 
periplasmic leakage. Periplasmic leakage can be induced from the osmotic pressure build-up, as a 
result of the accumulation of the recombinant protein, which is the driving force for transport 
across the outer membrane. RPP can induce alterations in the outer membrane leading to an 
increase the permeability, which may result in the release of the periplasmic content (Mergulhao 
et al., 2005).  
An increase in the permeability of the cell outer membrane can also be achieved by biochemical 
methods, such as the addition of detergents as Triton-X, or physical methods like osmotic shock 
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or sonication. Addition of some amino acids, such as glycine, to the culture medium also seem to 
favour the leakage of proteins to the extracellular environment (Chou and Lee, 2004).  
Several disadvantages are often associated with the extracellular secretion of recombinant 
proteins, as protein leakage to the culture medium is often a consequence of a reduction of the 
integrity of the outer membrane. Export system can be easily overloaded by the high protein 
production, mainly when strong promoters are used. In addition, the secretion of proteins to the 
culture medium results in highly diluted protein samples (Chou and Lee, 2004). 
 
1.4 High-cell-density culture techniques for RPP in E. coli 
Recombinant DNA technology made possible the large-scale production of recombinant proteins, 
with increased effectiveness, at lower cost by the development of high-cell-density culture (HCDC) 
techniques (Choi et al., 2006). Once the conditions for the production of a target protein had been 
optimised, the process can be transferred to a high-cell-density culture aiming to increase cell 
density and maximise product yields. Fermentation techniques provide control over chemical, 
physical and biological parameters that can affect cell growth and recombinant protein 
production, including temperature, pH, dissolved oxygen (DO) and culture medium composition 
(Huang et al., 2012). 
 
Culture medium 
The culture medium used to grow E. coli to high cell densities is constituted by essential 
components, as a carbon source, nitrogen source, essential salts and trace elements. Three types 
of media are available: chemically defined medium (CDM), semi-defined medium (SDM) and 
complex medium. CDM has a defined composition and concentration of chemicals, whereas SDM 
and complex medium compositions contain non-defined components, such as protein 
42 
  
hydrolysates or yeast extract. SDM is the most widely used in industry since non-defined 
components provide essential trace nutrients, allowing the achievement of high cell densities. 
However, CDM is gaining more acceptance due to inconsistent performance and lot-to-lot 
variation associated to undefined medium components (Huang et al., 2012). 
 
Type of fermentation 
Batch fermentation, in which cells are grown to a maximum specific growth rate with the nutrients 
supplied in the fermenter, is an easy technique to grow cells to moderately high cell densities in a 
short period of time. However, batch fermentation requires a high concentration of sugar to be 
present in the bioreactor to support cell growth, resulting in the formation of side metabolites, 
such as acetate, and in less extent, lactate and formate as a consequence of the overflow 
metabolism, which affects negatively cell growth and the host metabolism. Fed-batch 
fermentation is more widely used for industrial manufacturing, allowing the culture of E. coli up 
to a concentration greater than 100 grams of dry cell weight (DCW) per liter by continuous supply 
of nutrients, usually the carbon source, to ensure control over cell growth (Lee, 1996). 
A highly concentrated nutrient solution, also known as feed solution, is often provided after a 
sharp DO and pH increase, which indicates that the nutrients in the batch medium have been 
exhausted. Several feeding strategies have been developed: pH-stat, where feeding is activated 
when the pH of the medium increases; DO-stat, when the feed solution will be added after a sharp 
DO increase caused by substrate depletion; and exponential feeding profiles based on calculating 
for prediction of use of a specific nutrient, such as the carbon source (Huang et al., 2012). 
The selection of the feeding strategy is critical since it may affect metabolic pathway fluxes, 
limiting the maximum attainable cell concentration, recombinant protein production or the 
formation of by-products. To date, there is no general rule for the selection of a feeding strategy 
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but different feeding approaches, such as constant feeding rate or exponential feeding profiles, 
have proven to be successful for RPP (Choi et al., 2006). 
 
Fermentation scale-up 
The development of a fermentation process usually starts in a laboratory scale bioreactor, e.g. 1 – 
10 L, to optimise the growth and protein production conditions. Once optimal conditions have 
been achieved, the process is then transferred to pilot scale, e.g. 50 – 200 L, aiming to determine 
the optimal operating parameters, before transfer to manufacturing scale, above 500 L. The scale-
up process aims to achieve a high productivity and process consistency, nevertheless, factors 
affecting growth and protein expression may change during scale-up (Huang et al., 2012). At large 
scale, poor mixing efficiency, oxygen limitation or heat generation, may lead to imbalanced 
nutrient distribution (Choi et al., 2006; Enfors et al., 2001). 
Poor mixing efficiency can lead to limited dissolved oxygen and zonal nutrient distribution, as 
cells close to the feeding port are exposed to a high nutrient concentration whereas at other 
locations, cells may be starved of substrate, affecting cell growth and leading to amino acid 
misincorporation during RPP. Oxygen limitation can lead to the production of organic acids 
resulted from anaerobic reactions and the overflow metabolism, which decreases the pH and 
induces growth arrest, resulting in a low specific growth rate (μ) and low biomass and product 
yields (Overton, 2014; Enfors, 2001; Lee, 1996). In addition, cultures where there is a limitation 
of dissolved oxygen may result in low plasmid retention, even under selective pressure, resulting 
in poor protein yields. At large scale, when mixing efficiency is not optimal, the use of oxygen-
enriched air or pure oxygen may help to provide sufficient oxygenation to the culture, otherwise, 
the overgrowth of plasmid-free cells may eventually dominate the culture (Glick, 1995). It is 
important to understand the limitations of large-scale fermentations, which should be kept in 
mind during the development of a fermentation process at laboratory scale (Choi et al., 2006). 
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1.5 Common problems associated with recombinant protein production 
Fermentation scientists often have to face one if not more of the general problems associated with 
RPP: misfolded or truncated protein; no protein production; growth arrest; or cell death. The 
accumulation of misfolded or truncated proteins and growth arrest are often the result of high 
level of recombinant protein synthesis, which can be controlled at induction level or by reducing 
the cultivation temperature to 18 - 25 °C to slow down the protein synthesis rate (Fahner et al., 
2004). Common problems encountered during RPP can be found described in Table 1.5. 
 
1.5.1 Plasmid maintenance 
Optimal gene transcription depends largely on the copy number, the structural and segregational 
plasmid stability. A plasmid is considered segregationally stable when all daughter cells carry at 
least one copy of the plasmid. Structural plasmid stability is if all the plasmids generated have the 
correct base sequence. Structural and segregational plasmid stability depends largely on the copy 
number, which is determined by the origin of replication, but also can be severely affected by cell 
stress during RPP (Huang et al., 2012). 
The introduction of foreign DNA in a host organism may impair the organism’s normal metabolic 
functioning, as a result of the metabolic burden. The metabolic burden increases with plasmid size 
and copy number, the energy cost required for plasmid maintenance will be higher, being 
exacerbated when high copy number plasmids are used (Glick, 1995, Sørensen and Mortensen, 
2005). A simple strategy is the use of low rather than high copy number vectors or the integration 
of the foreign DNA directly into the chromosome of the host strain. By chromosomal integration 
plasmid instability is no longer a problem and avoids the waste of cellular resources synthesising 




Table 1.5. Common problems and possible solutions to RPP (Adapted from Terpe, 2006). 
 
Symptom Possible problem Possible solutions 
Cell death or no 
colonies on agar plates 
Too much recombinant 
protein expression 
Toxic protein 
High basal expression 
Cellular resources diverted 
from biomass to RPP 
Weaker promoter 
Higher control over basal 
expression 
Tightly controlled promoter 
Lowering temperature 




Reduction of disulphide 
bonds 
Minimise reduction in the 
cytoplasm 
Periplasmic protein production 
Insoluble proteins 
(inclusion bodies) 
Too much expression leading 
to poor recombinant protein 
folding 
Attenuate expression by: weaker 
promoter, lowering inducer 
concentration, lowering 
temperature, decrease plasmid copy 
number, fusion of a hydrophilic 
affinity tag 
Recombinant protein 
has no activity 
Misfolded protein 
Affinity tag can decrease 
activity 
Minimise reduction in the 
cytoplasm 
Periplasmic protein production 
Attenuate expression 
Change affinity tag 
No protein 
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1.5.2 Protein folding 
The production of misfolded proteins is one of the most common situations during RPP. 
Chaperones generally assist newly synthesised proteins to achieve the correct folding 
conformation. However, the use of strong promoters in combination with high inducer 
concentrations means that the number of nascent polypeptide chains easily exceeds the 
chaperone number, leading to the accumulation of misfolded or unfolded proteins in inclusion 
bodies (IBs). IB formation is often the result of unbalanced equilibrium between protein 
aggregation and solubilisation, which may result in the induction of the heat shock response 
(Baneyx and Mujacic, 2004). 
The cytoplasmic space is an extremely unfavourable protein-folding environment where 
transcription and translation processes are coupled and a protein chain is released from the 
ribosome every 35 seconds. In the macromolecular crowding of the cytoplasm, where protein 
concentration can reach 200 - 300 mg ∙ mL-1, small and single domain protein can easily fold, but 
large or multidomain proteins often require the assistance of molecular chaperones (Baneyx and 
Mujacic, 2004; Sørensen and Mortensen, 2005). 
Molecular chaperones are proteins whose main activity is to assist protein folding. The trigger 
factor (TF), is the first chaperone to be encountered by the nascent chain as it emerges from the 
ribosome, assisting protein folding (Figure 1.9). Other folding chaperones, such as DnaK or 
GroEL, mediate refolding and unfolding by ATP-dependent conformational change; thus, 
preventing aggregation and IB formation. Folding chaperones often work in association with 
holding chaperones, such as IbpA and IbpB, helping to stabilise partially folded proteins and 
protecting heat-denatured proteins from aggregation. The solubilisation of aggregated proteins is 






Figure 1.9. Protein folding and protease activity in E. coli. In the cytoplasm, proteins often 
associate to the trigger factor (TF) as soon as the newly synthesised protein exits the ribosomal 
tunnel, protecting the exposed hydrophobic patches from un-intended interactions. Incorrectly 
folded proteins are assisted by DnaK and GroEL, which reduce protein aggregation and promotes 
proteolysis of misfolded proteins. DnaK and ClpB also mediates the solubilisation or 
disaggregation of proteins. Disaggregation and IB formation is also prevented by GroEL, which 
operates protein transit between soluble and insoluble fractions. IbpA and IbpB are small heat 
shock proteins which protect heat-denatured proteins from irreversible aggregation. In the 
periplasm, partially folded proteins may aggregate, undergo proteolysis by DegP and Tsp or 
reach their native conformation assisted by Skp and FkpA (Adapted from Baneyx and Mujacic, 
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Despite all the progress made during the last years, the production of recombinant proteins 
frequently results in protein misfolding, low protein yields and laborious and time-consuming 
downstream process (Sørensen and Mortensen, 2005). Traditional approaches to improve folding 
include reducing the protein synthesis rate by using weaker promoters or decreasing the inducer 
concentration (Baneyx and Mujacic, 2004). The use of low cultivation temperatures is an 
alternative strategy, which has the advantages of slowing the protein synthesis and reducing the 
strength of hydrophobic interactions that contribute to protein misfolding (Baneyx and Mujacic, 
2004). Increased chaperone expression has also been associated during growth at low 
temperatures. Also, proteases induced during RPP are less active at cultivation temperatures of 
15 °C to 25 °C, leading to a significant reduction in proteolysis and degradation of expressed 
proteins (Shadev et al., 2008). The co-expression of chaperones, such as GroEL/GroES, have 
proven to be effective facilitating folding of some recombinant proteins (Huang et al., 2012). 
 
1.5.3 Proteolysis 
Proteolysis is a cellular mechanism used to minimise the accumulation of misfolded polypeptides 
within the cell, helping amino acid recycling (Baneyx and Mujacic, 2004). Misfolded, unfolded or 
truncated proteins are frequently unstable and prone to be targeted by proteolysis. Cell stress 
induced by high cultivation temperatures, protein overproduction or accumulation of misfolded 
proteins can increase proteolytic activity (Gottesman, 1996). 
In the cytoplasm, five heat shock proteases (Lon, ClpYQ/HslUV, ClpAP, ClpXP and FtsH) initiate 
proteolytic degradation, degrading unfolded protein substrates via energy-dependent 
proteolysis. The process is completed by the action of peptidases that hydrolyse peptides of 2–5 
residues in length. Lon protease plays a primary role in the degradation of many misfolded or 
unstable proteins. As the lon gene is under the control of a heat shock promoter, its synthesis can 
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be activated by the accumulation of unfolded proteins. Lon along with ClpYQ are considered to be 
primarily responsible for degradation of misfolded proteins (Baneyx and Mujacic, 2004). 
The accumulation of misfolded proteins in the periplasm is often the result of high cultivation 
temperatures, oxidative stress or incorrect disulphide bond formation, DegP being the primary 
housekeeping protease in the periplasmic space (Figure 1.9). DegP is regulated by the sigma 
factor E (σE) and its activity switches from protease to chaperone at low temperatures. A second 
protease, Tsp also exerts its activity in the periplasm (Baneyx and Mujacic, 2004). 
Other common proteases located in the cell envelope are DegQ, DegS, Protease III and OmpT 
(Baneyx and Mujacic, 2004). OmpT is a protease found in the outer membrane, which often 
remains active after cell disruption and under denaturing conditions (Gottesman, 1996). 
 
1.6 Reporter protein technology 
Reporter proteins are defined as proteins with a specific activity that can be identified over a 
background of endogenous proteins (Naylor, 1999). Reporter proteins have been widely used as 
markers for cellular localisation, and are especially valuable in the identification of protein regions 
that promote membrane translocation. Novel approaches rely on the use of protein fusions as 
marker proteins whose enzymatic activity depends on their cellular localisation (Manoil et al., 
1990). Commonly used reporter proteins are detailed in Table 1.7, including β-galactosidase, as 
a cytoplasmic protein marker; and alkaline phosphatase and β-lactamase, as periplasmic markers. 
 
β-galactosidase (LacZ) 
β-galactosidase catalyses the cleavage of the disaccharide lactose to glucose and galactose, and 




Table 1.6. Commonly used reporter proteins (Adapted from Naylor, 1999). 
 
Reporter protein Advantages Disadvantages 
Chloramphenicol 
acetyltransferase 
No endogenous activity in E. coli Narrow linear range 
β-galactosidase Well characterised 
Colorimetric assays available 
Endogenous activity E. coli 
Large molecular weight 
Luciferase High specific activity  
No endogenous activity E. coli 
Convenient assays 
Requires substrate (luciferin), O2 
and ATP 
Alkaline phosphatase Periplasmic protein 
Colorimetric assays available 
Endogenous activity E. coli 
 
β-lactamase No endogenous activity E. coli 
Periplasmic protein 
Colorimetric assays available 
High molecular weight and poor 
cell permeability of fluorescent 
substrates 
Fluorescent proteins Autofluorescent  
No endogenous activity E. coli 
Mutants with altered spectral 
qualities available 






quantified by using the colorimetric substrate O-nitrophenyl-galactopyranoside (OPNG) 
producing yellow coloured O-nitrophenol when cleaved by LacZ. β-galactosidase has been 
successfully expressed and used as a marker protein in both prokaryotes and eukaryotes 
(Vizcaino Caston, 2012). 
β-galactosidase has been widely used for molecular biology, especially in gene cloning as part of 
blue/white screening. It has been also involved in numerous localisations studies as a fusion 
partner for the identification of components of the translocation machinery, as it is enzymatically 
active only when accumulated in the cytoplasm (Feilmeier et al., 1998). 
 
Alkaline phosphatase (PhoA) 
In contrast to β-galactosidase, alkaline phosphatase is inactive in the cytoplasm. The lack of 
activity of the cytoplasmic alkaline phosphatase is the result of the lack of disulphide bonds; PhoA 
is active only when successfully translocated to periplasm. These characteristics made alkaline 
phosphatase the most common marker protein used to determine enzymatic or phenotypic 
activities of proteins depending on their subcellular location (Manoil et al., 1990).  
 
Fluorescent proteins (FPs) 
During the last decade, cell biology imaging has been revolutionised by the discovery of the green 
fluorescent protein (GFP) from the jellyfish Aequorea victoria. GFP is generally expressed alone or 
fused to other proteins, resulting in visible fluorescence with the only requirement being O2. 
Nonetheless, GFP is just one member of a large family of fluorescent proteins and mutagenesis of 
fluorescent proteins has expanded the possible choices, with diverse FP’s in terms of spectra, 
brightness and folding (Giepmans et al., 2006). 
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Nowadays, FPs are widely used as reporters for protein synthesis, as high-throughput screening 
tools or as sensors of physiochemical conditions. FPs are small and simple proteins which can be 
expressed in a large variety of host organisms, being easily detected using non-invasive 
techniques, such as microscopy or flow cytometry (Vizcaino-Caston et al., 2012). GFP monitoring 
using flow cytometry has been used for the development of stress-minimising protocols for RPP, 
improving the yield of correctly folded recombinant proteins while avoiding IB formation 
(Sevastsyanovich et al., 2009). However, solubility, correct folding and protein fluorescence are 
not always directly related, and it has been observed that inclusion bodies containing GFP fused 
to aggregation-prone proteins can still retain some fluorescence (Garcia-Fruitos et al., 2005). 
 
TEM-1 β-lactamase 
The TEM-1 β-lactamase (Bla) is periplasmic enzyme with a molecular weight of 29 kDa, the 
product of the ampicillin resistance gene, which provides resistance to β-lactam antibiotics by 
hydrolysis of the β-lactam ring (Xing et al., 2005). 
β-lactamase has been widely used as a marker protein for the study of protein translocation. As 
alkaline phosphatase, β-lactamase displays a measurable and distinctive phenotype depending on 
subcellular localisation. When β-lactamase is localised in the periplasm, it acts hydrolysing β-
lactam-derived antibiotics before they can inactivate penicillin-binding proteins 
(transpeptidases), which are essential for bacterial cell wall biosynthesis. In contrast, the 
cytoplasmic form of β-lactamase is unable to hydrolyse the antibiotic in the periplasm from its 
cytoplasmic localisation, and therefore, the host is sensitive to the antibiotic, resulting in cell lysis 
(Broome-Smith et al., 1990). 
β-lactamase has been widely used as marker protein in protein localisation studies, as fusion 
proteins provide a distinct phenotype, as colonies can be selected based on their resistance to 
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ampicillin (Broome-Smith et al., 1990). The activity of β-lactamase can also be quantified by using 
colorimetric substrates, such as nitrocefin, CENTA or PADAC, the last one being no longer 
commercially available (Bebrone et al., 2001). Fluorogenic substrates for imaging β-lactamase 
gene expression, such as CC1, CC2 and CR2 (CR2/AM) have also been developed (Gao et al., 2003). 
 
1.7 Scope of this project 
This project is part of a 3-years research collaboration between the University of Birmingham and 
Cobra Biologics Ltd. The research project was funded by the Technology Strategy Board (TSB), 
now known as InnovateUK, the Biotechnology and Biological Sciences Research Council (BBSRC) 
and the Engineering and Physical Sciences Research Council (EPSRC) as part of the Knowledge 
Transfer Partnership (KTP) scheme. The aim of this project is the development of high 
productivity expression and fermentation processes for the production of recombinant proteins 
in E. coli, aiming to develop a knowledge-based approach, which can be applied to GMP production 
of recombinant proteins. 
Initially, the work was focused in the optimisation of the conditions for the production of soluble 
recombinant proteins in the cytoplasm, using tumour necrosis factor α (TNFα) as a model protein. 
The aim was to optimise the fermentation conditions, including vector design, cultivation 
temperature, inducer concentration and induction point, to improve the production of soluble and 
active TNFα. 
Subsequently, the work was expanded to the production of recombinant proteins targeting the 
periplasm of E. coli, using a single-chain antibody fragment, scFv163R4, as model protein. 
However, translocation of proteins into the periplasm is often inefficient due to the saturation of 
the translocation pathways, which can be a major bottleneck in periplasmic protein production. 
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Different cultivation conditions and signal peptides were evaluated with the aim to optimise the 
production of scFv163R4 in the periplasm. 
The efficiency of protein translocation is highly dependent of the signal peptide used to direct the 
target protein to the periplasmic space. However, the selection of the optimal signal peptide is 
often challenging, and several signal peptides need to be evaluated in a trial and error approach. 
Aiming to expand the knowledge regarding periplasmic protein production, signal peptide 
libraries were generated by random mutagenesis and a high-throughput screening assay which 
allows the rapid evaluation of signal peptides was developed. The scFv163R4-A was used as a 
model protein fused to β-lactamase as a reporter protein. The resistance to β-lactam antibiotics 
was used as a selectable phenotype by directly screening for antibiotic resistance levels of E. coli 
colonies, and by the quantification of the β-lactamase activity of each individual clone. Signal 
peptides showing enhanced β-lactamase activity were evaluated by fed-batch fermentation to 





















Chemical, reagents and media components were obtained from Sigma-Aldrich, Merck Millipore, 
Thermo Fisher Scientific, or Becton, Dickinson and Company (BD), unless stated otherwise. 
 
2.1.2 Liquid growth media 
Luria broth (LB) was prepared by dissolving 10 g · L-1 phytone peptone, 5 g · L-1 yeast extract and 
5 g · L-1 NaCl in deionised water and autoclaving at 121 °C and 1.2 atmospheres (atm) for 20 
minutes. 
Terrific broth (TB) (Thermo Fisher Scientific) was prepared by dissolving 47 g · L-1 of premade 
terrific broth powder (11.8 g · L-1 SELECT peptone 140, 23.6 g · L-1 yeast extract, 9.4 g · L-1 K2HPO4 
and 2.2 g · L-1 KH2PO4) and 4 mL · L-1 of glycerol in deionised water and sterilised by autoclaving. 
 
2.1.3 Solid growth media 
Luria Bertani agar was prepared by dissolving 10 g · L-1 phytone peptone, 5 g · L-1 yeast extract, 5 
g · L-1 NaCl and 15 g · L-1 of extra pure agar in deionised water.  
Mueller-Hinton agar (Sigma-Aldrich) was prepared by dissolving 38 g · L-1 of premade Mueller-
Hinton agar powder (17 g · L-1 of agar, 2 g · L-1 of beef infusion solids, 17.5 g · L-1 of casein 
hydrolysate and 1.5 g · L-1 of starch) in deionised water. 
All solid media was sterilised by autoclaving. Media were cooled to at least 50 °C before addition 
of antibiotics or other supplements. Agar plates were poured under sterile conditions, 
approximately 20 mL of agar per petri dish, and stored at 4 °C. 
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2.1.4 Antibiotics and other supplement solutions 
Kanamycin stock solution (50 mg · mL-1 of kanamycin in 0.9% NaCl) from Streptomyces 
kanamyceticus was purchased from Sigma-Aldrich and stored at 4 °C. Ampicillin stock solution 
was prepared by dissolving 100 mg · mL-1 of ampicillin sodium salt (Sigma-Aldrich) in deionised 
water.  
Media supplement stock solutions, such as glucose, was prepared by dissolving 200 g · L-1 of 
glucose in deionised water to generate a 20% glucose stock solution. 20% casamino acid stock 
solution (Sigma-Aldrich) was prepared by dissolving 200 g · L-1 of casamino acids in deionised 
water. Arabinose, used as inducer for arabinose-inducible expression systems, was prepared by 
diluting 200 g · L-1 of arabinose in deionised water to generate a 20% arabinose stock solution. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG), used as inducer for lactose-inducible expression 
systems, was prepared by diluting IPTG in water (0.5 M IPTG stock solution). Lysozyme, used for 
periplasmic protein extraction, was prepared at final concentration of 2 mg · mL-1 in deionised 
water and stored at -20 °C. 
All the solutions were sterilised by filtration through a sterile 0.2 µm filter. 
Table 2.1 summarises the antibiotics and stock solutions used in the present work. 
 
2.2 Buffers and solutions 
2.2.1 Phosphate buffered saline (PBS) 
Dulbecco’s phosphate buffered saline (PBS) was prepared by dissolving 8 g · L-1 of NaCl, 0.2 g · L-1 
of KCl, 2.16 g · L-1 of Na2HPO4 · 7 H2O and 0.2 g · L-1 of KH2PO4 in deionised water. The pH was 
adjusted to 7.2 – 7.4 by the addition of 1 M HCl and sterilised by autoclaving. PBS was used for 
serially dilute culture samples.  
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Ampicillin 100 mg · mL-1 100 μg · mL-1 Water -20 °C 
Kanamycin 50 mg · mL-1 50 μg · mL-1 0.9% NaCl 4 °C 
Casamino acids 20% (w/v) 0.2% Water 4 °C 
Glucose 20% (w/v) 0.25% - 0.5% Water 4 °C 
Arabinose 20% (w/v) 0.002% - 0.2% Water 4 °C 
IPTG 0.5 M 1 mM Water -20 °C 




2.2.2 Buffers for DNA electrophoresis 
The 50x TAE buffer stock was prepared by dissolving 242 g · L-1 of Tris Acetate, 18.61 g · L-1 of 
Na2EDTA and 57.1 mL · L-1 of glacial acetic acid in deionised water. The pH should be 
approximately 8.2 - 8.4. 
The electrophoresis running buffer was prepared by diluting the 50x TAE buffer stock in 
deionised water to a final concentration of 1x (v/v). The 10x sample buffer was prepared 
containing 0.025% (w/v) bromophenol blue, 10% (v/v) glycerol in 10 mM Tris-HCl pH 7.5, 1 mM 
EDTA. 
 
2.2.3 Buffers and solutions for SDS-PAGE 
For 4-12% Bis-Tris NuPAGE SDS PAGE gels (Life Technologies), 1x (v/v) electrophoresis running 
buffer was prepared by diluting 20x NuPAGE MES SDS running buffer (Life Technologies) in 
deionised water. For reducing protein electrophoresis, 0.5 mL of NuPAGE antioxidant (Life 
Technologies) was added to 200 mL of running buffer and used to fill the inner chamber of the 
electrophoresis tank. 
For 18% Tris-Glycine SDS-PAGE gels (Life Technologies), 1x (v/v) electrophoresis running buffer 
was prepared by diluting 10x Tris-Glycine SDS running buffer (Life Technologies) in deionised 
water. 0.5 mL of NuPAGE antioxidant was added to 200 mL of running buffer and used to fill the 
inner chamber of the electrophoresis tank. 
Fixing solution was prepared by mixing 40% (v/v) methanol, 10% (v/v) glacial acetic acid with 
deionised water. The Colloidal Blue Staining kit (Life Technologies) was used for staining of SDS-
PAGE. Staining solution was prepared by mixing 20% (v/v) methanol, 20% (v/v) staining solution 




2.3 Bacterial strains and plasmids 
Strains of E. coli and their genotypes used in the present work are listed in Table 2.2. ElectroSHOX 
competent cells (Bioline) were used for highly efficient transformation and for plasmid DNA 
production, whereas E. coli BL21 strains were used for protein expression studies. 
Plasmids used during the present study are described in Table 2.3. 
 
2.3.1 Preparing bacteria for long term storage 
5 mL of LB was inoculated with a single colony of the strain to be stored and grown overnight at 
37 °C. An aliquot of the culture was transferred to a cryovial and mixed with sterile glycerol to a 
final concentration of 20% (v/v). The culture was snap-frozen in dry ice and stored at – 80 °C. 
 
2.3.2 Generation of research cell banks (RCB) 
A starter culture of 5 mL of LB was inoculated with a single colony of the strain to be stored. The 
starter culture was used to inoculate a 250 mL shake-flask containing 50 mL of LB and grown at 
37 °C. Once cultures have reached a target OD600 ≤ 2.0, sterile glycerol was added to a final 
concentration of 20% (v/v). The culture was aliquoted in 2 mL cryovials, snap-frozen in dry ice 
and stored at – 80 °C. 
 
2.3.3 Generation of master cell plates 
A starter culture grown in a 96-well plate containing 200 μL of LB was inoculated with a single 
colonies of the strains to be stored and grown overnight at 37 °C. 96-deep well plates were 
inoculated with 10 μL of culture obtained from the 96-well inoculum plate and grown overnight 
at 37 °C. Sterile glycerol was added to a final concentration of 20% (v/v) and stored at –80 °C.  
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Table 2.2. E. coli strains genotype used in the present work. 
 
E. coli strain Genotype Source 
E. shox F- mcrA Δ(mrr– hsdRMS– mcrBC) Φ80lacZ ΔM15 ΔlacX74 recA1 
endA1 ara Δ139Δ(ara, leu)7697 galU galK λ- rpsL (StrR) nupG 
Bioline 















Table 2.3. Plasmid vectors used in the present work. 
Plasmid name Description Source 
Expression of recombinant human tumour necrosis factor α 
pLT72 Medium copy number (pMB1), T7 expression vector used for NdeI-SalI cloning (KanR) Cobra Biologics 
pLT72-TNFα Derivative of pLT72, T7 expression vector used for the production of TNFα (KanR) Cobra Biologics 
pLT72-T7t-TNFα Derivative of pLT72-TNFα, containing the T7 terminator sequence (KanR) Cobra Biologics 
pLT72-T7tKan-TNFα 
Derivative of pLT72-TNFα, containing the T7 terminator and the kanamycin gene in 
reverse orientation (KanR) 
Cobra Biologics 
pLT72-T7tKanT2t-TNFα 
Derivative of pLT72-TNFα, containing the T7 and T2 terminator sequences flanking the 
kanamycin gene in reverse orientation (KanR) 
Cobra Biologics 
Expression of recombinant scFv163R4 and scFv163R4-A 
pLBAD2 Medium copy number (pMB1), pBAD expression vector used for NdeI-SalI cloning (KanR) Cobra Biologics 
ptrc2-STII-scFv163R4 ptrc2 vector used as source of the sequence coding for STII-scFv163R4 (KanR). Cobra Biologics 
pLBAD2-STII-scFv163R4 




pLBAD2-STII-scFv163R4 derivative in which the STII signal peptide has been replaced 
with the DsbA signal peptide using NdeI and PvuII restriction sites (KanR). 
This work 
pLBAD2-PelB-scFv163R4 
pLBAD2-STII-scFv163R4 derivative in which the STII signal peptide has been replaced 








pLBAD2-STII-scFv163R4 derivative in which the extra alanine located between the STII 
signal peptide and the scFv163R4 has been removed by overlapping-PCR (KanR). 
This work 
pLBAD2-DsbA-scFv163R4-A 
pLBAD2-DsbA-scFv163R4 derivative in which the extra alanine located between DsbA 
signal peptide and scFv163R4 has been removed by overlapping-PCR (KanR). 
This work 
pLBAD2-PelB-scFv163R4-A 
pLBAD2-PelB-scFv163R4 derivative in which the extra alanine located between PelB 
signal peptide and scFv163R4 has been removed by overlapping-PCR (KanR). 
This work 
pLBAD2-Bla -scFv163R4-A 
pLBAD2-STII-scFv163R4 derivative in which the STII signal peptide has been replaced 
with Bla signal peptide using NdeI and PvuII restriction sites (KanR). 
This work 
pET163R4 pET-23d(+) vector used for cytoplasmic expression of the scFv163R4 (AmpR). 
Martineau et al., 
1998 
Expression of β-lactamase 
pUC18 
High copy number vector used as source of the sequence coding for Bla-β-lactamase 
(AmpR). 
Norrander et al., 
1983 
pLBAD2-Bla-β-lactamase 




Derivative of pLBAD2, pBAD expression vector used for NdeI-SalI cloning of the 
cytoplasmic β-lactamase (KanR). 
This work 
Expression of scFv163R4-A::β-lactamase 
pMK-T-scFv163R4-A-linker-
Bla 
GeneArt vector used as source of the sequence coding for a fragment of the scFv163R4, 









pLBAD2-STII-scFv163R4-A derivative in which the sequence coding for the linker and β-
lactamase from pMK-T-scFv163R4-A-linker-bla vector has been fused to the scFv163R4-




pLBAD2-DsbA-scFv163R4-A derivative in which the sequence coding for the linker and 
β-lactamase from pMK-T-scFv163R4-A-linker-bla vector has been fused to the 




pLBAD2-PelB-scFv163R4-A derivative in which the sequence coding for the linker and β-
lactamase from pMK-T-scFv163R4-A-linker-bla vector has been fused to the scFv163R4-




pLBAD2-Bla-scFv163R4-A derivative in which the sequence coding for the linker and β-
lactamase from pMK-T-scFv163R4-A-linker-bla vector has been fused to the scFv163R4-




pLBAD2-STII-scFv163R4-A::Bla derivative in which the sequence an NdeI site was 
introduced to generate the cytoplasmic version of the scFv163R4-A::Bla (KanR). 
This work 
Vectors used for the development of the β-lactamase screening 
pMA-RQ-SapIPelBSapI 
GeneArt vector containing the sequence coding for PelB signal peptide flanked by the SapI 




pLBAD2-STII-scFv163R4-A::Bla derivative in which the SapI restriction site within the 




pLBAD2∆SapI-STII-scFv163R4-A::Bla derivative in which the STII signal peptide has 




2.4 Recombinant DNA techniques 
2.4.1 Primer design 
In general, primers were designed with a length of 18-30 nucleotides, aiming for a melting 
temperature (Tm) between 55 °C and 65 °C, and within 5 °C of each other. Primers intended to be 
used to introduce mutations were designed containing the mismatched bases located in the 
middle of the primers. Snapgene software (GSL Biotech LLC) was used for primer design and 
visualisation of plasmid vectors. 
Primers used during the present study are listed in Table 2.4. 
 
2.4.2 Plasmid DNA extraction 
Plasmid DNA was isolated at small scale using the QIAprep Spin Miniprep kit (Qiagen) following 
the protocol described by the manufacturer. Large-scale DNA purification was carried out using 
either the Qiagen Plasmid maxi kit (Qiagen) or the PureYield Plasmid Maxiprep System 
(Promega), according to the manufacturer’s instructions. Plasmid DNA was generally extracted, 
when possible, from E. shox cultures. 
 
2.4.3 Annealing and phosphorylation of oligonucleotides 
Lyophilised oligonucleotides were obtained from Eurofins Genomics and resuspended in 
annealing buffer (10 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM EDTA). Oligonucleotides were 
annealed by heating at 95 °C for 5 min and allowed to cool at room temperature. Annealed 
oligonucleotides used for the introduction of signal peptides and other sequences can be found 







Table 2.4. Primers used in the present study. 
Primer name Sequence 5’ to 3’ Description 
LBAD F ttagcggatcctacctgacg Anneal outside the MCS in pLBAD2 vectors 
LBADtrc R atcagaccgcttctgcgttc 
M13 F Gtaaaacgacggccagtg Anneal outside the MCS of pCR®-Blunt vector 
M13 R Cacaggaaacagctatgacc 
scFv F aaacagcatatgaaaaagaatatcgcat Introduction of NdeI and SalI to STII-scFv163R4 
scFv R Cttctctcatccgccaaaac 
STII mut F tacaaatgcctatgcagaggtgcagctggtgg Removal of extra alanine in scFv163R4 by overlapping-
PCR STII mut R ccaccagctgcacctctgcataggcatttgta 
DsbA mut F agcgcatcggcggaggtgcagctg Removal of extra alanine in scFv163R4 by overlapping-
PCR DsbA mut R cagctgcacctccgccgatgcgct 
PelB mut F ccggcgatggccgaggtgcagctg Removal of extra alanine in scFv163R4 by overlapping-
PCR PelB mut R cagctgcacctcggccatcgccgg 
Bla SalI F gtaaacttggtcgtcgacttaccaatgcttaatcagtgaggcacc Introduction of NdeI and SalI to Bla-β-lactamase gene 
Bla NdeI R tgaaaaaggaagcatatgagtattcaacatttccgtgtcgccctt 
Cyt Bla F tgccttcctgttcatatgcacccagaaacgctg Introduction of NdeI site to β-lactamase (M) gene 
NdeI F gctacaaatgcccatatggaggtgcagctggtg Introduction of NdeI site to scFv163R4-A::Bla (M) gene 
Seq Bla R Gcacccaactgatcttcagc Sequencing primer for β-lactamase fusions 
SapI F cgtcttttactggctctactcgctaaccaaaccgg Removal of SapI in pLBAD2 backbone 






Table 2.5. Oligonucleotides for annealing and introduction of sequences. 
Primer name Sequence 5’ to 3’ Description 
DsbA Fa Tatgaaaaagatttggctggcgctggct Oligonucleotides coding for DsbA 
signal peptide DsbA Fb Ggtttagttttagcgtttagcgcatcggcggccgaggtgcag 
DsbA Ra Ctgcacctcggccgccgatgcgctaaac 
DsbA Rb gctaaaactaaaccagccagcgccagccaaatctttttca 
PelB F tatgaaatacctgctgccgaccgctgctgctggtctgctgctcctcgctgcccagccggcgatggccgccgaggtgcag Oligonucleotides coding for PelB 
signal peptide PelB R ctgcacctcggcggccatcgccggctgggcagcgaggagcagcagaccagcagcagcggtcggcagcaggtatttca 
Bla F tatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctgaggtgcag Oligonucleotides coding for Bla 
signal peptide Bla R ctgcacctcagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactca 
SapIXbaISapI F tatgtgaagagctctagagctcttctgccgaggtgcag Introduction of SapI cloning sites 
into pLBAD2∆SapI-STII-scFv163R4-
A::Bla vector 




The previously described protocol was used for the annealing of PelB F and PelB R, Bla F and Bla 
R, SapIXbaISapI F and SapIXbaISapI R. Annealed oligonucleotides were phosphorylated using the 
T4 Polynucleotide kinase (PNK), incubated at 37 °C for 30 min. T4 PNK was inactivated by 
incubation at 70 °C for 15 min. 
For the annealing of the DsbA signal peptide, DsbA Fa and DsbA Rb oligonucleotides were 
phosphorylated using T4 PNK. The phosphorylated DsbA Fa and Dsb Rb oligonucleotides were 
mixed with an equal molar amount of DsbA Fb and Dsb Ra. Once annealed, oligonucleotides were 
phosphorylated as described previously. 
 
2.4.4 Polymerase chain reaction (PCR) 
Colony PCR was used to amplify the flanking regions of expression vectors for the screening of 
sequence insertions using MyTaqTM HS Red Mix (Bioline). PCR reaction mixes were made up to 10 
μL in deionised water, the relevant buffer supplied by the manufacturer and oligonucleotide 
primers to a final concentration of 1 μM. PCR reaction mixes were inoculated with one single fresh 
colony. DNA amplification was performed in a Hypaid or a MJ Research PCT thermal cycle and 
cycling conditions are described in Table 2.6 (A). 
 
PCR was carried out using Finnzymes PhusionTM High-Fidelity DNA polymerase (Bioline) and 
reaction conditions were adjusted according to manufacturer’s instructions. Appropriate 
oligonucleotide primers were used at a final concentration of 1 μM. PCR reaction mixes were made 
up to 50 μL in deionised water and the relevant buffer supplied by the manufacturer. Cycling 
conditions are described in Table 2.6 (B).
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Table 2.6. PCR protocols used in the present study. 
A. Colony PCR 
Denaturation Annealing Extension No. of cycles Hold 
95 °C, 2 min   1  
95 °C, 10 sec 60 °C, 10 sec 72 °C, 10 sec 25  
  72 °C, 10 min 1  
    4°C 
 
B. Phusion PCR 
Denaturation Annealing Extension No. of cycles Hold 
98 °C, 30 sec   1  
98 °C, 10 sec x °C[1], 20 sec 72 °C, 30 sec 25  
   72 °C, 10 min 1  
    4 °C 
 
C. Touch-down PCR 
Denaturation Annealing Extension No. of cycles Hold 
98 °C, 30 sec   1  
1 °C decrease per 
cycle 
98 °C, 10 sec 68 °C, 20 sec 72 °C, 30 sec 10 
98 °C, 10 sec 58 °C, 20 sec 72 °C, 30 sec 20 
  72 °C, 5 min 1  
    4 °C 
 
D. One-step overlap extension PCR 
Denaturation Annealing Extension No. of cycles Hold 
98 °C, 30 sec   1 Generation of 
chimeric product 98 °C, 10 sec 67 °C, 20 sec 72 °C, 30 sec 5 
  72 °C, 5 min 1 
    RT 
98 °C, 30 sec   1 Amplification of 
chimeric product 98 °C, 10 sec 67 °C, 20 sec 72 °C, 30 sec 35 
  72 °C, 5 min 1 
    4 °C 
 
[1] Variable annealing temperatures used for the Phusion PCR protocol. The annealing 




Touch-down PCR was used to increase the specificity of PCR reactions when there was a high 
difference in the annealing temperature between primers. Initially, the annealing temperature 
was set several degrees above the estimated melting temperature (Tm) of the primers, and 
gradually decreased during the first cycles (1 °C per cycle). Once reached the optimal Tm, the PCR 
was then continued at this temperature. Cycling conditions are described in Table 2.6 (C). 
 
One-step overlap extension PCR, as described by Wei et al. (2012), was used to remove the extra 
amino acid residue, coding for alanine, located between the signal peptide and the scFv163R4 
from the following vectors: pLBAD2-STII-scFv163R4, pLBAD2-DsbA-scFv163R4 and pLBAD2-
PelB-scFv163R4. A summary of the protocol, using as example the generation of the STII-
scFv163R4-A, can be found described in Figure 2.1. The protocol consisted of two rounds of PCR 
reactions. In the first PCR, the DNA fragment was amplified using primers LBAD F and STII mut 
R/DsbA mut R/PelB mut R primers. In the second PCR, the DNA fragment was amplified using the 
STII mut F/DsbA mut F/PelB mut F and LBADtrc R primers. The two PCR fragments generated 
shared a homology of approximately 30 bp. Thus, the sequence at the 3’ end of the first PCR 
fragment was identical to the sequence at the 5’ end of the second fragment. PCR reactions were 
conducted using Phusion DNA polymerase and the protocol detailed in Table 2.6 (B). 
The two PCR fragments generated were mixed, in which the overlapping sequences of the PCR 
fragments generated served as primers to allow the extension of the chimeric product. After 5 
cycles, the two flanking primers, LBAD F and LBADtrc R, were used to amplify the full-length 




Fragment 1: STII signal peptide + scFv163R4 
(179 bp) 
Fragment 2: scFv163R4 
(940 bp) 
Amplify 1221…1402 using: 
LBAD F 
STII mut R 
Amplify 1368…2310 using: 
STII mut F 
LBADtrc R 
PCR PCR 
Overlap and amplify 
1…179 
Overlap and amplify 
1…940 
OVERLAP EXTENSION PCR 
(1087 bp) 
LBAD F 
STII S mut R 
STII S mut F 
LBADtrc R 
[...] [...] 
32 bp homology 
STII-scFv163R4-A 
Figure 2.1. One-step overlap extension PCR. Diagram showing the one-step overlap extension 
PCR method used for the removal of the extra amino acid residue, coding for alanine, located 




2.4.5 Restriction digestion 
Restriction digests were carried out using between 0.1 to 5 μg of plasmid DNA, restriction 
digestion buffer, 1 to 5 U of restriction endonuclease, and nuclease-free water up to the desired 
volume. Restriction digests were incubated at the temperature and for the duration specified by 
the manufacturer. Restriction endonucleases were purchased from New England BioLabs (NEB). 
 
2.4.6 Vector dephosphorylation 
When required, plasmid vectors were dephosphorylated using calf intestinal alkaline 
phosphatase (CIP) or shrimp alkaline phosphatase (rSAP), both purchased from NEB. The 
desphophorylation reaction was carried out according to the manufacturer’s recommendations. 
 
2.4.7 Agarose DNA electrophoresis 
DNA fragments were analysed using agarose gel electrophoresis. 2% to 0.8% (w/v) agarose 
solutions in 1x TAE buffer were dissolved by boiling in a microwave. Once cooled to 50 °C, 0.5 μg 
· mL-1 (v/v) of ethidium bromide were added before being poured into an electrophoresis tray. A 
DNA ladder (1 kb, Agilent Technologies) was used to facilitate DNA size estimation. DNA samples 
were mixed with 10x (v/v) loading dye before loading. Agarose gels were run at 100 V for 1 hour. 
 
2.2.1 Agarose gel extraction 
DNA fragments were excised from agarose gel using a scalpel and extracted using the QIAquick 
Gel Extraction Kit (Qiagen). 1 mM (w/v) guanosine was added to agarose solutions and running 
buffer of gels used for gel extraction, to protect the DNA from UV damage (Gründemann and 




T4 DNA ligase (Promega) was used to ligate DNA inserts and plasmid vectors. Volumes used for 
ligation reactions were calculated using a 3:1 insert-to-vector ratio. Ligation reactions were 
incubated for 3 h at room temperature or at 16 °C overnight, as described by the manufacturer. 
 
2.4.9 DNA and protein sequencing 
Vector modifications were confirmed by sequencing. DNA sequencing was carried out by Genewiz, 
formerly Beckman Coulter Genomics, with the exception of the sequencing of signal peptide 
libraries, which it was carried out by Eurofins Genomics. N-terminal sequencing, obtained from 
SDS-PAGE gel slices of protein samples was carried out by Alta Bioscience. 
 
2.4.10 Alignment of DNA and protein sequences 
The alignment of DNA and protein sequences was carried out using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/), a multiple alignment sequence tool (EMBL-EBI) 
using the default settings. The calculation of the grand average of hydropathicity (GRAVY) was 
carried out using ProtParam tool (http://web.expasy.org/protparam/) using the default settings. 
 
2.5 Bacterial transformation 
2.5.1 Preparation of electrocompetent cells 
A single colony was used to inoculate 10 mL of LB and grown overnight at 37 °C. The starter 
culture was used to inoculate a 1 L shake-flask containing 200 mL of LB and cultures were grown 
at 37 °C to an OD600 of 0.4 - 0.6. Bacteria were collected by centrifugation at 4,000 g at 4 °C for 15 
min and resuspended in 100 mL of ice-cold 10% (v/v) glycerol. After 1-hour incubation on ice, 
cells were harvested by centrifugation and resuspended in 50 mL of ice-cold 10% glycerol. The 
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centrifugation step was repeated and bacteria was resuspended in 25 mL of ice-cold 10% glycerol. 
Cells were collected by centrifugation, resuspended in 0.5 mL of ice-cold 10% glycerol, aliquoted 
in cryovials and snap-frozen in dry ice. Competent cells were at stored at –80 °C. 
 
2.5.2 Transformation of E. coli with plasmid DNA 
Plasmid DNA (10 to 100 ng) was mixed with electrocompetent cells (30 to 50 μL) and transferred 
to a chilled electrocuvette. Bacteria were transformed by electroporation using MicroPulser 
electroporation apparatus (Bio-Rad) with the default settings for E. coli (1.8 kV). Immediately 
after electroporation, bacteria were resuspended in 1 mL of LB and incubated for at least 1 hour 
at 37 °C, to allow bacteria to recover and express the antibiotic resistance gene. A serially diluted 
aliquot of the cell suspension was plated onto selective LB agar and incubated overnight at 37 °C. 
 
2.6 Construction of vectors 
2.6.1 Vectors for the expression of scFv163R4 
The ptrc2-STII-scFv163R4 vector was used as source of the gene coding for the STII-scFv163R4. 
The STII-scFv163R4 gene was amplified by PCR using the scFv F primer, which introduced an 
NdeI restriction site, and the scFv R primer using the PhusionTM High-Fidelity DNA polymerase. 
The PCR product was cloned into pCR®-Blunt vector using the PCR Zero Blunt® PCR Cloning Kit 
(Life Technologies).  
The pLBAD2 and the pCR®-Blunt-STII-scFv163R4 vectors were digested using NdeI and SalI-HF. 
Digested products were loaded in 0.8% agarose gel and run at 100 V for 1 hour. Subsequently, the 
digested pLBAD2 vector and the STII-scFv163R4 insert were extracted from the gel using the 
Qiagen gel extraction kit, ligated together using the T4 DNA ligase and transformed by 
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electroporation into E. shox competent cells. The pLBAD2-STII-scFv163R4 was extracted, purified 
and transformed by electroporation into E. coli BL21-A for expression studies. 
 
A diagram depicting of the protocol used for the generation of the pLBAD2-DsbA-scFv163R4 and 
pLBAD2-PelB-scFv163R4 vectors can be found in Figure 2.2. The pLBAD2-STII-scFv163R4 vector 
was digested using NdeI and PvuII and dephosphorylated using CIP. The dephosphorylated 
pLBAD2-STII-scFv163R4 and the phosphorylated annealed oligonucleotides (annealing protocol 
described in Section 2.4.3) coding for DsbA or PelB signal peptides were ligated using the T4 DNA 
ligase. The pLBAD2-DsbA-scFv163R4 and pLBAD2-PelB-scFv163R4 vectors were transformed 
into E. coli BL21-A for expression studies. 
 
The removal of the extra alanine at position +1 from the scFv163R4 was carried out by generating 
a PCR product without the 3 bp coding for the alanine by one-step extension PCR, as described in 
Section 2.4.4. 
The pLBAD2 vector and the PCR products coding for STII-scFv163R4-A, DsbA-scFv163R4-A and 
PelB-scFv163R4-A were digested using the NdeI and SalI-HF, purified and ligated using the T4 
DNA ligase. The pLBAD2-STII-scFv163R4-A, pLBAD2-DsbA-scFv163R4-A and pLBAD2-PelB-




Figure 2.2. Construction of pLBAD2-DsbA-scFv163R4 and pLBAD2-PelB-scFv163R4. 
Diagram showing the annealing of oligonucleotides coding for the signal peptide DsbA (A) and 
PelB (B), the plasmid backbone used for cloning, pLBAD2-STII-scFv163R4 and the two final 
plasmid vectors, pLBAD2-DsbA-scFv163R4 and pLBAD2-PelB-scFv163R4 (C). 
DsbA Fa DsbA Fb 
DsbA Rb DsbA Ra 
A. DsbA signal (annealed oligonucleotides): 
PelB F 
PelB R 
B.   PelB signal peptide (annealed oligonucleotides): 
C.   pBAD2-STII-scFv163R4 
REPLACE 
NdeI (1313) - PvuII (1395) 
REPLACE 
NdeI (1313) - PvuII (1395) 
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2.6.2 Vectors for the expression of β-lactamase and scFv163R4-A::β-lactamase 
For the generation of the pLBAD2-Bla-β-lactamase vector, the Bla-β-lactamase gene was amplified 
by Phusion PCR using the Bla SalI and Bla NdeI primers from the pUC18 vector, using the touch-
down PCR protocol described in Table 2.6 (C). The pLBAD2 and the Bla-β-lactamase gene were 
digested using NdeI and SalI, purified and ligated using T4 DNA ligase. 
For the generation of the pLBAD2-β-lactamase vector (M), the pLBAD2-Bla-β-lactamase vector 
was used as a template for the amplification of the β-lactamase gene, lacking the signal peptide. 
The β-lactamase gene was amplified using the Cyt Bla F primer, which introduces an NdeI site and 
the initiation codon (methionine), and the LBADtrc R primer, by Phusion PCR. The β-lactamase 
PCR product was cloned in the pCR®-Blunt vector using the PCR Zero Blunt® PCR Cloning Kit 
according to the manufacturer’s instructions. The pLBAD2 and the pCR®-Blunt-β-lactamase were 
digested using NdeI and SalI, purified and ligated using T4 DNA ligase. 
The pLBAD2-Bla-β-lactamase and the pLBAD2-β-lactamase (M) vectors were purified and 
transformed by electroporation into E. coli BL21-A for expression studies. 
 
For the generation of the pLBAD2-STII-scFv163R4-A::Bla vector, the pLBAD2-STII-scFv163R4-A 
and the pMK-T-scFv163R4-A-linker-Bla were digested using NotI and SalI and ligated using T4 
DNA ligase. The pLBAD2-DsbA-scFv163R4-A::Bla and pLBAD2-PelB-scFv163R4-A::Bla vectors 
were generated using the same protocol. 
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For the generation of the pLBAD2-Bla-scFv163R4-A::Bla vector, the pLBAD2-STII-scFv163R4-
A::Bla was digested using NdeI and PvuII and dephosphorylated using CIP. The dephosphorylated 
pLBAD2-STII-scFv163R4-A::Bla and the phosphorylated annealed oligonucleotides (annealing 
protocol described in Section 2.4.3) coding for Bla signal peptide were ligated using the T4 DNA 
ligase. 
The pLBAD2-scFv163R4-A::Bla (M) vector was generated using the pLBAD2-STII-scFv163R4-
A::Bla vector as a template for the amplification of the scFv163R4-A::Bla gene. The scFv163R4-
A::β-lactamase gene, lacking the signal peptide, was amplified using the NdeI F primer, which 
introduces an NdeI site and the initiation codon (methionine), and the Seq Bla R primer by 
Phusion-PCR. The pLBAD2-STII-scFv163R4-A::Bla and the scFv163R4-A::Bla PCR product were 
digested using NdeI and NotI. 
The pLBAD2-STII-scFv163R4-A::Bla, pLBAD2-DsbA-scFv163R4-A::Bla, pLBAD2-PelB-
scFv163R4-A::Bla, pLBAD2-Bla-scFv163R4-A::Bla and pLBAD2-scFv163R4-A::Bla (M) vectors 
were purified and transformed by electroporation into E. coli BL21-A for expression studies. 
 
2.6.3 Vectors for the β-lactamase screening assay 
Initially, the removal of SapI/BspQI restriction site present in the vector backbone of the pLBAD2-
STII-scFv163R4-A::Bla was required for the generation of the pLBAD2-SapIXbaISapI-scFv163R4-
A::Bla, intended for the cloning of signal peptide libraries using the type IIs restriction enzyme 
SapI/BspQI. 
For the generation of the pLBAD2∆SapI-STII-scFv163R4-A::Bla, the SapI restriction site was 
removed by amplifying the sequence upstream the STII-scFv163R4-A::β-lactamase by Phusion-
PCR using the SapI F and the STII mut R primers. The SapI F primer introduced a 1 bp change 
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which removed the restriction site. A second Phusion-PCR, was carried out using the pLBAD2-
STII-scFv163R4-A::Bla as a DNA template, using LBADilac F and the product of the previous PCR 
as primers, to amplify a larger fragment containing the BspEI restriction site, required for cloning 
purposes. The product of the second PCR, which includes the sequence of the ori, the AraC and the 
STII signal peptide, was then amplified using the LBADilac F and the STII mut R primer. A diagram 
illustrating the steps leading to the generation of the PCR product used for the removal of the 
SapI/BspQI restriction site can be found in Figure 2.3. 
The pLBAD2-STII-scFv163R4-A::Bla vector and the final PCR product was digested using BspEI 
and NdeI. The sequence of the pLBAD2ΔSapI-STII-scFv163R4-A::Bla vector was confirmed by 
DNA sequencing. 
For the generation of the pLBAD2-SapIXbaISapI-scFv163R4-A::Bla vector, the pLBAD2ΔSapI-STII-
scFv163R4-A::Bla was digested using NdeI and PvuII and dephosphorylated using CIP. The 
dephosphorylated pLBAD2ΔSapI-STII-scFv163R4-A::Bla and the phosphorylated annealed 
oligonucleotides (annealing protocol described in Section 2.4.3) coding for SapIXbaISapI were 
ligated using the T4 DNA ligase. 
The pLBAD2-SapIXbaISapI-scFv163R4-A::Bla vector was transformed by electroporation into E. 
shox used as expression vector for the introduction of the signal peptide libraries for the β-
lactamase screening assay. 
 
2.7 Generation and cloning of signal peptide libraries 
2.7.1 Error-prone PCR signal peptide library 
Error-prone PCR was used for the introduction of random mutations in the PelB signal peptide 
sequence. The sequence coding for PelB signal peptide flanked by SapI/BspQI restriction sites was 
generated by GeneArt and provided in the pMA-RQ-SapIPelBSapI vector.  
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STII mut R 
araBAD 
araBAD scFv163R4-A STII 
LBADilac F 





STII mut R 
araBAD 




Figure 2.3. Removal of SapI/BspQI restriction site from plasmid backbone. Diagram 
illustrating the steps leading to the generation of the PCR product used for the removal of the 




Initially, 1 μg of the pMA-RQ-SapIPelBSapI vector was digested with SfiI with the aim to linearize 
the plasmid. 0.1 ng of the linearized plasmid was used as a template for the error-prone PCR, using 
the GeneMorph II Random Mutagenesis kit (Agilent). The PCR product obtained, named Ep-PCR 
1, was used as template for a second error-prone PCR. Four sequential error-prone PCRs were 
carried out, obtaining the Ep-PCR 1, 2, 3 and 4 products, to achieve between 1 and 8 mutations 
per oligonucleotide. A pool containing equivalent amounts of each Ep-PCR product was also 
generated (Ep-PCR 5 pool), containing a mixture of signal peptide sequences with high and low 
number of mutations. The primers used and the cycling conditions are shown in Table 2.7. 
 
2.7.2 Twist signal peptide library 
A second signal peptide library also using PelB signal peptide sequence as a template was 
chemically synthesised by Twist Biosciences. As part of a Beta program, Twist Biosciences 
generated an oligonucleotide library that consisted on 10,000 oligonucleotides containing 
between 2 to 4 mutations per oligonucleotide. Once generated, the oligonucleotide pool was made 
double-stranded by PCR and amplified to a final concentration of 10 pM. 
 
2.7.3 Restriction digestion and ligation 
The expression vector, pLBAD2-SapIXbaISapI-scFv163R4-A::Bla, was digested using BspQI for at 
least 4 hours. The digested pLBAD2-SapIXbaISapI-scFv163R4-A::Bla and the signal peptide 
libraries, the EP-PCR products 1, 2, 3, 4 and 5 or the Twist oligonucleotides, were mixed and 
digested using BspQI for 1 hour, generating the cohesive ends required for cloning. Subsequently, 
the T4 DNA ligase and ATP to a final concentration of 1 mM was added, and further incubated for 








Primer name Sequence 5’ to 3’ Description 
Mut F gcatcaacgagctcgctcttctatg Primers for error-prone PCR 
Mut R gcacccaactgatcttcagc 
 
 
B. Error-prone PCR 
 
Denaturation Annealing Extension No. of cycles Hold 
95 °C, 2 min 55 °C, 20 sec 72 °C, 60 sec 1  
95 °C, 30 sec 55 °C, 20 sec 72 °C, 60 sec 25  
95 °C, 30 sec 55 °C, 20 sec 72 °C, 10 min 1  





2.7.4 Bacterial transformation and plasmid DNA extraction 
Ligation products were transformed into E. shox competent cells by electroporation. Immediately 
after, cells were resuspended in 950 μL of LB and incubated for at least 1 hour before being 
transferred to a 1 L shake-flask containing 200 mL of LB broth supplemented with 50 μg · mL-1 of 
kanamycin. After 12-18 hours, cells were harvested, lysed, and the plasmid DNA extracted using 
PureYield® Plasmid Maxiprep System. 
Plasmid DNA stocks were transformed into E. coli BL21-A, and after 1-hour incubation, the cell 
suspension was transferred into a 250 mL shake-flask, containing 50 mL of LB supplemented with 
50 μg · mL-1 of kanamycin and incubated overnight at 37 °C. 
For the generation of research cell banks (RCBs), glycerol to a final concentration of 20% (v/v) 
was added to the culture, aliquoted in cryovials, snap-frozen in dry ice and stored at –80 °C. 
 
2.7.5 Selection of signal peptide mutants based on ampicillin resistance 
After incubation, 0.5 mL aliquots of each culture were transferred to a universal bottle containing 
10 mL of LB supplemented with 50 μg · mL-1 of kanamycin, and grown at 37 °C. Once reached an 
OD600 of 1 - 2, cultures were serially diluted to obtain a concentration of 104 CFU · mL-1 and plated 
onto M-H agar containing 0.2% (v/v) arabinose, 50 μg · mL-1 of kanamycin and a concentration of 
ampicillin ranging from 3 to 1600 μg · mL-1. After 12 - 18 hours of incubation at 37 °C, colonies 
grown on ampicillin-supplemented plates were selected to be evaluated by β-lactamase assay. 
 
2.8 β-lactamase enzymatic assay 
The evaluation of β-lactamase activity in whole cells can be found described in Angus et al. (1982) 
and the β-lactamase enzymatic assay was carried out as described in O'Callaghan (1972).  
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2.8.1  Preparation of nitrocefin stock solution 
For the preparation of the nitrocefin stock solution, 10 mg of nitrocefin (Carbosynth) was initially 
dissolved in 200 μL DMSO, and then mixed with 9.8 mL of 10 mM Na-HEPES pH 7.0. The nitrocefin 
stock solution (1 mg · mL-1) was stored in the dark at -20 °C.  
The nitrocefin working solution (0.1 mg · mL-1) was prepared by the addition of 9 mL of Na-HEPES 
pH 7.0 to 1 mL of nitrocefin stock solution. 
 
2.8.2 Growth of bacterial cells 
For the preparation of inoculum plates, 96-well plates containing 200 μL of Terrific broth were 
inoculated with E. coli BL21-A clones selected for the β-lactamase enzymatic assay. The plates 
were incubated at 25 °C overnight. After incubation, 10 μL of the culture was transferred to a new 
96-well plate containing 200 μL of Terrific broth and incubated at 25 °C. After 2 hours of 
incubation, 0.02% (v/v) arabinose was added to the plates and β-lactamase activity was evaluated 
at different intervals post-inoculation. 
 
2.8.3 β-lactamase enzymatic assay 
For the evaluation of β-lactamase activity, 96-well plates were centrifuged at 1,218 g for 15 
minutes. After centrifugation, the supernatant was discarded or stored for further analysis. Cell 
pellets were resuspended in 10 mM Na-HEPES pH 7.0 to the appropriate dilution and 100 μL of 
nitrocefin working solution was added to the plates. Immediately after the addition of nitrocefin, 




2.8.4 Quantification of β-lactamase activity 
The initial velocity (slope) was calculated by linear regression and adapted to obtain an R ≥ 0.9 
using GraphPad® software. The initial velocity of the hydrolysis of nitrocefin by β-lactamase was 
compared between different cell samples. Data was normalised by OD600. The 5% uncertainty of 
the prediction of the slopes was also calculated. 
 
2.9 Bacterial methods 
2.9.1 Minimum inhibitory concentration experiments 
Mueller-Hinton (M-H) agar was used for all minimum inhibitory concentration (MIC) 
experiments. A single colony was used to inoculate a starter culture of 10 mL of LB supplemented 
with 50 μg · mL-1 of kanamycin and grown at 37 °C.  Once cultures reached an OD600 between 1 
and 2, cultures were serially diluted in PBS to achieve a concentration of cells between 105 and 
108 CFU · mL-1. Serially diluted cultures were plated onto M-H agar containing 50 μg · mL-1 of 
kanamycin, 0.2% (v/v) arabinose and different concentrations of ampicillin ranging from 3 to 
1600 μg · mL-1. Control plates contained only kanamycin or arabinose and kanamycin. Unless 
stated otherwise, plates were incubated at 37 °C for 12-18 hours.  
 
2.9.2 Recombinant protein production in shake-flasks 
Starter cultures were grown overnight from a single colony of bacteria in 10 mL of LB medium 
supplemented with 50 μg · mL-1 of kanamycin and incubated at 30 °C. Inoculum was added to 
achieve a starting OD600 of 0.1. Cultures were grown in 50 mL of TB dispensed in 250 mL baffled 
shake-flasks and kanamycin was added to a final concentration of 50 μg · mL-1. Unless stated 
otherwise, bacteria were aerobically grown in TB medium for all shake-flask experiments. 
Cultivation temperature varied with experiments. 
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2.9.3 Recombinant protein production in fed-batch fermentation 
Starter cultures were grown in 10 mL of LB medium supplemented with 50 μg · mL-1 of kanamycin 
at 25 °C. Once reached an OD600 of 2, starter cultures were used to inoculate a 1 L baffled shake-
flask containing 200 mL of LB supplemented with 50 mg · L-1 of kanamycin. Cultures grew at 25 
°C until they reached an OD600 between 4 and 6. 
Fed-batch fermentations for the production of rhTNFα were carried out in 7 L STR bench-top 
fermenters (Applikon), 5 L working volume, equipped with 3 rushton impellers and 4 baffles. The 
aeration rate was constant at 1 vvm and the dissolved oxygen (DO) was maintained above 20% 
being controlled by the stirrer speed. All fermentations started with an initial volume of 3 L of 
culture medium, sterilised within the bench-top fermenter by autoclaving for 20 minutes at 121 
°C. Once cooled, the batch salts were supplemented with the post-autoclave additions and trace 
element solutions. A volume of 2 L of feed solution was prepared and sterilised by filtration. The 
composition of the batch medium, post-autoclave additions, and feed solutions are described in 
Table 2.8. The pH was maintained at 6.8 by the addition of 5 M NaOH, as base, and 5 M HCl, as 
acid, for the Cobra Biologics recipe, and at 7.0 by the addition of 5 M HCl and 20% NH4OH for the 
Want et al. (2009) recipe. Polypropylene glycol (PPG) 2000, used as antifoam, was added when 
required to prevent blockage of the outlet filter. Fed-batch fermentations were monitored using 
BioXpert® software package (Applikon). 
Fed-batch fermentations for the production of the scFv163R4-A::β-lactamase or scFv163R4-A 
were carried out using the Ambr250 modular (TAP Biosystems, Sartorius Stedim). The Ambr250 
modular uses single-use 250 mL bioreactors equipped with 2 rushton impellers and 4 baffles. Fed-
batch fermentations were started with an initial volume of 150 mL of batch medium and 100 mL 
of feed solution. All the culture medium components were filter-sterilised and added to the vessel 
prior to inoculation. The composition of the batch medium, post-autoclave additions, and feed 
solutions were obtained from Want et al. (2009) and can be found described in Table 2.8. 
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Table 2.8. Composition of the culture medium used during fed-batch fermentation. 
 Cobra Biologics recipe Want et al. (2009) recipe 
Batch salts 13.3 g · L-1 K2HPO4 
4 g · L-1 (NH4)2SO4 
1.7 g · L-1 Citric acid 
10 g · L-1 Yeast extract 
0.16 mL · L-1 PPG 2000 
 
 
14 g · L-1 (NH4)2SO4 
35 g · L-1 Glycerol 
20 g · L-1 Yeast extract 
2 g · L-1 KH2PO4 
16.5 g · L-1 K2HPO4 
7.5 g · L-1 Citric acid 
1.5 mL · L-1 Conc. H3PO4 




1 mL · L-1 Trace elements solution A 
10 mL · L-1 Trace elements solution B 
10 g · L-1 Glycerol  
1.2 g · L-1 MgSO4 · 7H2O 
1 mL·L-1 50 mg · mL-1 
Kanamycin stock 
34 mL · L-1 Trace elements solution 
10 mL · L-1 1 M MgSO4 · 7H2O 
2 mL · L-1 1 M CaCl2 · 2H2O 




600 g · L-1 Glycerol  
5 g · L-1 MgSO4 · 7H2O 
50 g · L-1 Yeast extract 
10 g · L-1 KH2PO4 
2.1 g · L-1 K2HPO4 
1 mL· L-1 50 mg · mL-1 
kanamycin stock 
714 g · L-1 Glycerol 
30 mL· L-1 1 M MgSO4 · 7H2O 





5 g · L-1 Citric acid 
2 g · L-1 CoCl2 · 6H2O 
1.2 g · L-1 CuCl2 · 2H2O 
2.5 g · L-1 H3BO3 
2 g · L-1 Na2MoO4 · 2H2O 
1.2 g · L-1 MnCl2 · 4H2O 
 
3.36 g · L-1 FeSO4 · 7H2O 
0.84 g · L-1 ZnSO4 · 7H2O 
0.15 g · L-1 MnSO4 · H2O 
0.25 g · L-1 Na2MoO4 · 2H2O 
0.12 g · L-1 CuSO4 · 5H2O 
0.36 g · L-1 H3BO3 




6 g · L-1 FeSO4 · 7H2O 
0.84 g · L-1 EDTA · 2H2O 




The pH was kept at 7.0 by the addition of 10% NH4OH, as base, and 1 M HCl, as acid. PPG 2000 was 
used as antifoam. The dissolved oxygen (DO) was maintained above 20% being controlled by the 
stirrer speed. When the increase in the stirrer speed was not sufficient, pure oxygen was added to 
the air flow. Fed-batch fermentations were monitored using Ambr250 runtime software package 
(TAP Biosystems, Sartorius Stedim). 
For all the fed-batch fermentations, the inoculum was added to achieve a final OD600 of 0.1. The 
feed solution was started at different time points depending of the fermentation experiment, to 









+ 𝑚) × 𝑋0 ×  𝑉 ×  𝑒
𝜇𝑡 
 
Where F is the feed rate in L · h-1, S is the substrate concentration in the feed in g · L-1, μ is the 
required specific growth rate, YXS is the yield coefficient in g biomass per g carbon source, m is the 
maintenance coefficient, X0 is the biomass in g, V is the volume of the culture medium in L, μ is the 
specific growth rate and t is time. The yield coefficient (YXS) and the maintenance coefficient (m) 
used during the production of rhTNFα were obtained from the literature, corresponding to 0.22 
(Passarinha et al., 2009) and 0.025 (Babaeipour et al., 2007). The YXS and m used during the 
production of scFv163R4-A::β-lactamase or scFv163R4-A were 0.4  and 0.04 (Wyre, 2015). 
When cell paste was required for down-stream purification process, the culture was centrifuged 
at 3,500 g at 4 °C for 30 min. Pellets were resuspended in PBS and homogenised using a Dounce 
homogeniser. The homogenised cell paste was centrifuged at 7,500 g at 4 °C for 30 min. The cell 
paste was stored at -20 °C. 
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2.9.4 Measuring growth, cell viability and plasmid retention 
The optical density of cultures at 600 nm (OD600) was measured using an Amersham Pharmacia 
Ultrospec 1100 Pro UV/Visible Spectrophotometer using 10 mm path length plastic cuvettes. 
Culture samples were serially diluted in PBS and plated onto LB agar for cell culturability and 
plasmid retention evaluation. LB agar plates were incubated at 37 °C overnight. Colonies were 
transferred by replica plating to LB agar and LB agar supplemented with 50 mg · L-1 of kanamycin 
and incubated overnight at 37 °C. Colonies replica plated and grown on LB agar and LB agar 
supplemented with kanamycin were enumerated to assess plasmid retention. 
 
2.10 Protein production analysis 
2.10.1 Cell lysis by freeze-thaw 
A volume of bacterial culture equivalent to a 1 mL at an OD600 of 1 was centrifuged at 12,000 g in 
a microcentrifuge for 10 min. Pellets were resuspended in 250 μL of 50 mM Tris-HCl pH 8, 10 mM 
MgCl2 supplemented with 1 μL of benzonase (Merck Millipore) and incubated on ice, 
corresponding to the whole cell lysate protein sample. Subsequently, samples were incubated on 
ice for 30 min after the addition of 0.12 mg · mL-1 of lysozyme. A minimum of 3 cycles of freeze 
(ethanol/dry ice bath) and thaw (37 °C) were carried out on each sample. Samples were 
centrifuged at 12,000 g for 30 min. The supernatant obtained after centrifugation constituted the 
soluble protein fraction. Pellets were resuspended in 250 μL of 50 mM Tris-HCl pH 8, 10 mM 
MgCl2, constituting the insoluble protein fraction. 
 
2.10.2 Cell lysis by sonication 
As before, a volume of bacterial culture equivalent to a 1 mL at an OD600 of 1 was centrifuged at 
12,000 g in a microcentrifuge for 10 min. Pellets were resupended in 250 μL of 50 mM Tris-HCl 
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pH 8, 10 mM MgCl2 supplemented with 1 μL of benzonase and incubated on ice, corresponding to 
the whole cell lysate protein sample. Subsequently, cell samples were sonicated (Model 505 Sonic 
Dismembrator, Fisher Scientific) with 80% amplitude, for eight cycles (30 seconds on, 30 seconds 
off). After sonication, the cell lysate was centrifuged at 12,000 g for 30 minutes. The supernatant 
obtained after centrifugation constituted the soluble protein fraction and the insoluble pellet was 
resuspended in 250 μL of 50 mM Tris-HCl pH 8, 10 mM MgCl2. 
The efficiency of cell lysis protocols was evaluated by quantifying the activity of the host protein 
β-galactosidase in the soluble and insoluble protein fractions, as efficient cell lysis should result 
in the complete release of β-galactosidase into the soluble fraction. 
 
2.10.3 Periplasmic extraction by cold osmotic shock 
A volume of bacterial culture equivalent to a 1 mL at an OD600 of 1 was centrifuged at 12,000 g in 
a microcentrifuge for 10 min. Pellets were resupended in 150 μL of ice-cold spheroplast buffer 
(100 mM Tris-HCl pH 8, 500 mM sucrose, 0.5 mM EDTA) and stored on ice for 5 min. 50 μL were 
transferred to a new centrifuge tube, constituting the whole lysate protein sample. The cell 
suspension was centrifuged at 12,000 g for 1 minute. The supernatant was discarded and the 
pellet was resuspended in 100 μL of ice-cold deionised water. Ice-cold MgCl2 was added to a final 
concentration of 20 mM, the cell suspension was centrifuged at 12,000 g for 2 minutes. The 
supernatant was extracted, constituting the periplasmic protein fraction, and the pellet was 
resuspended in 100 μL of 10 mM Tris-HCl pH 8, containing the spheroplast protein fraction. If 
required, the soluble and insoluble protein fractions were separated by sonication or freeze and 




2.10.4 Periplasmic extraction by modified cold osmotic shock 
As before, a volume of bacterial culture equivalent to a 1 mL at an OD600 of 1 was centrifuged at 
12,000 g in a microcentrifuge for 10 min. The cell pellet was resuspended in 50 μL of ice-cold 
spheroplast buffer (100 mM Tris-HCl pH 8.2, 500 mM sucrose, 5 mM EDTA). Subsequently, 0.8 mg 
· mL-1 of lysozyme were added, followed by the addition of 50 μL of ice-cold deionised water. The 
cell suspension was incubated for 5 minutes. MgSO4 to a final concentration of 20 mM was added 
before centrifugation at 12,000 g for 2 minutes. The supernatant constituted the periplasmic 
protein fraction, and the pellet was resuspended in 100 μL of 100 mM Tris-HCl pH 8, constituting 
the spheroplast protein fraction. This periplasmic extraction protocol was obtained from Albiniak 
et al. (2013). 
The efficiency of the periplasmic extraction protocols was evaluated by measuring the activity of 
the host protein alkaline phosphatase and quantifying the DNA content in the periplasmic and 
spheroplast protein fractions; as alkaline phosphatase activity should be only detected in the 
periplasmic fraction and DNA should only be present in the spheroplast fraction. 
 
2.10.5 Analysis of recombinant proteins by SDS-PAGE 
4-12% Bis-Tris NuPAGE SDS-PAGE gels were generally used to evaluate the production of 
recombinant proteins from samples obtained from shake-flask and fermentation experiments. 7 
μL of protein sample were mixed with 2 μL 4x (v/v) NuPAGE sample buffer (Life Technologies) 
and 1 μL 10x (v/v) NuPAGE reducing agent (Life Technologies), and heated for 10 min at 70 °C. 
SDS-PAGE gels run for at least 45 minutes at 200 V. 
For 18% Tris-Glycine SDS-PAGE gels, samples were prepared by mixing 4 μL of protein sample 
with 5 μL 2x (v/v) Tris-Glycine sample buffer (Life Technologies) and 1 μL 10x (v/v) NuPAGE 
reducing agent. Samples were heated for 2 min at 85 °C. SDS-PAGE gels run for 3 hours at 125 V. 
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SDS-PAGE gels were stained using the Colloidal Blue Staining kit (Life Technologies) according to 
the manufacturer’s instructions. SDS-PAGE gels were stained for a minimum of 3 hours and 
destained with deionised water for a minimum of 12 hours. 
 
2.10.6 Analysis of recombinant proteins by western blot 
Transfer buffer was prepared by the addition of 20x (v/v) NuPAGE transfer buffer  (Life 
Technologies), 10% (v/v) methanol  and 1 mL · L-1 (v/v) NuPAGE antioxidant. Blotting pads, filter 
papers and nitrocellulose membranes were submerged in transfer buffer before assembly of the 
transfer chamber. 
For western blots, SDS-PAGE gels were transferred to a 0.2 μm or 0.45 μm nitrocellulose 
membrane (Life Technologies) using the Xcell II blot module (Life Technologies). SDS-PAGE gels 
were transferred at 25 V for 1 h. Membranes were incubated in blocking buffer, 5% (w/v) 
skimmed milk (Sigma-Aldrich) in PBS for at least 1 hour.  
Primary antibodies used for western blot included the following: an anti-TNFα antibody (ab9635, 
Abcam) using 1:2500 dilution was used for the detection of rhTNFα; an anti-myc antibody (R950-
25, Life Technologies) using a 1:5000 dilution for the detection of the scFv163R4, the scFv163R4-
A and the scFv163R4-A::β-lactamase; and an anti-β-lactamase antibody (sc-66062, Santa Cruz 
Biotechnology) using a 1:500 dilution for the detection of β-lactamase. All the blots were 
incubated with the appropriate dilution of primary antibody in blocking buffer for at least 1 h. 
After washing with PBST buffer (0.05% (v/v) Tween-20 in PBS), blots were incubated with an 
anti-mouse IgG antibody conjugated with horseradish peroxidase (HRP) (A4416, Sigma-Aldrich) 
as a secondary antibody, using 1:5000 dilution in blocking buffer. After 1 hour incubation, blots 
were washed three times with PBST for 10 mins. Western blots were developed using 3,3′,5,5′-
tetramethylbenzidine (TMB) liquid substrate for horseradish peroxidase (HRP) (Sigma-Aldrich). 
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2.10.7 Quantification of recombinant proteins from SDS-PAGE 
AlphaEase® software (Alpha Innotech) was used to calculate the percentage of recombinant 
protein from total cell protein (TCP). Images were subjected to peak-to-peak background 
subtraction using the default settings. The percentage of soluble and insoluble recombinant 
protein was calculated by the software package. Densitometry was used to quantify the 
concentration of recombinant proteins and the ratio of protein in the soluble/insoluble or 
periplasmic/spheroplast protein fractions, being these results considered just an estimation of 
the protein concentration. 
rhTNFα reference material (10602-HNAE, Life Technologies) was used to quantify the 
concentration of rhTNFα by densitometry from culture samples. A standard curve was generated 
by loading different concentrations of rhTNFα reference material in a SDS-PAGE gel. The 
concentration of rhTNFα from culture samples was quantified using a standard curve with the 
AlphaEase® software. The rhTNFα yields were calculated based on the final OD600 of the culture. 
 
2.11 Protein purification methods 
2.11.1 Purification of rhTNFα 
The purification of rhTNFα obtained from fermentation studies was carried out by Dr Nicola 
Barison at Cobra Biologics. A proprietary purification protocol was used for the purification of 
rhTNFα, involving the disruption of cell paste obtained by fermentation by the use of a high-
pressure cell disruption system (Constant systems). rhTNFα was purified from the clarified 
soluble protein fraction by a process comprising an ammonium sulphate precipitation, followed 




2.11.2 Purification of scFv163R4-A 
The scFv163R4-A was extracted from culture medium samples obtained from fermentation 
experiments. Culture medium samples were clarified by using a 0.2 μm filter to remove cell debris. 
Imidazole and NaCl to a final concentration of 40 mM and 500 mM respectively, were added to the 
clarified culture medium sample, as a sample pre-treatment. 
A 1 mL prepacked Nickel Sepharose 6 Fast Flow column (HisTrap FF, GE Healthcare), was used 
for the purification of the scFv163R4-A. Initially, the HisTrap FF column was washed with 5 
column volumes (CV) of deionised water to remove any traces of the ethanol used for the storage 
of the column.  The HisTrap column was equilibrated with 5 CV of binding buffer (PBS pH 7.2, 40 
mM imidazole, 500 mM NaCl). 10 mL of the pre-treated culture medium sample, containing 40 
mM imidazole and 500 mM NaCl, were loaded onto the column. Subsequently, the column was 
washed with 15 CV of binding buffer. The scFv163R4-A was eluted with 5 CV elution buffer A (PBS 
pH 7.2, 100 mM imidazole, 500 mM NaCl). A second elution step was carried out with 5 CV elution 
buffer B (PBS pH 7.2, 500 mM imidazole, 500 mM NaCl). 
 
2.12 TNFα cytotoxic assay 
2.12.1  Cell culture 
The C3H mouse fibrosarcoma cell line L929, a cell line sensitive to the activity of TNFα, was used 
to evaluate the activity of rhTNFα produced by fed-batch fermentation. L929 cells were grown in 
T225 flasks with Eagle’s minimum essential medium (EMEM) supplemented with 10% (v/v) fetal 
bovine serum, 2 mM glutamine and 0.1% NaHCO3 (Gibco, Thermo Fisher Scientific). The cell 
culture was incubated at 37 °C and 5% CO2 for three days. Once they had reached confluency, cells 
were passaged to a new T225 flask, by removing the culture medium and washing the cells with 
PBS. Trypsin was used to facilitate the detachment of the L929 cells in combination with gentle 
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shaking or rocking of the flask. Once detached from the surface of the flask, cells were resuspended 
in fresh EMEM medium and distributed to a new T225 flask. 
 
2.12.2 Cytotoxic assay 
The cytotoxic bioassay was carried out following the protocol described by McGee and Clemens 
(1994). For the cytotoxic bioassay, 6 · 104 cells per well were added to 96-well plates and 
incubated at 37 °C and 5% CO2 for 18 hours. Once the cells had grown to reach confluency, the 
media was exchanged for fresh EMEM media containing actinomycin D, a cell growth inhibitor. 
The pre-treatment with actinomycin D prevents cell proliferation, sensitising the L929 cells to the 
activity of rhTNFα, which leads to apoptosis and subsequent cell death (McGee and Clemens, 
1994). Different concentrations of rhTNFα reference material, purified rhTNFα or buffer were 
added to the plates and incubated for 12 - 18 hours at 37 °C and 5% CO2. The activity of rhTNFα 
was quantified by the ability of the cells to uptake a staining solution containing crystal violet. The 
staining solution was subsequently released upon treatment with SDS, a detergent used to lyse 
the cells. Cells affected by the activity of rhTNFα were unable to uptake the crystal violet solution, 
which is removed during the washing steps. 
After incubation, the culture medium was discarded and 200 μL staining solution (0.5% (v/v) 
crystal violet, 20 % (v/v) methanol) was added to each well. After 10 minutes, the staining 
solution was discarded by inversion of the plate, and the excess of staining was removed by the 
addition of deionised water. L929 cells were solubilised by the addition of 100 μL of 1% (w/v) 
sodium dodecyl sulphate (SDS) solution. The plate was incubated for 1 hour on a rotary shaker at 




2.12.3 Interpretation of results 
Initially, the mean absorbance for each triplicate set of standards or samples assayed was 
calculated; using the mean absorbance data, the percentage of cytotoxicity was calculated using 
the following formula: 
 
% 𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 = [1 −
(𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑜𝑟 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑)
(𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 0 𝑈 · 𝑚𝐿−1 𝑇𝑁𝐹𝛼)
 ] 𝑥 100 
 
A TNFα standard curve was constructed by plotting the percentage cytotoxicity values for the 
TNFα standards using the GraphPad Prism® software. The standard curve was used to calculate 
the concentration of TNFα which generates a cytotoxicity value of 50% (LD50). The specific activity 
was calculated assuming that 1 U · mg-1 of TNFα specific activity is defined by the quantity of TNFα 
that produces 50% of the lysis of L929 cells. 
 
2.13 Enzyme-linked immunosorbent assay (ELISA) for the evaluation of the activity of 
scFv163R4-A 
MaxiSorp flat-bottom 96-well plates (Thermo Fisher Scientific) were coated with β-galactosidase 
(Sigma-Aldrich) to a final concentration of 10 μg · mL-1 in PBS. The plate was incubated at 4 °C 
overnight. 
After incubation, the coating solution was discarded and 200 μL of blocking buffer (5% (w/v) milk 
in PBS) was added to the plates, to block the remaining protein-binding sites. After 2 hours of 
incubation, plates were washed three times with PBS. 
Cell extracts, obtained by sonication using the protocol described in Section 2.10.2, including 
total cell lysates, periplasmic and spheroplast protein fractions and culture medium samples were 
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added to the plate. The purified scFv163R4-A (protocol described in Section 2.11.2), used as 
standard reference material, was also added to the plates. Samples were diluted across the plate 
with blocking buffer and incubated for 1 hour at room temperature. 
After 1 hour, plates were washed with PBS three times. The primary antibody, an anti-myc HRP-
conjugated antibody (R951-25, Life Technologies), was diluted to 1:5000 in blocking buffer and 
added to the plates. Plates were incubated for 1 hour at room temperature. After incubation, 96-
well plates were washed three times with PBS.  
100 μL TMB liquid substrate for ELISA (Sigma-Aldrich) was added to each well of the plate. After 
10 minutes, 100 μL of 1 M H2SO4 was added to stop the reaction. The OD450 was measured to 
quantify the amount of scFv163R4-A present in each sample. 
The concentration of the scFv163R4-A was quantified by interpolating the result from the 
unknown samples using a sigmoidal standard curve generated with data obtained from the 
purified scFv163R4-A, used as standard. GraphPad® was used to calculate the concentration of 













Production of recombinant human tumour necrosis factor α 





The development of novel fermentation strategies that allow the production of soluble and high 
quality recombinant proteins is still a major area of interest for the biotechnology industry. Today, 
a large number of human proteins have been produced using E. coli as a host organism, such as 
insulins, interleukins or growth factors, among others. With the aim to exploit different 
approaches to favour the production of soluble recombinant proteins by high-cell-density 
fermentation, a pharmaceutically relevant protein, human tumour necrosis factor α (hTNFα), was 
selected as model protein for these studies. 
Tumour necrosis factor α is a cell signalling protein involved in systemic inflammation and its 
primary role is the regulation of immune cells. It is produced mainly by macrophages, but it can 
also be produced by other cell types, such as CD4+ lymphocytes, neutrophils, eosinophils, natural 
killer cells, mast cells, or neurons. TNFα is able to induce fever, apoptotic cell death, inflammation, 
cachexia and to inhibit viral replication and tumourigenesis. 
In human cells, TNFα is primary produced in two biologically active forms, as a 233 amino acid 
transmembrane protein arranged in homotrimers, which is released from the membrane by 
proteolytic cleavage; and a soluble 51 kDa trimeric form. The soluble form of TNFα is an 
homotrimer comprising 17 kDa protomers forming a “jelly roll” structure. rhTNFα is currently on 
the market, being approved by the EMA in 1999, for the treatment of soft-tissue sarcoma and 
commercialised by Boehringer Ingelheim, under the trade name of Beromun® (tasonermin). 
The aim of the present work was the optimisation of the fermentation conditions for the 
production of recombinant human tumour necrosis factor α (rhTNFα) using E. coli BL21-T7, 
aiming to achieve a production of 5 g ∙ L-1 of rhTNFα for a target OD600 of 100. The expression of 
rhTNFα was driven by the T7 expression system, comprising the T7 RNA polymerase under the 
control of the arabinose promoter. Different conditions for the production of rhTNFα were 
evaluated by shake-flask studies, with the aim to favour the accumulation of the recombinant 
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protein in a soluble and functional form, minimising its accumulation as aggregates, in inclusion 
bodies (IBs). Factors affecting bacterial growth, such as medium supplements, temperature, 
induction point or inducer concentration were investigated in an attempt to improve the yield of 
soluble and active protein. Optimal conditions selected during shake-flask experiments were used 
for the production of rhTNFα by fed-batch fermentation at 5 L scale. rhTNFα produced during 
fermentation was recovered from the soluble protein fraction, purified and tested for activity. 
 
3.2 Results 
3.2.1 Selection of culture medium for the optimisation of the production of rhTNF α 
The expression of rhTNFα was driven by the T7 arabinose-inducible expression system, using E. 
coli BL21-T7 as host organism. A detailed description of this expression system can be found in 
Chapter 1, section 1.2.2.2. Initially, a shake-flask experiment was carried out comparing two 
culture media formulations, Luria broth (LB) and Terrific broth (TB), with the aim to evaluate the 
growth and the production of rhTNFα using the T7 expression system. 
Shake-flask experiments were carried out with E. coli BL21-T7 carrying the empty vector (pLT72) 
or the vector containing the sequence coding for rhTNFα (pLT72-TNFα) under induced and non-
induced conditions in both culture media. Cultures were grown at 30 °C and induced with 0.2% 
arabinose at an OD600 of 1. Upon induction, casamino acids were added to the culture medium to 
a final concentration of 2%, as it has been reported than the addition of casamino acids could have 
a beneficial effect on the production of rhTNFα (Oshima et al., 1989). Cell culturability, as an 
indication of cell viability, was evaluated by serially diluted culture samples being plated onto 
non-selective LB agar and incubated at 37 °C. After 12-18 hours of incubation, colonies were 
replica-plated onto non-selective and selective LB agar to evaluate plasmid retention. All shake-
flask experiments were carried out in duplicate. 
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In general terms, cultures grown in LB and TB showed some differences in terms of growth, cell 
viability and plasmid retention. Cultures growing in LB reached higher cell densities than those 
growing in TB, reaching a final OD600 of 14 under non-induced conditions (Figure 3.1 A). In 
contrast, non-induced cultures growing in TB only reached an OD600 of 10, after 24 hours of 
growth. Induced cultures, either carrying the empty vector (pLT72) or the vector containing the 
sequence coding for rhTNFα (pLT72-TNFα), generally reached a lower cell density and grew 
slower than non-induced cultures. The addition of arabinose had a negative effect on growth, not 
only in cultures producing rhTNFα, but also in cultures carrying the empty vector. Where the 
expression of rhTNFα was induced by the addition of arabinose, cultures growing either in LB or 
TB, reached an OD600 of 12 and 15, after 24 hours of growth. 
The slower growth of cultures expressing rhTNFα can be explained as the result of the high 
metabolic burden imposed on the cells during RPP, by the diversion of cell resources to the 
overproduction of rhTNFα. The negative effect on cell growth observed upon addition of 
arabinose was not only the result of protein production since this effect was also observed on 
cultures carrying the empty vector (Figure 3.1 A). This effect could not be caused by the addition 
of arabinose itself, as arabinose has not been reported to have a toxic effect, in contrast with other 
commonly used inducers, such as IPTG, where toxicity has been reported (Choi et al., 2000; 
Kosinski et al., 1992). In addition, arabinose cannot be utilised as a carbon source by E. coli BL21-
T7, as the arabinose utilisation genes, araB, araA and araD, have been completely or partially 
removed from bacterial chromosome, being replaced by the gene coding for the T7 RNA 
polymerase. 
A decrease in the number of colony forming units (CFU) after 2 hours of induction was also 
observed, being higher in cultures growing in LB than in TB (Figure 3.1 B). The CFU recovered 24 
hours after inoculation reaching 109 to 1010 CFU · mL-1. No loss of cell culturability was observed 





















Figure 3.1. Selection of culture medium for the optimisation of the production of rhTNFα. 
E. coli BL21-T7 cultures carrying the empty vector (pLT72) or the vector coding for rhTNFα 
(pLT72-TNFα) were grown at 30 °C; half of cultures were induced with 0.2% arabinose at an 
OD600 ≈ 1 (blue arrow). The OD600 of the culture was measured at intervals post-inoculation (A). 
Serial dilutions of culture samples at 2.5 h, 4.5 h and 24 h post-inoculation were plated onto non-
selective LB agar to assess the cell viability after induction (B). Colonies were replica-plated onto 
kanamycin-supplemented LB agar to reveal plasmid retention (C). Data shown are single values 
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Plasmid retention remained around 100% for all cultures 2 hours after induction, but it decreased 
drastically for arabinose-induced cultures 24 hours post-inoculation. Induced cultures producing 
rhTNFα (pLT72-TNFα) showed a plasmid retention of only 10 to 35% after 24 hours of growth 
(Figure 3.1 C). The overgrowth of plasmid-free cells could explain the unexpectedly high cell 
density after 24 hours of growth observed in rhTNFα producing cultures for both culture media 
(Figure 3.1 A), as a result of the low plasmid retention. 
The production of rhTNFα was evaluated by SDS-PAGE in samples collected at time points pre- 
and post-induction (Figure 3.2). Bacterial pellets obtained after 24 hours of growth were 
fractionated using the freeze-thaw method to obtain the soluble and insoluble protein fractions. 
Lysozyme was added to facilitate cell lysis, and it can be observed in the soluble and insoluble 
protein fractions, running as a 14.3 kDa protein. The quantity of rhTNFα increased over the time 
after induction, reaching a maximum of 20% of the total cell protein (TCP) after 24 hours of 
growth for both culture media evaluated. After 24 hours of growth, a high quantity of rhTNFα was 
accumulated in a soluble form, accounting for 55% of the total rhTNFα. 
An unexpected protein band was also detected in samples obtained from induced cultures, both 
cultures carrying the empty vector (pLT72) and the vector containing the sequence coding for 
rhTNFα (pLT72-TNFα), which accounted for a 10% of TCP in samples obtained from cultures 
carrying the empty vector (pLT72). It was hypothesised that this unknown protein could be the 
product of the kanamycin resistance gene, aminoglycoside 3' phosphotransferase (APH). APH 
catalyses the addition of phosphate from ATP to the 3'-hydroxyl group of a 4,6-disubstituted 
aminoglycoside, disrupting the mechanism of action of the antibiotic kanamycin. APH has a 
molecular weight of 31 kDa, similar to the unknown protein present in samples obtained from 
induced cultures (Figure 3.2). The lack of terminator sequences downstream the multiple cloning 
site of the backbone of the vector pLT72 may have allowed the read-through by the T7 RNA 




Figure 3.2. Accumulation of rhTNFα in cultures grown in LB and TB culture media. SDS-
PAGE gels showing the accumulation of rhTNFα from whole cell lysates from cultures grown in 
LB (A) and TB (B) media. Samples were obtained from induced and non-induced cultures 
carrying the empty vector (pLT72) or the vector encoding rhTNFα (pLT72-TNFα). The quantity 
of rhTNFα is expressed as a percentage of whole cell protein at the bottom of the gel. Samples 
collected at 24 hours were also fractionated to obtain soluble (sol) and insoluble (ins) protein 
fractions facilitated by the addition of lysozyme (orange square). The overproduction of the 
presumptive APH (orange circle) can be observed in all the samples obtained from cultures 


















































































               5%  10% 13% 15% 20% 



















In general terms, both culture media showed similar results in terms of growth, cell viability, 
plasmid retention and protein production. Both media formulations were found adequate for 
growth experiments. As a result of the improved buffering capacity of terrific broth, this medium 
formulation was selected as standard for all the shake-flask studies carried in the present work. 
 
3.2.2 Effect of inducer concentration on the production of rhTNFα 
As observed in the previous experiment; growth arrest, low cell viability and plasmid loss 
occurred upon recombinant protein induction. The previous experiment was carried out using a 
concentration of arabinose of 0.2%, the standard concentration recommended by the literature to 
induce the arabinose promoter (Guzman et al., 1995; Terpe, 2006). However, this concentration 
may be too high due to the amplification loop of the T7 RNA polymerase, resulting in a high 
metabolic burden, compelling the cells to lose the plasmid. Therefore, different concentrations of 
arabinose, ranging from 1% to 0.002%, were evaluated to determine whether the use of lower 
concentrations of arabinose could have a beneficial effect on growth and rhTNFα production. 
Cultures were grown at 30 °C in terrific broth supplemented with casamino acids to a final 
concentration of 2%. The expression of rhTNFα was induced with a concentration of arabinose 
ranging from 1% to 0.002% at an OD600 of 1. Cells carrying the empty vector (pLT72) or the vector 
coding for rhTNFα (pLT72-TNFα) under non-induced conditions were used as controls. 
The use of different concentrations of arabinose had a great effect on bacterial growth, and overall, 
all the induced cultures grew slower upon induction than non-induced cultures (Figure 3.3 A). As 
expected, the use of high concentrations of arabinose (1 to 0.02%) induced growth arrest but 
reaching a higher cell density than the control cultures, probably as a result of the overgrowth of 
plasmid-free cells. Growth arrest was not observed for cultures induced with the lowest 






   













pLT72 (non-induced) pLT72-TNFα (non-induced)
pLT72-TNFα (1%) pLT72-TNFα (0.2%)
pLT72-TNFα (0.05%) pLT72-TNFα (0.02%)
pLT72-TNFα (0.002%)
Figure 3.3. Effect of inducer concentration on the production of 
rhTNFα. Cultures grown at 30 °C were induced with a concentration of 
arabinose ranging from 1% to 0.002%, at OD600 ≈ 1 (blue arrow). The 
OD600 was measured at intervals post-inoculation (A). Plasmid retention, 
after 24 hours of growth, was obtained by replica-plating colonies in 
selective and non-selective LB agar (B). SDS-PAGE showing the 
accumulation of rhTNFα from whole cell lysates obtained 24 h post-
inoculation (C). Cultures carrying the empty vector (pLT72) and the 
vector coding for rhTNFα (pLT72-TNFα) under non-induced conditions 
were used as control. Data shown are mean values from two replica flasks 



































In terms of plasmid retention, the use of high concentrations of arabinose led to a drastic plasmid 
loss (Figure 3.3 B). Cultures induced with 1%, 0.2%, 0.05% and 0.02% showed a plasmid 
retention lower than 20%, after 24 hours of growth. In contrast, cultures induced 0.002% 
arabinose showed a great improvement on plasmid retention, with more than 80% of the cells 
being plasmid-positive at the end of the experiment. 
The production of rhTNFα was shown to be similar independently of the concentration of 
arabinose used to induce protein production, being the lowest concentration of arabinose 
evaluated, 0.002%, enough to fully induce the T7 expression system (Figure 3.3 C). In addition, 
the majority of the rhTNFα was found to be accumulated in the soluble protein fraction for all the 
induced cultures. 
Overall, a concentration of arabinose 100 times lower than the standard recommended 
concentration seems to be sufficient to completely induce protein production without entailing a 
reduction in the production of rhTNFα, but minimising the growth arrest and plasmid loss.  
 
3.2.3 Effect of induction point on the production of rhTNFα 
The effect of different induction points was evaluated by shake-flask. However, growth 
experiments carried out in shake-flasks only support growth up to a maximum OD600 of 10 to 20, 
limiting the evaluation of the effect of the induction point to low cell densities. Mid (induction at 
OD600 of 20-40) and late (induction at OD600 of 60-80) induction need to be evaluated by fed-batch 
fermentation. 
Cultures were grown in terrific broth supplemented with 2% casamino acids at 30 °C and induced 
with 0.2% arabinose. Three different induction points were evaluated at OD600 of 0.5, 2 and 3. The 
addition of inducer in previous studies was carried out at an OD600 of 1, and therefore, this 
induction point was not included in this experiment. 
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In general terms, there were no drastic differences between cultures induced at different cell 
densities (Figure 3.4 A). Cultures induced at an OD600 of 0.5 grew slower upon protein induction 
but reached a higher cell density than cultures induced at an OD600 of 2 or 3.  No significant 
differences in cell culturability were observed (data not shown). 
In terms of production of rhTNFα, there were no significant differences between the three 
induction points evaluated in this experiment, showing similar levels of production of rhTNFα 
after 2 and 4 hours of induction (Figure 3.4 B). 
Overall, an early induction of the production of rhTNFα did not have a negative effect on growth, 
however, further evaluations of the effect of different induction points at high cell densities need 
to be evaluated by fed-batch fermentation. Since no major differences after protein induction were 
observed, induction at an OD600 of 0.5 was selected as optimal for the following experiments. 
 
3.2.4 Effect of temperature on the production of rhTNFα 
The effect of different cultivation temperatures on RPP was also evaluated, since it has been 
reported than low cultivation temperatures favour the accumulation of some recombinant 
proteins in a soluble form (Alfasi, 2011; Sevastsyanovich et al., 2010). Previous shake-flask 
experiments were carried out at 30 °C and therefore, the effect of an increase of the cultivation 
temperature to 37°C and a decrease to 25 °C were evaluated during this experiment. The effect of 
the temperature was not only evaluated in terms of rhTNFα yield but more specifically, in terms 
of soluble and insoluble protein product being accumulated. 
Cultures were grown in terrific broth supplemented with 2% casamino acids and grown at a 
temperature of 37 °C, 30 °C or 25 °C. The expression of rhTNFα was induced by the addition of 





















pLT72 (non-induced) pLT72-TNFα (non-induced) pLT72-TNFα OD600=0.5
pLT72-TNFα OD600=2 pLT72-TNFα OD600=3
Figure 3.4. The effect of induction point on the production of rhTNFα. E. coli BL21-T7 
carrying the empty vector (pLT72) or the vector coding for rhTNFα (pLT72-TNFα) were grown 
at 30 °C under induced and non-induced conditions. Cultures were induced with 0.2% arabinose 
at an OD600 of 0.5, 2 or 3 (arrows). The OD600 was measured at intervals post-inoculation (A). 
SDS-PAGE gel showing the accumulation of rhTNFα from whole cell lysates before induction (BI), 
2 hours and 4 hours after induction (B). Data shown are mean values from two replica flasks for 
OD600, error bars are ±1 standard deviation. 
B) 
        M       BI     2h     4h      BI     2h    4h      BI    2h     4h     24h  24h      


























































The cultivation temperature had a significant effect on the proportion of rhTNFα accumulated in 
the soluble and insoluble protein fractions (Figure 3.5). Cultures grown at the highest cultivation 
temperature evaluated, 37 °C, showed that only 54% of the total rhTNFα produced was being 
accumulated in a soluble form, the remaining 46% was accumulated in the insoluble fraction.  At 
30 °C, 73% of total rhTNFα was found accumulated in the soluble fraction. A further decrease to 
25 °C showed an increase of the production of soluble rhTNFα up to 90% (Figure 3.5 A). The 
differences in the accumulation of rhTNFα in the soluble and insoluble fractions for the three 
temperatures was evaluated by SDS-PAGE and quantified by densitometry (Figure 3.5 B). 
In general terms, the correct folding of rhTNFα was favoured by lower cultivation temperatures, 
helping to slow down the protein synthesis rate, allowing the correct folding of the recombinant 
protein and avoiding the formation of IBs (Sahdev et al., 2008; Sevastsyanovich et al., 2010). 
 
3.2.5 Effect of temperature and inducer concentration on the production of rhTNFα 
The effect of different inducer concentrations in combination with lower cultivation temperatures 
was further evaluated with the aim to understand whether the plasmid loss observed in cultures 
producing rhTNFα could be minimised. Cultures were grown in terrific broth supplemented with 
2% casamino acids at 25 °C. The expression of rhTNFα was induced by the addition of different 
concentrations of arabinose, ranging from 0.2% to 0.001%, at an OD600 of 0.5. 
Cultures carrying the empty vector (pLT72) and the vector containing the sequence coding for 
rhTNFα (pLT72-TNFα) under non-induced conditions were used as control, achieving plasmid 
retention of >95% after 24 hours of growth (Figure 3.6 A). Cultures induced with 0.2% arabinose, 
showed a plasmid retention lower than 10%. In contrast, plasmid loss was minimal, accounting 




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Figure 3.5. Effect of temperature on the production of rhTNFα. SDS-PAGE gel showing the 
accumulation of the rhTNFα in the soluble and insoluble fraction 4 hours after induction. 
Cultures were induced with 0.2% arabinose and grown at 37 °C, 30 °C or 25 °C. Samples were 
fractionated to obtain the soluble (sol) and insoluble (ins) cell fractions (A). The accumulation 
of rhTNFα in the soluble and insoluble fraction was quantified by densitometry from SDS-PAGE 
gels by comparing the accumulation of rhTNFα in the soluble and insoluble protein fractions. 
Data shown here are single values.  
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Figure 3.6. The effect of temperature and inducer concentration on the production of 
rhTNFα. Plasmid retention of cultures carrying the empty vector (pLT72) or the vector coding 
for rhTNFα (pLT72-TNFα) grown at 25 °C under non-induced conditions or induced at an OD600 
≈ 0.5 with different concentrations of arabinose, ranging from 0.2% to 0.001%. Serial dilutions 
of culture samples obtained after 24 hours of growth were plated onto non-selective LB agar. 
Colonies were replica plated onto kanamycin-supplemented LB agar to reveal the plasmid 
retention. Data shown are mean values from two replica flasks, error bars are ±1 standard 
deviation (A). SDS-PAGE gel showing the accumulation of rhTNFα from whole cell lysates after 



































to 0.001%. A decrease in the temperature to 25 °C showed a great improvement when compared 
with previous results obtained at 30 °C, when plasmid retention was lower than 85% and 20%, 
for cultures induced with 0.002% and 0.02% arabinose, respectively (Figure 3.3 C). The use of a 
concentration of arabinose of 0.001% showed a high plasmid retention; however, the 
accumulation of rhTNFα was also lower than when higher concentrations of arabinose were used, 
not being enough to fully induce the T7 promoter (Figure 3.6 B). 
Lower cultivation temperatures in combination with a lower concentration of arabinose 
minimised the physiological stress imposed on the cells, favouring the plasmid retention and 
enhancing the production of soluble rhTNFα. As cell stress can often be found associated with 
plasmid loss, the reduction of the inducer concentration also had a positive effect on plasmid 
maintenance. In fed-batch fermentations, the low plasmid retention can severely affect the final 
product yield, since only a small percentage of the cell population is still carrying the plasmid, and 
therefore producing the recombinant protein of interest (Palomares et al., 2004). Overall, a 
temperature of 25 °C and a concentration of arabinose of 0.005% were found to be optimal for the 
production of rhTNFα. 
 
3.2.6 Selection of the optimal vector design to minimise the overproduction of APH 
Initial experiments carried out to evalute the production of rhTNFα in E. coli showed the 
overproduction of an unknown protein of approximately 31 kDa, for cultures grown under 
induced conditions (Figure 3.2). It was considered that this unknown protein could be the protein 
that confers resistance to kanamycin, the aminoglycoside-3'-phosphotransferase (APH).  
To confirm whether this unknown protein was APH and to reduce its hypothetical 
overproduction, several vector variations were generated. The main objective was to minimise 
the read-through of the T7 RNA polymerase by the addition of terminator sequences downstream 
the sequence coding for the rhTNFα (pLT72-T7t-TNFα) or by changing the orientation of the 
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kanamycin gene (pLT72-T7tKan-TNFα). The addition of two different terminator sequences 
flanking the kanamycin resistance gene was also evaluated (pLT72-T7tKanT2t-TNFα) (Figure 
3.7). The new plasmid vectors were kindly generated by Dr Steven Williams at Cobra Biologics. 
Cultures were grown in terrific broth supplemented with 2% casamino acids at 30 °C and induced 
with 0.02% arabinose at an OD600 of 0.5. These growth conditions are known to show high plasmid 
loss and were selected to determine whether the new vector designs could show an improvement 
in plasmid retention. Non-induced cultures carrying the empty vector (pLT72) and the vector 
coding for rhTNFα (pLT72-TNFα) were used as controls. 
The control cultures, carrying the empty vector (pLT72) and the vector coding for rhTNFα 
(pLT72-TNFα) under non-induced conditions showed a plasmid retention of 100% after 24 hours 
of growth (Figure 3.8 A). As observed in previous experiments, the original vector design (pLT72-
TNFα) showed a plasmid retention lower than 25%. In contrast, cultures carrying the vector 
containing the T7 terminator showed a slight improvement in plasmid retention, with more than 
45% of the cells being plasmid-positive. Plasmid retention was further improved in cultures 
carrying the vector with the T7 terminator and the sequence coding for the kanamycin resistance 
gene in the opposite orientation to the TNFα gene (pLT72-T7tKan-TNFα), with a plasmid 
retention of 80%. Plasmid retention was lower for the plasmid containing both the T7 and the T2 
terminators sequences (pLT72-T7tKanT2t-TNFα), with a plasmid retention of 45.7%. 
There were no significant differences between the four plasmid vector backbones in terms of 
production of rhTNFα (Figure 3.8 B). The accumulation of APH can be observed in cultures 
carrying the original vector design. A slight decrease in the accumulation of this protein can be 
observed in cultures carrying the vector containing the T7 terminator sequence, and even further 
reduced for vectors with the sequence coding for kanamycin resistance gene in reverse 






Figure 3.7. Diagram of the new vector designs to minimise the overproduction of APH. The 
original vector design (pLT72-TNFα) was modified in three ways: with the T7 terminator 
sequence downstream the sequence coding for the TNFα gene (pLT72-T7t-TNFα); with the T7 
terminator sequence and the sequence coding for the kanamycin resistance gene in the opposite 
orientation to the TNFα gene (pLT72-T7tKan-TNFα); and with the T7 terminator sequence and 
the sequence coding for the kanamycin resistance gene in reverse orientation and the T2 
terminator sequence (pLT72-T7tKanT2t-TNFα). 



































































Figure 3.8. Selection of optimal vector design to minimise the overproduction APH.  
Cultures carrying the empty vector (pLT72) and the different vectors coding for rhTNFα 
(pLT72-TNFα, pLT2-T7t-TNFα, pLT72-T7tKan-TNFα and pLT72-T7tKanT2-TNFα), were grown 
at 30 °C under non-induced and induced conditions. Arabinose to a final concentration of 0.02% 
was added at an OD600 ≈ 0.5.  Plasmid retention, after 24 hours of growth, was evaluated by 
replica plating onto non-selective LB agar. Data shown are mean values from two replica flasks, 
error bars are ±1 standard deviation (A). SDS-PAGE gel showing the accumulation of rhTNFα 
and APH from whole cell lysates at 4 h, 8 h, 10 h, 12 h and 24 h post-inoculation (B). 
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Overall, the vector design carrying the T7 terminator sequence and the sequence coding for the 
kanamycin resistance gene in reverse orientation (pLT72-T7tKan-TNFα) showed a lower 
accumulation of APH and a higher plasmid retention than other vector designs. This result 
confirmed that the high plasmid loss observed in previous experiments was caused by the 
overproduction of both proteins, rhTNFα and APH. 
 
3.2.7 Production of rhTNFα by fed-batch fermentation 
The optimal conditions for the production of rhTNFα defined during shake-flask studies were 
transferred to 5 L scale to produce rhTNFα using a bench-top fermenter. All the fed-batch 
fermentations were carried out at a temperature of 25 °C and cultures were induced with 0.005% 
arabinose at an OD600 of 0.5, since these conditions were found to be optimal to reduce plasmid 
loss and favour the accumulation of soluble rhTNFα. The dissolved oxygen was maintained at 20% 
by continuous increments of the stirrer speed and unless stated otherwise, the pH was kept at 6.8 
by the addition 5 M NaOH, as a base, and 5 M HCl, as acid. 
Initial fermentations were carried out using a semi-defined culture medium composition obtained 
from Cobra Biologics supplemented with 2% casamino acids and using the original design of the 
vector (pLT72- TNFα). Subsequent fermentations were carried out using the improved design of 
the vector (pLT72-T7tKan-TNFα) with and without casamino acid supplementation.  A second 
semi-defined culture medium composition published in Want et al. (2009) was also evaluated. 
Glycerol was used as a carbon source for both culture media recipes. The addition of the feed 
solution was started 10 hours after inoculation, upon glycerol consumption, as determined by a 
previous batch fermentation. The specific growth rate (μ) was maintained at 0.1 h-1 being 




a) Production of rhTNFα by fed-batch fermentation using BL21-T7 pLT72-TNFα 
The production of rhTNFα was evaluated by fed-batch fermentation at 5 L scale. The culture was 
grown in a semi-defined culture medium obtained from Cobra Biologics supplemented with 2% 
casamino acids, at a temperature of 25 °C and induced with 0.005% arabinose at an OD600 of 0.5. 
The culture grew constantly after inoculation reaching a final OD600 of 90.8 after 48 hours of 
growth (Figure 3.9 A). Initially, the culture grew exponentially reaching a maximum specific 
growth rate of 0.5 during the first hours after inoculation. The growth rate was reduced after 6 
hours of growth, ranging from 0.05 to 0.1 h-1 between 24 and 48 hours post-inoculation. The CFU 
increased during the first hours of growth, followed by a decrease after induction, from 8 · 108 
CFU · mL-1 to 108 CFU · mL-1 (Figure 3.9 B). The CFU recovered after 24 hours, showing a 
continuous increase between 24 and 48 hours post-inoculation. 
Plasmid retention was almost 100% during the first hours of growth, followed by a decrease 
between 11 and 24 hours, from 97% of the cells being plasmid-positive to only 42% (Figure 3.9 
B). After 24 hours, the culture was overtaken by plasmid-free bacteria and plasmid retention was 
further decreased. Only 2% of the bacteria still carried the plasmid 48 hours post-inoculation. 
The concentration of rhTNFα increased over the time after induction reaching a maximum of 25% 
of the total cell protein (TCP) between 24 and 32 hours of growth, however, it decreased to 20% 
at the end of the fermentation (Figure 3.10 A). The biomass increase observed between 32 and 
48 hours of growth did not correspond with an increase in the concentration of rhTNFα, as a result 
of the low plasmid retention observed at the end of the fermentation. The low plasmid retention 
and lower accumulation of rhTNFα, caused a loss of productivity which affected the final protein 
yield. The production of APH can be noticed after 9 hours of growth since the original plasmid 
vector (pLT72-TNFα) was used for this fermentation. 
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OD600 Specific growth rate
A) 
Figure 3.9. Fed-batch fermentation for the production of rhTNFα using BL21-T7 pLT72-
TNFα. E. coli BL21-T7 carrying the vector coding for rhTNFα (pLT72-TNFα) was grown at 25 °C 
and induced with 0.005% arabinose at an OD600 ≈ 0.5 (blue arrows). The OD600 was measured at 
intervals post-inoculation and the specific growth rate was calculated. The addition of feed 
solution was started 10 hours post-inoculation (orange arrow) (A). Serial dilutions of culture 
samples post-inoculation were plated onto non-selective LB agar to assess the cell viability after 
induction. Colonies were replica plated onto kanamycin-supplemented LB agar to reveal the 
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Figure 3.10. Production of rhTNFα by fed-batch fermentation using BL21-T7 pLT72-TNFα. 
The production of rhTNFα from whole cell lysates obtained before induction (3h) and after 
induction (5h, 9h, 11h, 24h, 26h, 28h, 30h, 32h and 48h post-inoculation). The quantity of 
rhTNFα is expressed as a percentage of whole cell protein at the bottom of the gel (A). Samples 
obtained from whole cell lysates were disrupted to obtain the soluble (sol) and insoluble (ins) 
cell fractions facilitated by the addition of lysozyme, to reveal the proportion of soluble and 
insoluble rhTNFα (B). The accumulation of aminoglycoside-3'-phosphotransferase (APH) can 
also be observed in samples taken post-induction. A sample obtained from a culture carrying the 
empty vector (pLT72) after 24 hours of growth was used as a negative control.  
122 
  
rhTNFα was mainly accumulated in the soluble fraction, being only 8% of TCP accumulated in the 
insoluble fraction, concluding that the optimisation of the fermentation conditions successfully 
yielded a soluble product (Figure 3.10 B). However, further studies need to be carried out to 
improve plasmid retention during fed-batch fermentations. The rhTNFα in the soluble fraction 
was purified and used to evaluate the activity of the rhTNFα (Sections 3.2.9 and 3.2.10). 
 
b) Production of rhTNFα by fed-batch fermentation using BL21-T7 pLT72-T7tKan-TNFα 
The previous fermentations showed a high accumulation of soluble rhTNFα, however, the final 
yield of rhTNFα was affected by the severe plasmid loss observed at the end of the fermentation. 
The improved vector design containing the T7 terminator and the gene coding for the kanamycin 
resistance gene in reverse orientation (pLT72-T7tKan-TNFα) was used with the aim to improve 
plasmid retention and minimise the overproduction of APH. Cultivation conditions were the same 
as described for the previous fermentation. 
The culture grew steadily reaching a final OD600 of 68 after 48 hours of growth (Figure 3.11 A). 
The CFU also increased over the time, with small fluctuations over the course of the fermentation, 
reaching 1.8 · 1010 CFU · mL-1 after 48 hours of growth. Plasmid retention was almost 100% 
(Figure 3.11 B), in contrast with the previous fermentation carried out with the original vector 
design (pLT7-TNFα), where only 2% of the cells were plasmid-positive at the end of the 
fermentation (Figure 3.9 B). 
The concentration of rhTNFα increased after induction, reaching an accumulation of 20% of total 
cell protein after 48 hours of growth. The protein was accumulated mainly in the soluble fraction, 
and less than 20% was accumulated in an insoluble form (Figure 3.12). The use of the improved 
vector design helped to minimise plasmid loss during fermentation, avoiding the overgrowth of 
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Figure 3.11. Fed-batch fermentation for the production of rhTNFα using BL21-T7 pLT72-
T7tKan-TNFα. E. coli BL21-T7 carrying the vector coding for rhTNFα (pLT72-T7tKan-TNFα) 
was grown at 25 °C and induced with 0.005% arabinose at an OD600 ≈ 0.5 (blue arrows). The 
OD600 was measured at intervals post-inoculation and the specific growth rate was calculated. 
The addition of feed solution was started 10 hours post-inoculation (orange arrow) (A). Serial 
dilutions of culture samples post-inoculation were plated onto non-selective LB agar to assess 
the cell viability after induction. Colonies were replica plated onto kanamycin-supplemented LB 











































Figure 3.12. Production of rhTNFα by fed-batch fermentation using BL21-T7 pLT72-
T7tKan-TNFα. The production of rhTNFα from whole cell lysates obtained before induction (5h) 
and after induction (9h, 11h, 24h, 27h, 30h, 33h and 48h). Samples obtained from whole cell 
lysates were disrupted by sonication to obtain the soluble (sol) and insoluble (ins) protein 
fractions, to reveal the proportion of soluble to insoluble rhTNFα. A sample obtained from a 
culture carrying the empty vector (pLT72) after 24 hours of growth was used as a negative 
control. The quantity of rhTNFα is expressed as a percentage of whole cell protein at the bottom 
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c) Production of rhTNFα by fed-batch fermentation using BL21-T7 pLT72-T7Kan-TNFα 
without the addition of casamino acids 
In order to comply with the current Good Manufacturing Practices (cGMP), which provides the 
minimum requirements that a manufacturer must meet to ensure that the product is of high 
quality and do not represent any health risk to the consumer, any animal-derived products need 
to be excluded from the culture medium. Casamino acids are a mixture of amino acids and small 
peptides obtained from acid hydrolysis of casein and therefore, they should be removed from the 
medium final formulation. 
With the objective of developing a fermentation process fully compliant with the cGMP guidelines, 
casamino acids were removed from the semi-defined culture medium obtained from Cobra 
Biologics. The medium was supplemented with 14 g · L-1 of ammonium sulphate and 0.3 g · L-1 of 
calcium chloride, since the concentration of ammonium and calcium could be limiting due to the 
absence of casamino acids. Cultivation conditions were the same as described in Section 3.2.7 B. 
The biomass concentration increased steadily over the time reaching a final OD600 of 72. However, 
no great increase in the cell biomass was observed between 32 and 48 hours and the growth rate 
decreased from 0.1 h-1 to 0.01 h-1 between 24 and 48 hours post-inoculation (Figure 3.13 A). The 
CFU also increased over time reaching 5.1 · 1010 CFU · mL-1. The plasmid retention was almost 
100% during the first hours post-inoculation, however, it decreased to 35% after 24 hours, and 
less than 10% of the cells still carried the plasmid at the end of the fermentation (Figure 3.13 B). 
The concentration of rhTNFα increased over the time after induction, reaching a maximum of 26% 
of TCP. A decrease in the concentration of rhTNFα was observed between 32 and 48 hours of 
growth, from 25% to 18%, which could be the result of proteolysis or the high plasmid loss 
observed at the end of the fermentation. The concentration of rhTNFα in the soluble fraction was 
lower than in previous fermentations, and only 50% of the rhTNFα produced was found in the 
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Figure 3.13. Fed-batch fermentation for the production of rhTNFα using BL21-T7 pLT72-
T7tKan-TNFα without casamino acids. E. coli BL21-T7 carrying the vector coding for rhTNFα 
(pLT72-T7tKan-TNFα) was grown at 25 °C and induced with 0.005% arabinose at an OD600 ≈ 0.5 
(blue arrows). The OD600 was measured at intervals post-inoculation and the specific growth rate 
was calculated. The addition of feed solution was started 10 hours post-inoculation (orange arrow) 
(A). Serial dilutions of culture samples post-inoculation were plated onto non-selective LB agar to 
assess the cell viability after induction. Colonies were replica plated onto kanamycin-supplemented 




Figure 3.14. Production of rhTNFα by fed-batch fermentation using BL21-T7 pLT72-
T7tKan-TNFα without casamino acids. The production of rhTNFα from whole cell lysates 
obtained before induction (3h) and after induction (5h, 9h, 24h, 28h, 30h, 32h and 48h). Samples 
obtained from whole cell lysates were disrupted by sonication to obtain the soluble (sol) and 
insoluble (ins) protein fractions, to reveal the proportion of soluble to insoluble rhTNFα. A 
sample obtained from a culture carrying the empty vector (pLT72) after 24 hours of growth was 
used as a negative control. The quantity of rhTNFα is expressed as a percentage of whole cell 






























Sol     Ins 
  25%  26% 20%  20% 20%  18%  
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d) Production of rhTNFα by fed-batch fermentation using BL21-T7 pLT72-T7tKan-TNFα with 
an alternative culture medium formulation 
Previous fermentations showed an improvement of plasmid retention by using the improved 
vector design, however, a dramatic plasmid loss was still observed when casamino acids were 
removed from the culture medium. As casamino acids are not compliant with the cGMP guidelines, 
a different semi-defined culture medium composition reported to be used by the other 
biopharmaceutical companies (Hodgson et al., 2011), was evaluated with the aim to develop a 
fully compliant GMP fermentation process for the production rhTNFα. 
The culture was grown in a semi-defined culture medium obtained from Want et al. (2009), using 
glycerol as carbon source. The culture was grown at 25 °C and induced with 0.005% arabinose at 
an OD600 of 0.5. The pH was maintained at 7.0 by the addition of 20% NH4OH, as a base, and 5 M 
HCl, as acid. The addition of the feed solution was started after 10 hours of inoculation and the 
specific growth rate was maintained at 0.1 h-1 by the use of an exponential feeding profile. 
The culture grew constantly after induction reaching a final OD600 of 111 after 48 hours of growth 
(Figure 3.15 A). The growth rate increased during the first hours of growth reaching a maximum 
of 0.8 h-1 and decreasing drastically to 0.1 h-1, after 24 hours of growth. Cell culturability was high 
through the fermentation, and the CFU increased steadily with the increase cell biomass. The 
plasmid retention was almost 100% through the fermentation (Figure 3.15 B). 
The concentration of rhTNFα increased over time after induction, reaching a maximum of 30% of 
the total cell protein between 24 and 30 hours of growth. At the end of the fermentation, rhTNFα 
constituted 25% of the TCP, being primarily accumulated in the soluble fraction (Figure 3.16).  
Overall, this fermentation process successfully generated a greater yield of rhTNFα than previous 
fermentations, being the majority accumulated in a soluble form, minimising the plasmid loss by 












































































CFU · mL-1 % Plasmid retention
A) 
Figure 3.15. Fed-batch fermentation for the production of rhTNFα using BL21-T7 pLT72-
T7tKan-TNFα with the alternative culture medium formulation. E. coli BL21-T7 carrying the 
vector coding for rhTNFα (pLT72-T7tKan-TNFα) was grown at 25 °C and induced with 0.005% 
arabinose at an OD600 ≈ 0.5 (blue arrows). The OD600 was measured at intervals post-inoculation 
and the specific growth rate was calculated. The addition of feed solution was started 10 hours 
post-inoculation (orange arrow) (A). Serial dilutions of culture samples post-inoculation were 
plated onto non-selective LB agar to assess the cell viability after induction. Colonies were replica 







Figure 3.16. Production of rhTNFα by fed-batch fermentation using BL21-T7 pLT72-
T7tKan-TNFα with the alternative culture medium formulation. The accumulation of 
rhTNFα from whole cell lysates obtained before induction (5h) and after induction (9h, 11h, 24h, 
27h, 30h, 33h and 48h). Samples obtained from whole cell lysates were disrupted to obtain the 
soluble (sol) and insoluble (ins) cell fractions facilitated by the addition of lysozyme, to reveal 
the proportion of soluble to insoluble rhTNFα. A sample obtained from a culture carrying the 
empty vector (pLT72) after 24 hours of growth was used as a negative control. The quantity of 
rhTNFα is expressed as a percentage of whole cell protein at the bottom of the gel. 
























Sol     Ins 
  16%  26% 30%  30%  27%  25%  
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3.2.8 Evaluation of results obtained from fermentation studies 
A summary of the results obtained from fed-batch fermentations experiments can be found in 
Table 3.1. Results shown in this table are the result of single fermentation experiments. Data 
corresponding to OD600 and wet cell weight (WCW) was measured at the end of each fermentation. 
For fermentation 1, the dry cell weight (DCW) was measured and compared to the WCW to obtain 
the ratio of DCW:WCW, which it was found to be approximately 1:4. This ratio was used to 
calculate the DCW for fermentations 2, 3 and 4. The yield of rhTNFα was determined using 
densitometry from SDS-PAGE gels of whole cell lysates and calculated to obtain the final rhTNFα 
yield for total biomass generated at harvest. 
Initial fermentations showed a high biomass production, with a final OD600 of 90.8, equivalent to 
a wet cell weight of 85 g · L-1, and a high accumulation of rhTNFα, accounting for 20% of the total 
cell protein content. The accumulation of rhTNFα, corresponded to a final yield of 3.82 g · L-1 of 
rhTNFα, the majority being accumulated in a soluble form. However, low plasmid retention was 
observed with only 2% of the cells being plasmid positive after 48 hours of growth, affecting the 
final rhTNFα yield. It was considered that the suboptimal plasmid design allowed the read-
through of the T7 RNA polymerase, which resulted in the overexpression of the kanamycin 
resistance gene, could be a contributing factor to the high plasmid loss observed during fed-batch 
fermentations (Table 3.1, fermentation 1). This problem was partially overcome by the use of 
an improved plasmid design containing the T7 terminator sequence and by changing the 
orientation of the kanamycin gene. By using the improved vector design, the plasmid retention 
was maintained at 100% through the whole fermentation process achieving a similar 
accumulation of rhTNFα to previous fermentations. In contrast with the previous fermentation, 
the biomass production was slightly lower, reaching a final OD600 of 68, equivalent to 106 g · L-1 of 








Table 3.1. Summary of results obtained at harvest from fermentation studies carried out for the production of rhTNFα. 
 Fermentation 1 Fermentation 2 Fermentation 3 Fermentation 4 
E. coli strain BL21-T7 BL21-T7 BL21-T7 BL21-T7 
Plasmid name pLT72-TNFα pLT72- T7tKan-TNFα pLT72-T7tKan-TNFα pLT72-T7tKan-TNFα 







(Want et al., 2009) 
Casamino acids Yes Yes No No 
Temperature 25 °C 25 °C 25 °C 25 °C 
Arabinose concentration 0.005% 0.005% 0.005% 0.005% 
Induction point OD600 ≈ 0.5 OD600 ≈ 0.5 OD600 ≈ 0.5 OD600 ≈ 0.5 
Plasmid retention 2% 100% 9.4% 100% 
Final OD600 90.8 68 72 111 
Wet cell weight (WCW) 85 g · L-1 [1] 106 g · L-1 96 g · L-1 133 g · L-1 
Dry cell weight (DCW) 20.4 g · L-1 26.5 g · L-1 [2] 29.4 g · L-1 [2] 33.25 g · L-1 [2] 
% of rhTNFα of TCP[3] 20 % 20% 18% 25% 
% of soluble rhTNFα 92% 80% 50% 70% 
rhTNFα yield 3.82 g · L-1 1.92 · g L-1 1.84 · g L-1 5.35 g · L-1 
[1] WCW could be lower than expected due to cell paste loses due to resuspension and washing steps of the bacterial pellets.  
[2] Dry cell weight calculated from wet cell weight using a 1:4 ratio (1 g · L-1 of wet cell weight equivalent to 0.25 g · L-1 of dry cell weight). 




WCW could be the result of cell filamentation, evaluated by microscopy, which may have resulted 
in the underestimation of biomass based on the OD600 measurement (Vizcaino Caston, 2012). The 
lower WCW obtained for fermentation 1 was probably caused by the loss of cell paste during the 
resuspension and washing of the cell pellet; step that was not carried out for fermentation 2, 3 
and 4. 
As previous fermentations were carried out using a culture medium supplemented with casamino 
acids, a fed-batch fermentation in absence of those was also carried out to provide Cobra Biologics 
with a cGMP compliant fermentation process. Similar to previous fermentation, a final OD600 of 72 
was obtained, equivalent to 96 g · L-1 of WCW. Unfortunately, a lower yield of rhTNFα was 
obtained, accounting for 18% of the total cell protein, which corresponded to only 1.84 g · L-1 
rhTNFα. Also a high plasmid loss was observed and less than 10% of the cells still carried the 
plasmid after 48 hours of growth (Table 3.1, fermentation 3).  
As it became obvious than the addition of casamino acids provided an essential component to the 
medium, a new medium formulation extracted from Want et al. (2009) was evaluated for the 
production of rhTNFα. The evaluation of a new culture medium was found to be easier than 
attempting the supplementation of Cobra’s culture medium recipe with different amino acid, 
vitamin or trace element solutions, an extremely time-consuming approach. With the new 
medium formulation, a higher biomass was obtained, with a final OD600 of 111. High plasmid 
retention was also achieved with 100% of the cells being plasmid-positive after 48 hours of 
growth. A higher accumulation of rhTNFα was also obtained, accounting for 25% of the total cell 
protein being rhTNFα (Table 3.1, fermentation 4). 
In general terms, all the fed-batch fermentations carried out showed a high concentration of 
rhTNFα in a soluble form. The new medium recipe evaluated showed the most promising results, 
with a final yield of rhTNFα of 5.35 g · L-1, being majorly accumulated in a soluble form. The 
production of rhTNFα was similar to protein titres obtained by other manufacturing companies, 
134 
 
such as Fujifilm Diosynth, that for a target OD600 of 100 reported a final yield of rhTNFα ranging 
between 1.5 and 6.5 g · L-1, depending on the expression system used (Hodgson et al., 2011). 
 
3.2.9 Purification of rhTNFα produced by fed-batch fermentation 
The purification of rhTNFα was carried out by Dr Nicola Barison at Cobra Biologics. A proprietary 
purification protocol was used for the purification of rhTNFα. Briefly, the cell paste obtained from 
fermentation studies was resuspended and cells were disrupted by the use of a high-pressure cell 
disruption system. rhTNFα was purified from the soluble fraction. The final product presented a 
purity greater than 95%, as quantified by densitometry from SDS-PAGE gels (Figure 3.17). 
 
3.2.10 Evaluation of the activity of rhTNFα produced by fed-batch fermentation 
The final goal of any fermentation process is the production of high quantities of a soluble and 
active product, and protein solubility is often a good indication of activity. However, this statement 
is not always true, and recombinant proteins can be accumulated in a soluble form but with an 
incorrect conformation, which limits or abolishes its activity. The C3H mouse fibrosarcoma cell 
line L929, a cell line sensitive to the activity of TNFα, was used to evaluate the activity of rhTNFα 
produced by fed-batch fermentation. 
rhTNFα produced by fed-batch fermentation, corresponding to the bacterial paste purified by Dr 
Nicola Barison at Cobra Biologics, was evaluated for activity (Table 3.1, fermentation 1). The 
TNFα cytotoxicity assay is based on the ability of L929 cells to uptake a staining solution 
containing crystal violet. Cells affected by the activity of rhTNFα are unable to uptake the staining 
solution, which is removed during the washing steps. In contrast, cells not exposed to rhTNFα are 
able to uptake the staining solution, which subsequently released upon treatment with SDS. The 











































Figure 3.17. Final material obtained after the purification of rhTNFα. The rhTNFα was 
accumulated mainly in the monomeric form. Traces of the rhTNFα dimer and trimer can also be 
detected by SDS-PAGE (A) and western blot (B). Traces of other contaminant proteins can also 
be observed (green circles). The final product presented a purity greater than 95%. The western 
blot was developed using an anti-TNFα antibody, which confirmed the identity of the monomer, 




The activity of rhTNFα was calculated as the percentage of cytotoxicity, which is calculated by 
comparing the absorbance of the cells exposed to the activity of rhTNFα and the absorbance of 
the cells exposed to the buffer, which is used as blank for the cytotoxic assay (0% cytotoxicity). In 
repeated assays following the protocol described by McGee and Clemens (1994), rhTNFα samples 
generated a 50% of cytotoxicity for L929 cells at a concentration of 0.35 ng · mL-1, being in the 
concentration range of 0.05 to 20 ng · mL-1 where TNFα exerts its biological activity for most in 
vitro applications. The specific activity was found to be 2.8 · 106 U · mg-1, being one unit of specific 
activity defined by the quantity of TNFα that produces 50% of the lysis of L929 cells. It has been 
published that the specific activity of TNFα is in the range of 106 U · mg-1 to 108 U · mg-1 (Meager 
et al., 1989), suggesting that the rhTNFα produced by fed-batch fermentation fulfilled the 
expected specific activity for this protein. Overall, the result of the cytotoxicity assay showed that 




3.3.1 Metabolic stress induced by recombinant protein production in E. coli 
The optimisation of the conditions for recombinant proteins production (RPP) is usually a 
challenging process, since nature has not optimised E. coli as a protein factory for the 
pharmaceutical industry (Hoffmann and Rinas, 2004). The “Holy Grail” of RPP is still the 
availability of generic approaches that could be applied to all the different types of recombinant 
proteins (Sevastsyanovich et al., 2010). However, after more than 30 years of industrial 
production of biopharmaceuticals, there is still no single approach that can be applied to all 
protein products. Different variables are routinely evaluated, including the host strain, the 
expression vector, medium composition, induction protocol, cultivation temperature or 
chaperones co-expression, among others (Sevastsyanovich et al., 2010). 
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Plasmid replication and gene expression often interfere with the physiological balance of host 
cells, which often results in a high metabolic burden imposed on the host cells. Metabolic burden 
can be defined as the portion of resources that it is redirected from the host’s metabolism – either 
in the form of energy or metabolic resources - for maintenance and expression of the foreign DNA, 
RNA or proteins (Glick, 1995; Hoffmann and Rinas, 2004). The extent of the metabolic burden will 
depend on the size and copy number of the plasmid vector, the levels of production of the 
recombinant protein of interest, the composition of the growth medium and the metabolic state 
of the cells (Glick, 1995). In consequence, different conditions need to be evaluated in a trial-and-
error approach in order to reduce the metabolic burden and cell stress with the aim to favour the 
successful production of recombinant proteins. 
 
3.3.2 Plasmid maintenance and overexpression of APH 
The metabolic burden is not only the result of high levels of protein synthesis, but it can also be 
induced by DNA replication. However, it is considered that the metabolic burden associated with 
plasmid maintenance is often negligible for an average plasmid size (5-10 kbp), and alterations 
associated to plasmid-positive cells have been mainly described when high copy number plasmids 
are used. However, cultures carrying the empty vector under induced conditions did show signs 
of growth inhibition when compared to non-induced cultures (Figure 3.1). This effect could not 
be explained as part of the physiological effects attributed to the overexpression of rhTNFα, since 
this vector does not contain the sequence coding for the recombinant protein and instead, it could 
be the result of the constitutive expression of the antibiotic resistance gene (Hoffmann and Rinas, 
2004). 
The growth arrest, loss of cell culturability and plasmid loss observed for cultures carrying the 
empty vector was caused by the read-through of the T7 RNA polymerase due to the lack of 
terminator sequences downstream the rhTNFα gene (Figures 3.1). The overexpression of the 
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kanamycin resistance gene resulted in a high production of the aminoglycoside-3’-
phosphotransferase (APH), which accounted for 10% of the total cell protein (Figures 3.2). The 
addition of terminator sequences and the change in the orientation of the kanamycin resistance 
gene showed a four-fold improvement in plasmid retention and a considerable reduction in the 
production of APH (Figure 3.8). This highlights the importance of the optimal plasmid design in 
order to reduce unnecessary extra metabolic load to the host cell, which may have a debilitating 
effect on the host organism, hampering recombinant protein production (Glick, 1995). 
 
3.3.3 Inhibition of growth, loss of cell viability and metabolic burden 
The inhibition of growth, and the less documented loss of cell culturability, is often the result of 
the high cell stress upon RPP. There are two main causes of the cell stress imposed upon the host 
organism, the first is caused by the diversion of metabolic resources from biosynthesis and cell 
division; and the second is caused by the accumulation of unfolded or incorrectly folded proteins, 
due to the inability of the cellular apparatus to keep pace with the protein synthesis rate 
(Sevastsyanovich et al., 2010). 
Initial experiments carried out to optimise the conditions for the production of rhTNFα showed 
signs of high cell stress in induced cultures. The use of strong promoters, such as the T7 expression 
system, causes metabolic stress by draining cell resources to maintain the high level of protein 
production demanded by the T7 RNA polymerase (Hoffmann and Rinas, 2004). Growth arrest, low 
cell viability and plasmid loss was observed in all cultures induced with high concentrations of 
arabinose (Figure 3.1). Hofmann and Rinas (2004) reported that the growth rate and the level of 
accumulation of recombinant proteins is inversely correlated as a function of the inducer 
concentration. Cultures producing rhTNFα showed low cell viability and plasmid loss, which was 
minimised by a decrease of the arabinose concentration. A 100 times lower concentration of 
arabinose than the standard recommended by the literature showed an eight-fold increase in 
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plasmid retention (Figure 3.3 B). In addition, plasmid-positive cells often grow slower than 
plasmid-free cells, outcompeting plasmid containing cells, which may lead to a concomitant 
decrease in the amount of protein being produced (Glick, 1995). This effect was even more 
obvious during fed-batch fermentation, where plasmid-free cells outgrew the productive culture, 
entailing a reduction of the final rhTNFα yield (Figures 3.9 and 3.10). 
High overproduction of recombinant proteins may also affect cell division, showing a decline in 
the ability to form colonies on agar plates, being “viable but not culturable”, since cells still exhibit 
metabolic activity but are unable to divide when grown on agar plates. No increase in the CFU 
associated with the increase in biomass was often observed during the production of rhTNFα in 
the late stages of the fermentation (Figures 3.11 B and 3.13 B). 
 
3.3.4 Effect of temperature on the production of correctly folded rhTNFα 
Protein production is the most energy consuming process in the cell, thus, energy generation 
becomes critical for the host organism during RPP (Hoffmann and Rinas, 2004). The level of 
induction, the gene codon bias and the mRNA stability determine the expression rates and correct 
folding of recombinant proteins. Slowing down the rate of product synthesis is often the most 
obvious approach to prevent the accumulation of unfolded products which can be achieved by 
reducing the cultivation temperature and inducer concentration, favouring the accumulation of a 
soluble and correctly folded product (Sevastsyanovich et al., 2010; Fahner et al., 2004). 
Three different cultivation temperatures were evaluated for the production of rhTNFα, achieving 
the highest production of soluble rhTNFα at the lowest temperature evaluated. The accumulation 
of soluble rhTNFα increased with a reduction of the cultivation temperature, reaching a total of 
90%, when cultures were grown at 25 °C. As expected, when higher cultivation temperatures were 
used, almost half of the total protein produced was accumulated in an insoluble form (Figure 3.5) 
(Fahner et al., 2004). When a low cultivation temperature (25 °C) and a low concentration of 
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inducer (0.002% arabinose) were used, the plasmid retention reached almost 100%, but still 
maintained the high level of protein production (Figure 3.6), observed under harsher conditions, 
as a temperature of 37 °C and a strong induction with 0.2% arabinose (Figure 3.5). Once these 
conditions were translated to fed-batch fermentation, high yields of rhTNFα were found in the 
soluble protein fraction (Figure 3.10). 
 
3.3.5 Production, purification and evaluation of activity of rhTNFα 
Once the conditions for the production of rhTNFα had been optimised, high-cell-density cultures 
were carried out to increase rhTNFα titres. Two different semi-defined culture media were 
evaluated by fed-batch fermentation during the production of rhTNFα, in combination with the 
addition of casamino acids as a supplement (Table 3.1). The composition of both semi-defined 
culture media was similar: glycerol was used as a carbon source, ammonium sulphate was used 
as a nitrogen source and both formulations were supplemented with yeast extract. However, the 
casamino acid supplementation shown to have a great impact on plasmid retention when Cobra’s 
growth medium was used (Table 3.1). In contrast, the culture medium composition extracted 
from Want et al. (2009) showed superior growth without the addition of casamino acids, 
exceeding a final OD600 of 100, the target cell density set by Cobra Biologics. A high plasmid 
retention and greater production of rhTNFα was also achieved when compared with 
fermentations using Cobra’s semi-defined medium recipe (Figures 3.9 – 3.16, Table 3.1). In 
general, a higher cell density and production of rhTNFα was obtained with Want’s medium 
formulation, with a final OD600 of 111 in contrast with 68 and 72, and accumulation of rhTNFα of 
25%, comparing with 18 to 20%, of the total cell protein (Table 3.1). These results confirm the 
importance of an optimal culture composition for the production of recombinant proteins, and 
how it can help to improve growth and obtain a higher yield of the final product. 
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The nutrient feed strategy also plays a key role allowing the high productivity of recombinant 
proteins. During the production of rhTNFα, an exponential feeding strategy was used during 
fermentation, allowing the culture to grow at a constant specific growth rate, by using the carbon 
source, glycerol, as growth-limiting nutrient. A specific growth rate of 0.1 h-1 was selected as 
optimal with the aim to slow down growth and protein synthesis rates favouring the production 
of a correctly folded product (Choi et al., 2006). 
The optimal conditions selected during the shake-flask studies, such as a cultivation temperature 
of 25 °C or a low concentration of inducer (0.002% arabinose), minimised plasmid loss and led to 
a high production of rhTNFα favouring the accumulation of soluble protein. Nonetheless, 
solubility is not necessarily a synonym of activity, even though the production of a recombinant 
protein in a soluble form is often a good indication of activity. The activity of rhTNFα evaluated by 
TNFα cytotoxic bioassay, confirmed that rhTNFα produced by fed-batch fermentation was not 
only soluble but also an active protein product. 
 
3.4 Conclusions and future work 
Recombinant protein production still remains a challenge and different approaches need to be 
evaluated in a trial-and-error approach. The strategy used for the production of rhTNFα was 
based on the use of low concentrations of inducer to minimise cell stress during RPP; low 
cultivation temperature to decrease the protein synthesis rate and reduce protein misfolding; and 
a slow specific growth rate regulated by the feed regime which allowed a controlled growth during 
the production phase. In general terms, the optimisation of the conditions for production of 




However, during the production of recombinant proteins by high-cell-density cultures, highest 
productivities have been reported when the growth and production phases are separated, by 
delaying the induction time until the cell density reaches the desired value (Wyre and Overton, 
2014; Choi et al., 2006). This approach needs to be explored since it has been reported that late 
induction may allow the production up to 12 g L-1 of rhTNFα (Hodgson et al., 2011). 
Nevertheless, the production of recombinant proteins targeting the cytoplasm is not an adequate 
approach for the production of protein therapeutics containing disulphide bonds. Disulphide-
bonded recombinant proteins, are often targeted to the periplasm, which allows the formation of 
disulphide bonds due to its oxidising nature and the presence of the disulphide bond (DSB) 
generation machinery (Choi and Lee, 2004). Periplasmic protein production is increasing in 
relevance for the pharmaceutical industry, since antibody fragments are often produced using this 
route (Huang et al., 2012). Therefore, the development of new approaches and screening tools is 





















The advent of the hybridoma technology in 1975 facilitated the production of monoclonal 
antibodies with defined antigen specificities and, nowadays, a large number of monoclonal 
antibodies have been approved for the treatment of cancer, inflammatory diseases or viral 
infections (Weiner et al., 2010). A major breakthrough in the field was the production of different 
formats of antibody fragments, such as antigen-binding fragments (Fab) or single-chain antibody 
variable fragments (scFv) (Figure 4.1), which are currently on the market or in late phases of 
clinical trials, emerging as credible alternatives to monoclonal antibodies. Examples of approved 
antigen-binding antibody fragments are Lucentis® (ranibizumab), ReoPro® (abciximab) and 
Cimzia® (certolizumab pegol) (Nelson and Reichert, 2009). In contrast to full-length monoclonal 
antibodies, antibody fragments are minimally immunogenic due to smaller size, but retain the 
binding specificity of the parental monoclonal antibody. Antibody fragments can be produced at 
large scale with a lower cost using microbial hosts, and their smaller size allows the construction 
of fusion molecules, such as fusion proteins, nanoparticles or immunosensors, without a loss of 
binding function, guiding the way to a broad range of new therapeutic applications (Hagemeyer 
et al., 2009). 
ScFvs are commonly produced in E. coli, containing a leader sequence fused to the N-terminus that 
allows their translocation to the periplasmic space. The oxidising nature of the periplasm and the 
presence of the disulphide bond generation machinery allows the formation of the disulphide 
bonds that links the two β-sheets present in each antibody domain (Figure 4.1). As the disulphide 
bonds make a greater contribution to the stability of the scFv, lower yields of soluble and correctly 
folded scFv are expected when the protein is not translocated to the periplasm. With the main 
objective of exploring different approaches for periplasmic protein production, a single-chain 



























Figure 4.1. Schematic representation of a Mab, a Fab and a scFv. A full monoclonal antibody 
(Mab) is constituted by the fragment crystallisable (Fc) and the antigen-binding (Fab) regions. 
The Fc interacts with cell surface receptors, also called Fc receptors, and some proteins of the 
complement system and the Fab regions constitutes the region of the antibody that recognises 
and binds to the antigen. The Fab region is constituted by the constant and variable domains, 
with the variable domain containing the antigen-binding site, comprising the complementary 
determining regions (CDR). The antigen-binding site (Fab) is constituted by the constant and the 
variable regions of the heavy and light chains of an antibody. The Fv region the smallest antibody 
fragment that still contains the antigen-binding site. The single-chain antibody variable fragment 
(scFv) is a fusion of the variable regions of the heavy (VH) and light (VL) chains by a short peptide 
linker, which avoids the dissociation of the two antibody chains (Adapted from Plückthun, 1991). 
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Initially, a series of growth experiments were carried out for the optimisation of the conditions 
for the production of the single-chain antibody Fv fragment 163R4 (scFv163R4) using E. coli BL21. 
Martineau et al. (1998) described the generation of mutant variations of anti-β-galactosidase scFv, 
leading to the selection of the scFv163R4, due to its superior production in the cytoplasm. The 
scFv163R4 was used as a model protein for the present work and its expression was driven by 
the arabinose expression system, comprising the gene coding for the scFv163R4 under the control 
of the arabinose promoter. In addition, the scFv163R4 has C-terminal 6xHistidine and myc tag, to 
facilitate its purification and detection by western blot. Different conditions affecting the 
production of scFv163R4, such as temperature, inducer concentration or the effect of catabolite 
repression were evaluated by shake-flask experiments, with the aim to favour the production of 
the antibody fragment in the periplasm and to improve the yields of soluble and active protein. 
In general terms, proteins are synthesised in the cytoplasm, as precursor proteins, requiring a 
short amino acid sequence, the signal peptide, to direct their translocation to the periplasmic 
space. Therefore, the selection of the optimal signal peptide is key for periplasmic protein 
production (Choi and Lee, 2004). The use of different signal peptides may also determine the 
translocation pathway, the SecB-dependent, SRP-mediated and TAT translocation pathways, 
depending on the amino acid composition of the signal peptide. The SEC and SRP translocation 
pathways are used for the translocation of unfolded polypeptides from the cytoplasm, post-
translationally or co-translationally, respectively. In contrast, the TAT translocation pathway 
preferentially allows the secretion of folded or partially folded proteins to the periplasmic space 
(Holland, 2004). A more detailed description of the periplasmic translocation pathways can be 
found in Chapter 1, section 1.3.2.2. Among others, commonly used signal peptides for 
periplasmic protein production are: PelB, OmpA, PhoA or STII targeting the SEC pathway, DsbA, 
TolB or SfmC targeting the SRP pathway or TorA, which targets the TAT complex (Choi and Lee, 




The use of different signal peptides has a great impact on the production and processing of 
recombinant proteins, and the efficiency of secretion may vary depending on the type of protein 
to be produced. At present, there is no general rule for the selection of the optimal signal peptide 
that can guarantee successful translocation to the periplasm; different signal peptides need to be 
evaluated in a trial-and-error approach (Choi and Lee, 2004). In order to accelerate the selection 
of the optimal signal peptide to facilitate the translocation of the scFv163R4, a fusion protein, 
comprising the scFv163R4 fused to the TEM-1 β-lactamase, was used to rapidly screen and 
evaluate the production of the recombinant protein in the periplasmic space. The TEM-1 β-
lactamase, also known as penicillinase, is an enzyme that provides resistance to β-lactam 
antibiotics by hydrolysis of the β-lactam ring. Hence, the production of periplasmic β-lactamase 
confers protection to ampicillin, which can be evaluated by minimum inhibitory concentration 
(MIC) experiments and colony screening, and its activity can be quantified by enzymatic assay. 
 
4.2 Results 
4.2.1 Effect of the cultivation temperature on the production of scFv163R4 
Preliminary experiments were carried out by shake-flask with the aim to evaluate the optimal 
conditions for the production of the single-chain antibody 163R4 (scFv163R4). The expression of 
the scFv163R4 was driven by the arabinose expression system, using E. coli BL21-A (ΔaraBAD), 
as host organism. A detailed description of this expression system can be found in Chapter 1, 
section 1.2.2.2. Initial screening included the evaluation of the optimal temperature for the 
production of the scFv163R4. The heat stable enterotoxin II (STII) signal peptide was used to 
direct the translocation of the scFv163R4 to the periplasm, mediated by the SecB-dependent 
translocation pathway. 
Shake-flask experiments were carried out with E. coli BL21-A carrying a plasmid containing the 
sequence coding for the scFv163R4 under the control of the arabinose promoter (pLBAD2-STII-
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scFv163R4). Cultures were grown in terrific broth, at 30 °C or 25 °C, induced with 0.02% 
arabinose at an OD600 of 0.5. Cultures grown under non-induced conditions were used as a control 
for this experiment. Cell culturability, used as indication of cell viability, was evaluated by serially 
diluted culture samples being plated onto non-selective LB agar. Plasmid retention was evaluated 
by replica plating. Shake-flask experiments were carried out in duplicate. 
As expected, cultures grown at 30 °C showed a faster growth than cultures grown at 25 °C, 
although large differences were observed after induction of the expression of the scFv163R4 
(Figure 4.2 A). Cultures grown at 30 °C under induced conditions, showed a decrease in the cell 
density, from an OD600 of 17.9 to 7.5 between 9 and 24 hours of growth, probably as a result of cell 
lysis. In contrast, cultures grown at 25 °C showed a normal growth, showing a similar growth 
profile than cultures grown under non-induced conditions. In terms of cell culturability, a drastic 
reduction in the colony forming units (CFU) can be observed between 8 and 24 hours post-
inoculation (Figure 4.2 B). The loss of culturability was more severe for cultures grown at 30 °C 
after 6 hours of induction, but cultures grown at both temperatures reached a similar number of 
CFU after 24 hours of growth. Plasmid retention showed that 90 to 100% of the cells were 
plasmid-positive after 24 hours of growth for all the cultures (data not shown). 
Culture samples were collected at time points pre- and post-induction and processed fresh to 
extract the periplasmic protein fraction, by cold osmotic shock (Humphreys, 2007). Once 
extracted, the periplasmic and the spheroplast fractions were stored at -20 °C for further analysis. 
When required, spheroplasts were resuspended and disrupted by sonication. Subsequently, the 
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Figure 4.2. Selection of the cultivation temperature for the production of scFv163R4. E. coli 
BL21-A carrying the vector coding for the scFv163R4 were grown at 30°C or 25 °C; half of 
cultures were induced with 0.02% arabinose at an OD600 ≈ 0.5 (blue arrow). The translocation of 
the scFv163R4 to the periplasm was facilitated by the STII signal peptide. The OD600 of the culture 
was measured at intervals post-inoculation (A). Serial dilutions of culture samples at 2 h, 3 h, 8 
h and 24 h post-inoculation were plated onto non-selective LB agar to assess the cell viability 




In terms of protein production, the production of the scFv163R4 was slightly higher in cultures 
grown at 30 °C than at 25 °C, as it can be observed comparing the concentration of the scFv163R4 
from whole cell lysates obtained 24 hours post-inoculation (Figure 4.3). Nevertheless, the high 
concentration of the scFv163R4 in the whole cell lysate did not correlate with a higher 
concentration of protein in the periplasm, being accumulated mainly in the insoluble protein 
fraction. Cultures grown at 25 °C also showed a high production of the scFv163R4, the majority of 
the protein being also accumulated in an insoluble form. Similar amounts of recombinant protein 
were accumulated in the periplasm, independently of the cultivation temperature, the ratio of 
total to periplasmic accumulation of recombinant protein being slightly higher for those cultures 
grown at 25 °C. This suggests than the use of lower cultivation temperatures may have helped to 
slow down the protein synthesis rate, resulting in a lower production of recombinant protein but 
a higher quantity being produced in a soluble form.  
Nevertheless, results obtained from the partitioning could also lead to misleading conclusions, 
since the presumptive high concentration of the scFv163R4 in the cytoplasmic fraction could be 
the result of an incomplete extraction of the periplasmic content. Hence, it is important to 
highlight that no differences in the molecular weight of the scFv163R4 were observed between 
samples of different protein fractions (Figure 4.3). During periplasmic protein production, once 
the recombinant protein is successfully translocated to the periplasmic space, the signal peptide 
is cleaved off by the signal peptidase I, yielding the mature form of the protein, with a slightly 
lower molecular weight. However, no difference in the molecular weight of the precursor (30.9 
kDa), accumulated in the spheroplast, and mature form (28.3 kDa), accumulated in the periplasm, 
was observed by SDS-PAGE, so it was not possible to determine whether the scFv163R4 was 
successfully translocated to the periplasmic space or if the signal peptide had been cleaved off. 






Figure 4.3. Effect of temperature on the production of scFv163R4. SDS-PAGE gels showing 
the accumulation of scFv163R4 from total (T), periplasmic (P), cytoplasmic soluble (S) and 
cytoplasmic insoluble (I) protein fractions. Samples were obtained from induced and non-
induced cultures carrying the vector encoding scFv163R4 (yellow square) after 24 hours of 
growth. Cultures were grown at a temperature of 30 °C and 25 °C and induced with 0.02% 
arabinose. The translocation of the scFv163R4 to the periplasmic space was facilitated by the 
STII signal peptide. Samples obtained from whole cell lysates of cultures carrying the empty 
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4.2.2 Effect of catabolite repression (0.5% glucose) on the production of scFv163R4 
Previous experiments failed to achieve a high production of the scFv163R4 in the periplasmic 
space, the majority being accumulated in an insoluble form. Since a lower cultivation temperature 
may have facilitated the production of a higher quantity of scFv163R4 in the periplasm, it was 
considered that a decrease of the activity of the arabinose promoter could further improve the 
production of mature scFv163R4.  Wycuff and Matthews (2000) reported that the addition of 
glucose was able to repress the activity of the arabinose promoter, allowing the modulation of the 
production of target protein by the addition of different concentrations of arabinose. With the aim 
to understand whether catabolite repression could be used as a strategy to improve the protein 
production in the periplasm, combinations of different concentrations of arabinose and glucose 
were evaluated. 
Shake-flask experiments were carried out with E. coli BL21-A carrying a plasmid containing the 
sequence coding for the scFv163R4 and grown at 25 °C.  Cultures grown under non-induced 
conditions were used as a control. As in the previous experiment, the STII signal peptide was used 
to direct the translocation of the scFv163R4 to the periplasmic space. Protein expression was 
induced with different concentrations of arabinose, ranging from 0.2% to 0.0002%, at an OD600 of 
0.5. In order to evaluate the effect of glucose repression on the production of the scFv163R4, upon 
induction, glucose was added to a final concentration of 0.5% to all the cultures. Cell culturability, 
as an indication of cell viability, was evaluated by serially diluted culture samples being plated 
onto non-selective LB. 
In terms of growth, no significant differences were observed between cultures induced with 
different concentrations of arabinose and cultures grown under non-induced conditions (Figure 
4.4 A). All the cultures reached a high cell density after 24 hours of growth, with a final OD600 
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Figure 4.4. Effect of catabolite repression (0.5% glucose) on growth and cell viability. E. 
coli BL21-A carrying the vector coding for the scFv163R4 were grown at 25 °C; cultures were 
induced with different concentrations of arabinose, ranging from 0.0002% to 0.2% of arabinose, 
at an OD600 ≈ 0.5 (blue arrow). The translocation of the scFv163R4 was facilitated by the STII 
signal peptide. The OD600 of the culture was measured at intervals post-inoculation (A). Serial 
dilutions of culture samples at 2 h, 8 h and 24 h post-inoculation were plated onto non-selective 
LB agar to assess the cell viability after induction (B). Data are shown as mean values from 
replica flasks, error bars are ±1 standard deviation. 
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Minor differences were also observed in terms of cell culturability, and only slight decrease in the 
CFU was observed for cultures induced with the highest concentration of inducer evaluated, 0.2% 
arabinose, after 24 hours of growth (Figure 4.4 B). The loss of cell culturability was minimal, with 
a decrease from 1010 to 3.5 ∙ 109 CFU · mL-1, between 8 and 24 hours post-inoculation. In general 
terms, no significant differences were observed between cultures induced with different 
concentrations of arabinose. 
As expected, the catabolite repression had a strong effect on the production of the scFv163R4 
(Figure 4.5 A). When low concentrations of arabinose, from 0.0002% to 0.002%, were used to 
induce protein production, no protein was detected 24 post-inoculation. However, when the 
concentration of arabinose was increased to 0.02%, the production of the scFv163R4 could be 
detected by western blot after 24 hours of growth. The highest accumulation of scFv163R4 was 
observed in samples obtained from cultures induced with 0.2% arabinose, accounting for 9.4% of 
the total cell protein (TCP), and the titration of the production of scFv163R4, induced by the 
catabolite repression, can be observed at a concentration of arabinose ranging from 0.02% and 
0.2% after 24 hours of growth. 
In order to evaluate whether the glucose repression had an effect on the proportion of the 
scFv163R4 being translocated to the periplasm, the periplasmic fraction was extracted by cold 
osmotic shock. A high concentration of scFv163R4 was detected in the periplasm for cultures 
induced with 0.2% arabinose and repressed with 0.5% glucose, corresponding to 22% of the total 
scFv163R4 produced being accumulated in the periplasm (Figure 4.5 B). Nonetheless, a high 
concentration of the recombinant protein was still detected in the cytoplasmic soluble and 








SDS-PAGE Western blot 
              9.4% 
Figure 4.5. Effect of catabolite repression (0.5% glucose) on the production of 
scFv163R4. SDS- PAGE gel showing the accumulation of scFv163R4 from whole cell lysates 
obtained from cultures grown at 25 °C, supplemented with 0.5% glucose and induced with 
different concentrations of arabinose, ranging from 0.2% to 0.0002%, at an OD600 of 0.5. 
Samples were obtained after 24 hours of growth. A sample obtained from a culture carrying the 
empty vector after 24 hours of growth was used as a negative control. The production of the 
scFv163R4 was confirmed by western blot using an anti-myc antibody (A). The accumulation 
of scFv163R4 (yellow square) from total (T), periplasmic (P), cytoplasmic soluble (S) and 
cytoplasmic insoluble (I) protein fractions after 24 hours of growth (B). The quantity of the 
scFv163R4 is expressed as percentage of whole cell protein and the ratio of protein 
accumulated in the periplasm (A) and spheroplast protein fractions are expressed as 
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The addition of glucose upon induction allowed the repression of the arabinose promoter even in 
the presence of high concentrations of arabinose. The concentration of glucose in the medium was 
reduced progressively during cultivation, since E. coli preferentially uses glucose as a carbon 
source, allowing the slow de-repression of the arabinose promoter, inducing the expression of the 
scFv163R4 (Figure 4.5 B). This slow de-repression seems to favour the translocation of the 
protein to the periplasm, and a higher quantity of scFv163R4 was found in the periplasm when 
compared with previous experiments (Figure 4.3). 
 
4.2.3 Effect of catabolite repression (0.25% glucose) on the production of scFv163R4 
As previous experiments showed a great improvement in the production of the scFv163R4 in the 
periplasm, the effect of glucose repression on the arabinose promoter was further evaluated. With 
the objective to find the optimal balance between the concentration of inducer and repressor, a 
concentration of glucose of 0.25% was evaluated in combination with a concentration of inducer 
ranging from 0.0002% to 0.2% arabinose. 
Shake-flask experiments were carried out with E. coli BL21-A carrying a plasmid containing the 
sequence coding for the scFv163R4 fused to the STII signal peptide, under the control of the 
arabinose promoter. Cultures were grown at 25 °C and induced with a concentration of arabinose 
ranging from 0.2% to 0.0002%, at an OD600 of 0.5. In order to evaluate the effect of glucose 
repression on the production of the scFv163R4, upon induction, glucose was added to a final 
concentration of 0.25% to all the cultures. Cultures grown under non-induced conditions were 
used as a control for this experiment. 
In terms of growth, no significant differences were observed between cultures induced with 
different concentrations of arabinose and cultures grown under non-induced conditions. All the 
cultures reached a high cell density after 24 hours of growth, with a final OD600 ranging from 17 
to 20 (Figure 4.6 A). However, significant differences were detected in terms of cell culturability 
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(Figure 4.6 B). Cultures induced with high concentrations of arabinose, ranging from 0.2% to 
0.02%, showed a decrease in CFU when compared to cultures induced with lower concentrations 
of arabinose. This decrease in the CFU was not observed in cultures grown under non-induced 
conditions, being probably the result of the cell stress induced by the high levels of production of 
the scFv163R4. 
The production of the scFv163R4 was detected on a western blot even when low concentrations 
of arabinose, such as 0.0002% or 0.002%, were used to induce protein expression (Figure 4.7 A), 
in contrast with previous experiments, where high concentrations of arabinose were required to 
induce the production of scFv163R4 (Figure 4.5 A). The production of the scFv163R4 was 
detected even at the lowest concentration of arabinose, 0.0002%, despite the addition of glucose 
to the culture medium (Figure 4.7 A). 
In terms of the proportion of protein accumulated in each protein fractions, the accumulation of 
the scFv163R4 was detected in the periplasmic fraction for cultures induced with the highest 
concentrations of arabinose, ranging from 0.02% to 0.2% (Figure 4.7 B). The concentration of the 
scFv163R4 in the periplasm was higher, accounting for 21% of the total scFv163R4 produced 
when 0.02% arabinose was used to induce protein production, whereas 6% and 73% was found 
accumulated in the soluble and insoluble cytoplasmic fractions, respectively. Only 15% of the total 
scFv163R4 was accumulated in the periplasm when the culture was induced with 0.2% arabinose, 
being 14% and 71% accumulated in the cytoplasmic soluble and insoluble fractions. 
In general terms, the concentration of the scFv163R4 in the periplasmic fraction was higher when 
glucose was added to repress the activity of arabinose promoter for both concentrations 
evaluated, 0.5% and 0.25% (Figures 4.5 and 4.7), showing a great improvement from initial 
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Figure 4.6. Effect of catabolite repression (0.25% glucose) on growth and cell viability. E. 
coli BL21-A carrying the vector coding for the scFv163R4 were grown at 25 °C; cultures were 
induced with different concentrations of arabinose, ranging from 0.0002% to 0.2% of arabinose, 
at an OD600 ≈ 0.5 (blue arrow). The translocation of the scFv163R4 was facilitated by the STII 
signal peptide. The OD600 of the culture was measured at intervals post-inoculation (A). Serial 
dilutions of culture samples at 2 h, 8 h and 24 h post-inoculation were plated onto non-selective 
LB agar to assess the cell viability after induction (B). Data are shown as mean values from 
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Figure 4.7. Effect of catabolite repression (0.25% glucose) on the production of 
scFv163R4. SDS-PAGE gel showing the accumulation of scFv163R4 from whole cell lysates 
obtained from cultures grown at 25 °C, supplemented with 0.25% glucose and induced with 
different concentrations of arabinose, ranging from 0.2% to 0.0002%, at an OD600 of 0.5. 
Samples were obtained after 24 hours of growth. A sample obtained from a culture carrying the 
empty vector after 24 hours of growth was used as a negative control. The production of the 
scFv163R4 was confirmed by western blot using an anti-myc antibody (A). The accumulation 
of scFv163R4 (yellow square) from total (T), periplasmic (P), cytoplasmic soluble (S) and 
cytoplasmic insoluble (I) protein fractions after 24 hours of growth (B). The quantity of the 
scFv163R4 is expressed as percentage of whole cell protein and the ratio of protein 
accumulated in the periplasm (A) and spheroplast protein fractions are expressed as 
percentage at the bottom of the gel (B). 
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be still found in the insoluble protein fraction. The production of the scFv163R4 was higher for 
cultures repressed with 0.25% glucose, accounting for 20% of the total cell protein (TCP) for 
cultures induced with 0.2% arabinose (Figure 4.7). In contrast, when a concentration of 0.5% 
glucose was used to repress the activity of the arabinose promoter, only 9.4% of TCP 
corresponded to the scFv163R4, with the same concentration of inducer (Figure 4.5). 
Overall, the use of glucose repression seems to allow the modulation of the production of 
scFv163R4 by varying the concentration of arabinose used to induce the activity of the arabinose 
promoter. Fine tuning the concentration of arabinose used to the induce protein expression and 
the amount of glucose required to repress the activity of the arabinose promoter seems to provide 
better control over the level of protein expression (Wycuff and Matthews, 2000). However, this 
approach is not feasible at larger scale, since E. coli cells preferentially use glucose as a carbon 
source, being difficult to maintain the glucose concentration in the medium without losing the 
control of the growth rate during fed-batch fermentations. In addition, the slow de-repression of 
the arabinose promoter produced by the consumption of the glucose present in the culture 
medium would be an extremely complex process to scale-up and reproduce at high-cell-density 
fermentations. 
 
4.2.4 Effect of different signal peptides on the production of scFv163R4 
The efficiency of protein translocation varies extremely depending on the signal peptide and the 
type of protein to be translocated to the periplasm. In addition, protein translocation is strongly 
influenced by the first amino acids of the sequence of the target protein. At the moment, there is 
no universal signal peptide that guarantees successful translocation for a given recombinant 
protein and several signal peptides need to be screened in a trial-and-error approach (Choi and 
Lee, 2004). In previous experiments, the translocation of the scFv163R4 to the periplasmic space 
was facilitated by the STII signal peptide. However, this signal peptide may not be the optimal for 
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the production of the scFv163R4 and therefore, the use of other signal peptides should be 
evaluated. 
For this purpose, two new signal peptides were selected: the disulphide oxidoreductase A (DsbA) 
and the pectate lyase B (PelB). The DsbA signal peptide targets the SRP translocation pathway, 
allowing the co-translational translocation of recombinant proteins to the periplasm (Bibi, 2007). 
On the other hand, the PelB signal peptide is a non-E. coli signal peptide obtained from 
Pectobacterium carotovorum, previously known as Erwinia carotovora, which targets the Sec 
translocation pathway, analogously to the STII signal peptide. 
Shake-flask experiments were carried out with E. coli BL21-A carrying a plasmid containing the 
sequence coding for the scFv163R4, fused to the DsbA (pLBAD2-DsbA-scFv163R4) or the PelB 
(pLBAD2-PelB-scFv163R4) signal peptides, under the control of the arabinose promoter. Cultures 
were grown at 25 °C and induced with 0.02% arabinose at an OD600 of 0.5. Catabolite repression 
was used in this experiment for screening purposes, with the aim to evaluate whether the use of 
different signal peptides could favour a higher production of the scFv163R4 in the periplasm 
under the similar growth conditions than in previous experiments. Upon induction, glucose to a 
final concentration of 0.5% or 0.25% was added to the culture medium. Non-induced cultures, 
used as a control, were supplemented with glucose to a final concentration of 0.5%. 
Cultures carrying the plasmid vector containing the sequence coding for DsbA and PelB signal 
peptides fused to the scFv163R4 under non-induced conditions reached a final OD600 of 19 and 
20, after 24 hours of growth (Figure 4.8 A). Cultures grown under induced conditions where the 
translocation of the scFv163R4 to the periplasm was facilitated by the PelB signal peptide also 
reached high cell density, with a final OD600 of 18 after 24 hours of growth, for both concentrations 
of glucose evaluated. In contrast, cultures carrying the DsbA signal peptide showed a severe 


















DsbA-scFv163R4 (Non-induced) DsbA-scFv163R4 (0.5% glucose)
DsbA-scFv163R4 (0.25% glucose) PelB-scFv163R4 (Non-induced)















DsbA-scFv163R4 (Non-induced) DsbA-scFv163R4 (0.5% glucose)
DsbA-scFv163R4 (0.25% glucose) PelB-scFv163R4 (Non-induced)
PelB-scFv163R4 (0.5% glucose) PelB-scFv163R4 (0.25% glucose)
Figure 4.8. Effect of different signal peptides on growth and cell viability. E. coli BL21-A 
carrying the vector coding for the scFv163R4 fused to the DsbA or PelB signal peptides were 
grown at 25 °C. Cultures were induced with 0.02% of arabinose and repressed by the addition 
of 0.25% or 0.5% of glucose at an OD600 ≈ 0.5 (blue arrow). The OD600 of the culture was 
measured at intervals post-inoculation (A). Serial dilutions of culture samples at 2 h, 8 h and 24 
h post-inoculation were plated onto non-selective LB agar to assess the cell viability after 






4.7 for cultures supplemented with 0.25% glucose, after 24 hours of growth. The decrease in cell 
density observed between 8 and 24 hours post-inoculation was probably the result of cell lysis. 
A similar pattern to the growth profile was observed in terms of cell culturability (Figure 4.8 B). 
Non-induced cultures carrying the vector coding for either the DsbA or the PelB signal peptides 
showed a high cell culturability, reaching approximately 5 ∙ 1010 CFU · mL-1 after 24 hours of 
growth. Cultures carrying the PelB signal peptide and supplemented with either 0.25% or 0.5% 
glucose also showed a high cell culturability, comparable to non-induced cultures. However, 
cultures carrying the vector coding for the DsbA signal peptide fused to the scFv163R4 showed a 
drastic decrease in cell viability, with approximately only 107 CFU · mL-1 after 24 hours of growth 
for cultures supplemented with either 0.5% or 0.25% of glucose. The loss of cell culturability was 
so severe that after 24 hours of growth, the number of CFU was lower than the CFU obtained 
before induction, 2 hours post-inoculation. The decrease in the CFU observed for cultures carrying 
the DsbA signal peptide after 24 hours of growth correlated with low final OD600, which it was 
probably caused by cell lysis. 
In terms of the production of the scFv163R4, there were significant differences depending on the 
signal peptide used to favour the translocation of the scFv163R4 (Figure 4.9 A). When DsbA was 
used as a signal peptide, a high production of recombinant protein was observed soon after 
induction, and high levels of protein production were detected after 24 hours of growth, 
accounting for 18% and 25% of the total cell protein, in cultures supplemented with 0.5% and 
0.25% glucose, respectively. Unfortunately, this high level of protein production correlated with 
poor growth and low cell viability (Figure 4.8). In contrast, when PelB was used as a signal 
peptide, the production of the antibody fragment was lower, when compared with samples taken 
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Figure 4.9. Effect of different signal peptides on the production of scFv163R4. SDS-PAGE gel 
showing the accumulation of scFv163R4 from whole cell lysates. Samples were obtained from 
induced and non-induced cultures carrying the vector encoding the scFv163R4 fused to the DsbA 
or PelB signal peptides after 8 and 24 hours of growth. Cultures were induced with 0.02% of 
arabinose and repressed by the addition of 0.5% or 0.25% glucose. The quantity of scFv163R4 is 
expressed as a percentage of whole cell protein at the bottom of the gel (A). The accumulation of 






As in previous experiments, the repression of the arabinose promoter was higher 8 hours post-
inoculation, and large differences were observed depending on the concentration of glucose used 
(Figure 4.9 B). As a result of the de-repression of the arabinose promoter caused by the 
consumption of glucose by the cells, no significant differences were observed 24 hours post-
inoculation, independently of the concentration of glucose used, for cultures carrying the PelB 
signal peptide. A higher production of the scFv163R4 was observed for cultures carrying the DsbA 
signal peptide, for cultures and repressed with 0.25% glucose, accounting for 25% of the total cell 
protein. 
The addition of glucose repressed the activity of the arabinose promoter, and lower scFv163R4 
yields were obtained at a glucose concentration of 0.5% than with 0.25%. (Figure 4.10). Cultures 
carrying the STII signal peptide showed an increase in the production of the scFv163R4, from 9% 
to 12%, when the concentration of glucose added to the culture medium was reduced from 0.5% 
to 0.25%. Comparably, the production of the scFv163R4 for cultures carrying the DsbA signal 
peptide was increased from 18% to 25%, for a concentration of glucose of 0.5% and 0.25%, 
respectively. In contrast with results obtained with the STII and DsbA signal peptides, the addition 
of glucose had a limited effect on cultures where the production of the scFv163R4 was facilitated 
by the PelB signal peptide, accounting for a maximum of 5% of the total cell protein, independently 
of the concentration of glucose used. 
 
4.2.5 Effect of different signal peptides on the production of scFv163R4-A 
The vector pET163R4, from where the original sequence of the scFv was obtained, was designed 
for the cytoplasmic expression of the scFv163R4, and its sequence can be found described in 
Martineau et al. (1998). Since the original sequence was designed for its production targeting the 




















































































Figure 4.10. Effect of catabolite repression and the use of different signal peptides on the 
production of scFv163R4. Production of the scFv163R4 in cultures grown at 25 °C, induced 
with 0.02% arabinose and supplemented with 0.5% or 0.25% glucose at an OD600 of 0.5. The 
production of the scFv163R4 is represented as a percentage of the total cell protein (TCP) 
obtained after 24 hours of growth. Data shown here are single values obtained by quantifying 




codon. The introduction of the extra amino acid was probably resulted in an increase of the 
stability of scFv163R4 when produced as a soluble protein in the cytoplasm. This extra amino acid 
was no longer required for its production in the periplasm, since the stability of the protein is 
favoured by the formation of the two disulphide bonds within the light and heavy chains of the 
scFv, and it should not be present in order to produce the protein with its native N-terminus. 
Shake-flask experiments were carried out with E. coli BL21-A carrying a plasmid containing the 
sequence coding for the scFv163R4, without the alanine at the first position of the mature amino 
acid sequence, renamed scFv163R4-A. With the aim to evaluate the impact of the removal of the 
extra amino acid on the production and translocation of the scFv163R4-A to the periplasm, the 
STII, DsbA or PelB signal peptides were fused to the sequence of the scFv163R4-A (pLBAD2-STII-
scFv163R4-A, pLBAD2-DsbA-scFv163R4-A and pLBAD2-PelB-scFv163R4-A). Cultures were 
grown at 25 °C, induced with 0.02% arabinose at an OD600 of 0.5. Upon induction, glucose was 
added to a final concentration of 0.25%. Cell viability was evaluated by serially diluted culture 
samples being plated onto non-selective LB agar. 
In terms of growth, large differences were observed between non-induced cultures, used as 
control, and cultures grown under induced conditions (Figure 4.11 A). These differences were 
even greater depending on the signal peptide used to direct the translocation of the scFv163R4-A 
to the periplasm. Growth arrest and possible cell lysis were observed in cultures where the 
translocation of the scFv163R4-A was facilitated by the STII and DsbA signal peptides after 24 
hours of growth. A decrease in the cell density was observed between 9 and 24 hours of growth, 
from 18 to 12, for cultures carrying the STII signal peptide; and from 14 to 6.5, for cultures 
carrying the DsbA signal peptide. Growth arrest was not observed in cultures where the 
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Figure 4.11. Effect of the removal of the extra alanine on growth and cell viability. E. coli 
BL21-A carrying the vector coding for the scFv163R4-A fused to the STII, DsbA and PelB signal 
peptides were grown at 25 °C. Cultures were induced with 0.02% of arabinose and repressed by 
the addition of 0.25% of glucose at an OD600 ≈ 0.5 (blue arrow). The OD600 of the culture was 
measured at intervals post-inoculation (A). Serial dilutions of culture samples at 3 h, 9 h and 24 
h post-inoculation were plated onto non-selective LB agar to assess the cell viability after 





In terms of cell culturability, a decrease in the number of colony forming units was observed for 
all the cultures grown under induced conditions. The decrease in the CFU was more severe for 
cultures carrying the STII and DsbA signal peptides (Figure 4.11 B). The loss of cell culturability 
can be already observed after 9 hours of growth, reaching 6 · 107 CFU · mL-1 and 1.6 · 107 CFU · mL-
1, 24 hours post-inoculation, for cultures carrying the STII and DsbA signal peptides, respectively. 
A less severe decrease in the CFU was observed for cultures carrying the PelB signal peptide, from 
1.3 · 1010 to 2.7 · 109 CFU · mL-1, between 9 and 24 hours post-inoculation. 
In terms of the production of the scFv163R4-A, the total accumulation of the antibody fragment 
was higher for cultures where the translocation of the scFv163R4 was directed by the STII and 
DsbA signal peptides (Figure 4.12 A). The production of the scFv163R4-A could also be detected 
in cultures where the translocation of the protein was facilitated by the PelB signal peptide, 
however, the production of the antibody fragment was lower when compared with cultures 
carrying the the STII and DsbA signal peptides. The accumulation of the scFv163R4 was detected 
in whole cell lysates, periplasmic and spheroplast protein fractions (Figure 4.12 B). 
Unfortunately, the concentration of scFv163R4-A detected in the periplasm was low, and the 
recombinant protein was detected mainly in the spheroplasts. 
In general terms, the STII and DsbA signal peptides favoured a high production of the scFv163R4-
A, but it was not correlated with a higher accumulation of the scFv163R4 in the periplasmic 
fraction. The high production of the scFv163R4-A was associated with growth arrest, cell lysis and 
low cell viability when compared with cultures grown under non-induced conditions. In contrast, 
cultures where protein translocation was facilitated by the PelB signal peptide showed a lower 
production of the scFv163R4-A when compared with the STII and DsbA signal peptides, 
nevertheless, a higher concentration of scFv163R4-A was detected in the periplasm. Better 
growth and cell viability was observed in cultures carrying the PelB signal peptide, and therefore, 





Figure 4.12. Effect of the removal of the extra alanine on the production of scFv163R4-A. 
SDS-PAGE gel showing the accumulation of scFv163R4-A from total (T), periplasm (P) and 
spheroplast (Sp) protein fractions. Samples were obtained from induced and non-induced 
cultures carrying the vector encoding the scFv163R4-A fused to the STII, DsbA and PelB signal 
peptides after 24 hours of growth. Cultures were induced with 0.02% of arabinose and repressed 
by the addition of 0.25% of glucose (A). The accumulation of the scFv163R4-A was detected by 
western blot using a mouse anti-myc antibody (B). Lanes shown here were obtained from 
different blots and rearranged for clarity. 
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In general terms, no great differences were observed compared to previous growth experiments, 
where the extra alanine at the first position of the amino acid sequence was still present. As the 
scFv163R4 was used as a model for periplasmic protein production, subsequent growth 
experiments were carried out by using the sequence coding for the scFv163R4-A, sometimes 
abbreviated to scFv-A, which it does not contain the extra amino acid. 
 
4.2.6 Confirmation of the accumulation of scFv163R4-A in the periplasmic space 
In general terms, the expression of the scFv163R4-A is initiated in the cytoplasmic space, where 
the protein is translated, and subsequently translocated to the periplasm, by the SEC or SRP 
pathways, depending on the signal peptide used. If the protein is translocated to the periplasmic 
space, the signal peptide is cleaved off, and the mature form of the protein is then accumulated in 
the periplasm. In contrast, if the scFv163R4 is not translocated, the antibody fragment is 
accumulated, as a precursor, in the cytoplasmic compartment. 
The identification and quantification of the production of the scFv163R4-A was carried out by 
SDS-PAGE. SDS-PAGE gels and western blots were proven to be excellent tools to evaluate the 
production of the scFv163R4-A from whole cell lysates, nonetheless, it still remained difficult to 
determine whether the antibody fragment was being correctly translocated to the periplasm. 
Previous experiments have shown only one form of the protein being produced and no differences 
in molecular weight between the precursor (≈30 kDa) and the mature form (≈28 kDa) of the 
scFv163R4-A were observed by SDS-PAGE, either periplasmic or cytoplasmic. 
In order to identify whether the scFv163R4-A is being correctly translocated to the periplasmic 
space, cultures were grown under “stressful” conditions as an attempt to favour the accumulation 
of the precursor protein, helping to identify whether the majority of scFv163R4 produced was 
accumulated as precursor or the mature form of the protein. Cultures carrying the vector coding 
for the signal peptides STII, DsbA or PelB fused to scFv163R4-A were grown in falcon tubes with 
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20 mL of terrific broth at 37 °C. Cultures carrying the vector coding for the cytoplasmic version of 
the scFv163R4 were used to facilitate the identification of the mature form of the antibody 
fragment. Cultures carrying a vector coding for β-lactamase were used as a used as model protein 
to help visualise the differences between the precursor and the mature form of the β-lactamase in 
a SDS-PAGE gel, since it has a similar molecular weight to scFv163R4. With the exception of the 
vector coding for the cytoplasmic version of scFv163R4, all the cultures were induced with 0.2% 
arabinose at an OD600 of 0.5. The production of the cytoplasmic scFv163R4 was induced with 1 
mM IPTG (pET163R4 vector). 
The production of the β-lactamase and scFv163R4-A in whole cell lysates was evaluated by SDS-
PAGE and western blot. The precursor (31.6 kDa) and the mature (29.1 kDa) form of the β-
lactamase can be easily identified in both colloidal blue stained SDS-PAGE and western blot 
(Figure 4.13). Two bands corresponding to the mature form of the β-lactamase were identified 
and they corresponded with the oxidised and reduced forms of the β-lactamase (Georgiou et al., 
1986). In contrast, the accumulation of the precursor form of the scFv163R4-A was not detected, 
and only one single protein band was identified in samples obtained from cultures overproducing 
scFv163R4-A. The scFv163R4-A, independently of the signal peptide used, showed a similar 
molecular weight to the cytoplasmic version of scFv163R4 (28.2 kDa), without a signal peptide, 
suggesting that it corresponded with the mature form of scFv163R4. No traces of the precursor 
form of the scFv163R4 were detected from samples obtained from cultures carrying the STII, 
DsbA or PelB signal peptides. Samples excised from SDS-PAGE gels were analysed by N-terminal 
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Figure 4.13. Evaluation of the production of the precursor and mature scFv163R4-A. 10-
20% Tris-Glycine SDS-PAGE gel showing the accumulation of scFv163R4-A from whole cell 
lysates. Samples were obtained from induced cultures carrying the vector encoding the STII, 
DsbA and PelB signal peptides fused to scFv163R4-A. Cultures expressing β-lactamase with its 
native signal peptide were used as control. Cultures were grown at 37 °C and induced with 0.2% 
of arabinose. The cytoplasmic form of the scFv163R4 was used as control and its production 
from the pET163R4 vector was induced by the addition of 1 mM IPTG. Samples were taken at 
2.5 and 3.5 h after induction (A). The accumulation of the scFv163R4-A was detected by western 
blot using a mouse anti-myc antibody. The accumulation of the β-lactamase was confirmed by 
western blot using an anti-TEM-1 β-lactamase antibody. The precursor and the mature form of 
the β-lactamase can be observed and the two forms (reduced and oxidised) of the mature β-
lactamase can be observed (asterisks) (B). Lanes shown here were obtained from different blots 














Whole cell lysates samples obtained from cultures where the translocation of the scFv163R4-A 
was directed by the STII, DsbA and PelB signal peptides, showed predominantly, the amino acid 
sequence corresponding to the mature scFv163R4-A, detected by N-terminal sequencing (Figure 
4.13 C). No secondary amino acid sequences were detected for cultures where the translocation 
of the scFv163R4 was driven by the STII and PelB signal peptides. Samples obtained from cultures 
where the translocation of the scFv163R4-A was directed by DsbA showed traces of the secondary 
amino acid sequence corresponding to the precursor form of the protein, but the strongest signal 
detected corresponded to the mature form of the scFv163R4. The cytoplasmic version of the 
scFv163R4 was also sent for N-terminal sequencing, confirming that the amino acid sequence of 
the mature form of the scFv163R4 had been determined correctly. 
N-terminal sequencing results confirmed that all the signal peptides evaluated, STII, DsbA and Bla, 
were able to direct the translocation of the signal peptide to the periplasmic space. Primarily the 
sequence coding for mature form of the protein was detected in samples obtained from whole cell 
lysates, confirming that the signal peptide was cleaved off. The scFv163R4 detected in the 
spheroplast from previous experiments (Figures 4.3, 4.5, 4.7 and 4.12) was probably the result 
of an inefficient extraction of the periplasmic protein content. 
  
 
4.2.7 Effect of different signal peptides on the production of scFv163R4-A::β-lactamase  
In order to further understand the effect of different signal peptides to direct the translocation of 
recombinant proteins to the periplasmic space, the sequence coding for the scFv163R4-A was 
fused by the C-terminus via a four amino acid linker to β-lactamase. The TEM-1 β-lactamase was 
selected as reporter protein, since it confers resistance to β-lactam antibiotics, such as ampicillin, 
and its activity can be quantified by measuring its enzymatic activity. In addition, it is a disulphide- 
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bonded protein, which is naturally translocated by E. coli to the periplasm, where it exerts its 
activity deactivating β-lactam antibiotics. 
A growth experiment was carried out with the objective of evaluating the production of β-
lactamase and the fusion protein scFv163R4-A::β-lactamase in the periplasmic space. Several 
plasmid constructs containing the sequence coding for β-lactamase were generated: wild type β-
lactamase with its native signal peptide (Bla-β-lactamase); cytoplasmic versions of the β-
lactamase (β-lactamase (M)) and scFv163R4-A fused to β-lactamase (scFv163R4::Bla (M)); 
scFv163R4-A::β-lactamase fused to the STII, DsbA, PelB and Bla signal peptides (STII-scFv163R4-
A::Bla, DsbA-scFv163R4-A::Bla, PelB-scFv163R4-A::Bla and Bla-scFv163R4-A::Bla) (Figure 4.14). 
Cultures carrying the empty vector (pLBAD2) were used as a negative control. Cultures were 
grown in terrific broth at 25 °C and induced with 0.02% arabinose at an OD600 of 0.5. Cell 
culturability, as an indication of cell viability, was evaluated by serially diluted culture samples 
being plated onto non-selective LB agar. 
In terms of growth, large differences were observed depending on the signal peptide used to direct 
the translocation of the scFv163R4-A::β-lactamase to the periplasm (Figure 4.15 A). Cultures 
carrying the DsbA and Bla signal peptides showed signs of growth arrest and cell lysis between 7 
and 9 hours post-inoculation, reaching an OD600 of 2 and 4, after 24 hours of growth. 
A healthier growth profile was observed for cultures where the translocation of the scFv163R4- 
A::β-lactamase was directed by the STII and PelB signal peptides, reaching an OD600 of 14, after 24 
hours of growth (Figure 4.15 A). Growth arrest was not observed for the control cultures carrying 
the empty vector, the periplasmic β-lactamase and the cytoplasmic β-lactamase and scFv163R4-
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scFv163R4-A β-lactamase DsbA 
scFv163R4-A β-lactamase PelB 
scFv163R4-A β-lactamase Bla 
Empty vector (pLBAD2) 
Figure 4.14. Representation of plasmid constructs generated for the β-lactamase 
screening. The signal peptide (blue), scFv163R4-A (yellow) and the reporter protein 
(orange). Cytoplasmic versions of β-lactamase and scFv163R4-A::β-lactamase are referred by 
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PelB-scFv163R4-A::β-lactamase Bla-scFv163R4-A::β-lactamase
A) 
Figure 4.15. Evaluation of growth and cell viability of constructs generated for the β-
lactamase screening.  E. coli BL21-A carrying the empty vector (pLBAD2), the vector coding for 
β-lactamase, the cytoplasmic β-lactamase and scFv163R4-A::β-lactamase and the vector coding 
for the STII, DsbA,  PelB and Bla signal peptides fused to the scFv163R4-A::β-lactamase were 
grown at 25 °C. Cultures were induced with 0.02% of arabinose at an OD600 ≈ 0.5 (blue arrow). 
The OD600 of the culture was measured at intervals post-inoculation (A). Serial dilutions of 
culture samples at 3 h, 9 h and 24 h post-inoculation were plated onto non-selective LB agar to 
assess the cell viability after induction (B). Data are shown as mean values from replica flasks, 




Low cell culturability was observed for all the cultures producing the scFv163R4-A::β-lactamase 
in the periplasmic space (Figure 4.15 B). A decrease in the CFU was observed for cultures 
carrying the DsbA and the Bla signal peptides, reaching only 2.25 · 106 CFU · mL-1 and 2.9 · 107 
CFU · mL-1 after 24 hours of growth. The decrease in the CFU was noticeable 6 hours post-
induction, being less severe for cultures carrying the STII and PelB signal peptides. No loss of cell 
culturability was observed for any of the control cultures. 
The production of β-lactamase in the periplasm and in the cytoplasm was also evaluated, as these 
two constructs will be used as control cultures to evaluate the activity of the fusion protein 
scFv163R4-A::β-lactamase by minimum inhibitory concentration experiments and by enzymatic 
assay. The production of β-lactamase was evaluated by SDS-PAGE gel and western blot. The 
periplasmic and spheroplast protein fractions were obtained by modified cold osmotic shock. A 
high concentration of β-lactamase was detected in samples corresponding to the total and 
periplasmic protein fractions (Figure 4.16). β-lactamase was also detected in the spheroplast 
fraction, possibly as a result of residual periplasmic protein content present in the sample. In 
contrast with previous experiments, the precursor form of the β-lactamase, containing the Bla 
signal peptide, was not detected (Figure 4.13). β-lactamase was also detected in culture medium 
samples (Figure 4.16). Samples obtained from cultures expressing the β-lactamase lacking its 
signal peptide (β-lactamase (M)) showed a high accumulation of the protein in the total and 
spheroplast protein fractions, and as expected, β-lactamase was not detected in the periplasmic 
fraction. 
As a result of the high molecular weight of the fusion protein scFv163R4-A::β-lactamase (57.5 
kDa) when compared to the scFv163R4-A (28.2 kDa), it was required to evaluate if the levels of 
production of the scFv163R4-A::β-lactamase would be similar to those obtained with the 
scFv163R4 (Figure 4.10) and scFv163R4-A (Figure 4.12). Large differences in the production of 






      Bla-β-lactamase   β-lactamase (M) 
Figure 4.16. Evaluation of the production of β-lactamase. 18% Tris-Glycine SDS-PAGE gel 
showing the accumulation of β-lactamase from whole cell lysates (T), periplasm (P) and 
spheroplast (Sp) protein fractions or the culture medium (M). Samples were obtained from 
cultures containing the plasmid coding for the periplasmic (Bla-β-lactamase) and cytoplasmic 
β-lactamase (β-lactamase (M)), at 9 and 24 hours post-inoculation. The periplasm and 
spheroplast protein fractions were obtained by modified cold osmotic shock. Samples obtained 
from cultures grown under non-induced conditions after 24 hours of growth were used as a 
negative control (A). β-lactamase was detected by western blot using a mouse anti-β-lactamase 
antibody (B). 
 















































the translocation of the fusion protein to the periplasm (Figure 4.17). The differences observed 
are not only in terms of the amount of protein being produced but also with regards to the kinetics 
of its production. The use of the DsbA and Bla signal peptides seem to favour a rapid and high 
production of the fusion protein, which it can be already detected 2 hours post-inoculation, 
accounting for 5.4% and 2% of the total cell protein (TCP) (Figures 4.17 and 4.18). The 
production of the scFv163R4-A::β-lactamase reached 15.4% of TCP after 24 hours of growth for 
cultures carrying the DsbA signal peptide, lower than production levels achieved with STII and 
Bla signal peptides. This was probably the result of cell lysis and the leakage of the cell content to 
the culture medium as suggested by the low OD600 reached at the end of the experiment (Figure 
4.15). Other signal peptides, as the STII leader peptide, seems to favour a slower production of 
the scFv163R4-A::β-lactamase, but obtaining a high protein production, reaching 24% of TCP, 
after 24 hours of growth. In contrast, the use of PelB as a signal peptide seems to favour a slower 
and lower production of the scFv163R4-A::β-lactamase, accounting for 9.3% of TCP after 24 hours 
of growth (Figures 4.17 and 4.18), which seems to correlate with a better growth and cell 
viability (Figure 4.15). 
All the signal peptides evaluated in this experiment allowed the production of the fusion protein 
scFv163R4-A::β-lactamase in the periplasmic space. Unfortunately, a high concentration of the 
fusion protein was detected in the spheroplasts (Figure 4.17 B). The low concentration of 
scFv163R4-A::β-lactamase could be the result of the inefficient periplasmic extraction, as no 
differences in molecular weight, between the precursor (≈60 kDa) and the mature (57.5 kDa) 
protein  were observed when compared with the cytoplasmic scFv163R4-A::β-lactamase. 
In general terms, results obtained showed great differences in growth, cell viability, kinetics of 
protein production and translocation of the scFv163R4-A::β-lactamase to the periplasm. DsbA and 










Figure 4.17. Evaluation of the production of scFv163R4-A::β-lactamase using the STII, DsbA, PelB and Bla signal peptides. SDS-PAGE 
gel showing the accumulation of scFv163R4-A from total whole cell lysates obtained from induced cultures carrying the vector encoding the 
scFv163R4-A::Bla fused to the STII, DsbA and PelB signal peptide at 2, 4, 6 and 24 hours post-inoculation (A). The periplasmic (P) and 
spheroplast (Sp) protein fractions were obtained by modified cold osmotic shock from samples obtained 6 hours post-induction (B). The 
accumulation of the scFv163R4-A::Bla was detected by western blot using a mouse anti-myc antibody. Samples obtained from cultures carrying 
the empty vector taken after 24 hours of growth were used as a negative control. Samples obtained from cultures overproducing the scFv163R4-
A::Bla in the cytoplasm (M) taken after 24 hours of growth were used to compare the migration of the mature form of the fusion protein on an 
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4 hours 0.0% 5.4% 0.0% 2.0%
6 hours 1.0% 11.5% 1.3% 6.7%
8 hours 6.3% 13.5% 5.4% 15.2%

































Figure 4.18. Quantification of the production of scFv163R4-A::β-lactamase using the STII, 
DsbA, PelB and Bla. Production of the scFv163R4-A::β-lactamase in cultures grown at 25 °C, 
induced with 0.02% arabinose at an OD600 of 0.5. The production of the scFv163R4 is 
represented as a percentage of the total cell protein (TCP) obtained after 24 hours of growth. 
Data shown here are single values obtained by quantifying the accumulation of the scFv163R4 




effect on growth and cell culturability (Figure 4.18). In contrast, the use of PelB as a signal peptide 
yielded a lower concentration of the scFv163R4-A::β-lactamase but showed a better growth and 
cell viability, which is an essential requirement for its production by fed-batch fermentation. The 
accumulation of the scFv163R4-A::β-lactamase with regards to the total cell protein at each time 
point is depicted in Figure 4.18, quantified by densitometry from SDS-PAGE gels, as a 
representation of the kinetics of protein production of each signal peptide. 
 
4.2.8 Minimum inhibitory concentration experiments 
Minimum inhibitory concentration (MIC) experiments were carried out in order to further 
understand whether the scFv163R4-A::β-lactamase was being translocated to E. coli’s periplasmic 
space and conferring protection against β-lactam antibiotics. In order to confer protection to β-
lactam antibiotics, β-lactamase needs to be accumulated in the periplasm, to impede the binding 
of β-lactam antibiotics to the enzyme transpeptidase, which is required for the formation of 
peptidoglycan cross-links in the bacterial cell wall. MIC experiments are considered the “gold 
standard” to determine the sensitivity of a microbial organism to a chemical, the minimum 
inhibitory concentration being the lowest concentration of an antimicrobial that is able to prevent 
visible growth (Andrews, 2001). 
E. coli BL21-A cultures carrying the empty vector (pLBAD2) or the vector containing the sequence 
coding for β-lactamase, the cytoplasmic β-lactamase or scFv163R4-A::β-lactamase, and the STII, 
DsbA, PelB and Bla signal peptides fused to the scFv163R4-A::β-lactamase were grown at 37 °C. 
At an OD600 of 1 to 2, cultures were serially diluted and plated onto Mueller-Hinton (M-H) agar 
containing 50 μg · mL-1 of kanamycin, 0.2% arabinose and different concentrations of ampicillin 
ranging from 3 to 1600 μg · mL-1. Control plates containing only kanamycin were used as a control.  
All the plates were supplemented with kanamycin to ensure plasmid maintenance during the 
experiment. Plates were incubated at 37 °C for 12 - 18 hours.  
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As expected, cultures used as a negative controls, the empty vector and the cytoplasmic β-
lactamase and the scFv163R4-A::β-lactamase, were not able to grow on M-H agar plates 
containing ampicillin (Figure 4.19). Cultures overproducing β-lactamase with its native signal 
peptide, used as a positive control, showed normal visible growth up to a concentration of 
ampicillin of 200 μg · mL-1. Growth was observed up to a concentration of 1600 μg · mL-1, but the 
CFU decreased with increasing concentrations of ampicillin and colonies were smaller. 
Great differences were observed from cultures expressing the fusion protein constructs 
depending on the signal peptide used to favour the translocation of the scFv163R4-A::β-lactamase 
to the periplasm (Figure 4.19). Visible growth was observed on plates seeded from cultures 
carrying the STII and PelB signal peptides, up to a concentration of ampicillin of 200 μg · mL-1 and 
100 μg · mL-1, respectively. In contrast, agar plates seeded from cultures carrying the DsbA and 
Bla signal peptides showed no visible growth on any of the plates supplemented with ampicillin. 
Growth was only observed on the control plates containing kanamycin, although no colonies were 
visible on plates supplemented with 0.2% arabinose but without ampicillin, suggesting that the 
induction of recombinant protein production in cultures carrying the DsbA and Bla signal peptides 
had a detrimental effect in cell culturability. The low cell culturability correlated with the results 
obtained from previous experiments (Figure 4.15 B), the lack of colonies being the result of the 
effect of protein induction and not the deficiency in the translocation of the fusion protein to the 
periplasm. 
With the objective to evaluate whether the lack of colonies was the result of the cell stress induced 
by high levels of production of the fusion protein, minimum inhibitory concentration experiments 
were repeated at lower cultivation temperature, 25 °C, and protein expression was induced with 


















Control 0 μg · mL-1 3 μg · mL-1 6 μg  · mL-1 12 μg  · mL-1 25 μg  · mL-1
50 μg  · mL-1 100 μg  · mL-1 200 μg  · mL-1 400 μg  · mL-1 800 μg  · mL-1 1600 μg · mL-1
Figure 4.19. MIC evaluation of the production of β-lactamase and scFv163R4-A::β-lactamase at 37 °C with 0.2% arabinose. E. coli BL21-
A carrying a plasmid containing the sequence coding for the empty vector (pLBAD2), the β-lactamase, the cytoplasmic β-lactamase and the 
scFv163R4-A::β-lactamase, and STII, DsbA, PelB and Bla signal peptides fused to the scFv163R4-A::β-lactamase were grown in TB at 37 °C. 
Samples serially diluted were plated onto Mueller-Hinton (M-H) agar containing kanamycin to a final concentration of 50 μg ∙ mL-1, 0.2% 
arabinose and different concentrations of ampicillin ranging from 3 to 1600 μg ∙ mL-1. An M-H agar plate supplemented only with kanamycin to 
a final concentration of 50 μg ∙ mL-1 was used as control. M-H agar plates were incubated at 37 °C for 12 - 18 hours. Data are shown as mean 
values from two independent experiments, error bars are ±1 standard deviation. 
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When grown at 25 °C and induced with 0.02% arabinose, cultures overexpressing the wild type 
β-lactamase, showed visible growth up to a concentration of 100 μg ∙ mL-1; and less than 10 CFU 
were observed on plates containing 200 μg ∙ mL-1 of ampicillin (Figure 4.20). No colonies were 
visible on plates supplemented with ampicillin for cultures carrying the empty vector, the 
cytoplasmic β-lactamase and the scFv163R4-A::β-lactamase, confirming that the translocation of 
the β-lactamase to the periplasm is essential to confer resistance to ampicillin. Under “non-
stressful conditions”, incubation at 25 °C and 0.02% arabinose, visible growth was observed on 
plates supplemented with different concentrations of ampicillin for all the cultures where the 
translocation of the scFv163R4-A::β-lactamase was favoured by a signal peptide (Figure 4.20). 
The minimum inhibitory concentration for cultures carrying the STII, DsbA, PelB and Bla signal 
peptides was 12, 50, 12 and 25 μg ∙ mL-1, respectively. Colonies were detected for all the cultures 
at higher concentrations of ampicillin, but the CFU was lower than the control plates and 
decreased with increasing concentrations of ampicillin. 
In conclusion, MIC experiments showed that the scFv163R4::β-lactamase was being produced and 
translocated to the periplasmic space, demonstrated by the growth observed on M-H agar plates 
supplemented with ampicillin. Visible growth was observed for cultures carrying the DsbA and 
Bla signal peptides when grown under “non-stressful” conditions (Figure 4.20), in contrast with 
previous experiments where no growth was detected under induced conditions (Figure 4.19). 
In addition, ampicillin selection can be used as a screening tool for selection of signal peptides 
which allows the translocation of the fusion protein scFv163R4-A::β-lactamase to the periplasmic 
space. Depending on the cultivation and induction conditions, MIC experiments can also be used 
to evaluate viability upon protein induction, and as an indication of which signal peptides allowed 

















Control 0 μg · mL-1 3 μg · mL-1 6 μg  · mL-1 12 μg  · mL-1 25 μg  · mL-1
50 μg  · mL-1 100 μg  · mL-1 200 μg  · mL-1 400 μg  · mL-1 800 μg  · mL-1 1600 μg · mL-1
Figure 4.20. MIC evaluation of the production of β-lactamase and scFv163R4-A::β-lactamase at 25 °C with 0.02% arabinose. E. coli 
BL21-A carrying a plasmid containing the sequence coding for the empty vector (pLBAD2), the β-lactamase, the cytoplasmic β-lactamase and 
the scFv163R4-A::β-lactamase, and STII, DsbA, PelB and Bla signal peptides fused to the scFv163R4-A::β-lactamase were grown at 25 °C. 
Samples serially diluted were plated onto Mueller-Hinton (M-H) agar containing kanamycin to a final concentration of 50 μg ∙ mL-1, 0.02% 
arabinose and different concentrations of ampicillin ranging from 3 to 1600 μg ∙ mL-1. An M-H agar plate supplemented only with kanamycin to 
a final concentration of 50 μg ∙ mL-1 was used as control.  M-H agar plates were incubated at 25 °C for 48 hours. Data are shown as mean values 
from two independent experiments, error bars are ±1 standard deviation. 
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4.2.9 β-lactamase enzymatic assay for the production of scFv163R4-A::β-lactamase 
Results observed during the MIC experiments showed that the four signal peptides evaluated 
allowed the translocation of the scFv163R4-A::β-lactamase to the periplasmic space, however, 
MIC experiments cannot be used to quantify the production of the fusion protein. With the aim to 
relatively quantify the production of the scFv163R4-A::β-lactamase, the activity of the β-
lactamase was measured by enzymatic assay on whole live cells (Angus et al., 1982). The activity 
of β-lactamase was evaluated by using nitrocefin, a chromogenic cephalosporin, as a substrate. β-
lactamase catalyses the hydrolysis of the nitrocefin β-lactam ring, producing a shift of ultraviolet 
absorption from intact nitrocefin (yellow ~380 nm) to degraded nitrocefin (red ~495 nm) 
allowing the quantification of the activity of the β-lactamase. E. coli BL21-A carrying the empty 
vector or the vector containing the sequence coding for β-lactamase, the cytoplasmic β-lactamase, 
the cytoplasmic scFv163R4-A::β-lactamase and the STII, DsbA, PelB and Bla signal peptides fused 
to the scFv163R4-A::β-lactamase were grown at 25 °C and induced with 0.02% arabinose 2 hours 
post-inoculation. Upon nitrocefin addition, the relative activity of β-lactamase was determined by 
continuous measurement of the OD495 from cells obtained before induction (2h) and after 
induction (4, 6, 8 and 24 hours post-inoculation). The initial velocity (slope) was calculated by 
linear regression, adapted to obtain an R ≥ 0.9, and compared between the different samples, as a 
quantification of the relative β-lactamase activity.  
As expected due to tight regulation of the arabinose promoter, no β-lactamase activity was 
detected for any of the cultures before induction, 2 hours post-inoculation (Figure 4.21). No 
significant β-lactamase activity was detected at any time point for cultures carrying the empty 
vector (pLBAD2), used as negative control.  Cultures carrying the wild type β-lactamase, used as 
a positive control, showed high levels of β-lactamase activity. Unexpectedly, the cytoplasmic 
version of β-lactamase (β-lactamase (M)), did also show a high β-lactamase activity post-
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Figure 4.21. Evaluation of β-lactamase activity by enzymatic assay. E. coli BL21-A carrying 
the empty vector (pLBAD2), a plasmid containing the sequence coding for the β-lactamase, the 
cytoplasmic β-lactamase and the scFv163R4-A::β-lactamase, and STII, DsbA, PelB and Bla signal 
peptides fused to the scFv163R4-A::β-lactamase construct were grown at 25 °C and induced with 
0.02% arabinose after 2 hours of growth. Whole cells samples were evaluated live for β-
lactamase activity by quantification of the hydrolysis of the substrate nitrocefin by continuous 
measurement of the OD495 before induction (2h) and after induction (4, 6, 8 and 24 hours post-
inoculation). The OD600 was also quantified at each time point and used to normalise the data 
obtained by the nitrocefin enzymatic assay. The initial velocity (slope) was calculated by linear 
regression, adapted to obtain an R ≥ 0.9, and compared between the different samples. The error 




retain some degree of activity (Kadonaga et al., 1984) and therefore, being able to catalyse the 
hydrolysis of the nitrocefin. It is unclear if the substrate, nitrocefin, is able to diffuse through the 
cytoplasmic membrane, resulting in the detection of high levels of β-lactamase activity. In 
contrast, E. coli cells expressing the fusion protein (scFv163R4-A::β-lactamase (M)) in the 
cytoplasm, did not show high levels of β-lactamase activity, probably due to low production of the 
scFv163R4-A::β-lactamase or the proteolytic degradation thereof. 
Cultures where the production of the scFv163R4-A::β-lactamase was directed to the periplasmic 
space by the STII, DsbA, PelB and Bla signal peptides, showed great differences in terms of β-
lactamase activity (Figure 4.21). For cultures carrying the DsbA and Bla signal peptides, a high β-
lactamase activity was detected 2 hours post-induction, which increased over time, showing rapid 
production of the protein early after induction. Cultures where the translocation of the 
scFv163R4-A::β-lactamase was directed by the STII signal peptide, the β-lactamase activity 
increased gradually during the first hours post-induction, but reaching a high level after 24 hours 
of growth. In contrast, for cultures carrying the PelB signal peptide, low β-lactamase activity was 
detected during the first hours post-induction, which reached a lower level of β-lactamase activity 
after 24 hours of growth than cultures carrying the STII, DsbA and Bla signal peptides. 
Overall, the β-lactamase enzymatic assay has proven to be a useful tool for the quantification of 
the production of the scFv163R4-A::β-lactamase, not only as an indication of total protein 
production but also regarding how rapidly the protein is being produced. Unfortunately, β-
lactamase also showed some degree of activity when produced and accumulated in the cytoplasm. 
However, low levels of activity were detected when the cytoplasmic compartment was targeted 
for the production of the fusion protein, the scFv163R4-A::β-lactamase (Figure 4.21). 
In order to seek confirmation of whether the fusion protein scFv163R4-A::β-lactamase was being 
correctly translocated to the periplasmic space, samples obtained from whole cell lysates of 
cultures carrying the PelB signal peptide fused to the scFv163R4-A::β-lactamase were sent for N-
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terminal sequencing. Results showed that the protein was being translocated to the periplasm, 
and only the mature sequence of the protein lacking the leader peptide was detected. No traces of 
minor sequences were detected in the sample (data not shown). 
 
4.3 Discussion 
The development of a successful periplasmic protein production process depends on the healthy 
balance between gene regulation, cell physiology and protein folding. In an attempt to maximise 
recombinant protein yields, a common strategy is the use of strong regulatory sequences to 
achieve a high transcription, translation and secretion efficiency (Fu et al., 2005). Unfortunately, 
this approach often causes cell stress induced by the high level of protein production, resulting in 
the accumulation of incorrectly folded and aggregated protein products (Plückthun et al., 1996). 
 Stress minimisation conditions, such as low inducer concentrations in combination with low 
cultivation temperatures, were applied to the production of the scFv163R4, in order to improve 
not only the total protein yield but also the amount of target protein being translocated to the 
periplasmic space. In general terms, the use of lower cultivation temperatures favoured the 
production of the scFv163R4, as well as growth and cell viability, and a higher concentration of 
recombinant protein was found to be accumulated in the periplasm (Figure 4.3). This results 
correlated with previously published data that suggested that the optimal cultivation temperature 
for the production of antibody fragments is 25 °C (Plückthun et al., 1996). 
 
4.3.1 Catabolite repression as a tool to modulate the activity of the arabinose promoter 
The successful expression of high quantities of antibody fragments in E. coli’s periplasm is a 
compromise between protein synthesis and protein folding, in order to maximise the amount of 
functional protein produced (Plückthun et al., 1996). Wycuff and Matthews (2000) showed that 
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the use of glucose, which repress the activity of the arabinose promoter, in combination with a 
broad range of arabinose concentrations could be used as strategy to adjust protein expression 
levels. The expression of recombinant proteins is therefore modulated by the addition of 
arabinose, used as inducer, and glucose, used as a repressor, helping to achieve a greater control 
over protein expression. 
The strong repression of the arabinose promoter by the addition of 0.5% glucose was observed 
when combined with low arabinose concentrations, from 0.002% to 0.0002%. At these 
concentrations, no protein accumulation was detected in samples obtained from whole cell lysates 
(Figure 4.5). In contrast, at a higher concentration of arabinose, 0.2%, the slow de-repression of 
the arabinose promoter favoured the production of the scFv163R4 and the translocation of the 
protein to the periplasmic space (Figure 4.5). A concentration of glucose of 0.25%, in combination 
with a concentration of arabinose of 0.02% arabinose, showed a similar accumulation in the 
periplasm, without compromising growth and cell viability (Figures 4.6 and 4.7). 
In general, glucose repression combined with different concentrations of arabinose provided a 
greater control over the level of protein expression (Wycuff and Matthews, 2000). However, even 
when this approach has been proven to be useful to reduce the accumulation of certain 
recombinant proteins in IBs and favour the translocation of proteins to the periplasm, as 
interferon α (Lee and Jung, 2007), this approach would not feasible at large scale.  The production 
at fermentation scale without compromising the control over the growth rate would have been 
difficult, due to the preferential use of glucose as a carbon source (Aidelberg et al., 2014). 
 
4.3.2 Selection of signal peptides for periplasmic protein production 
The optimal selection of the leader sequence is the first step for the efficient secretion of a 
recombinant protein and the level of production often has a great impact in growth and cell 
viability (Yoon et al., 2010). There are three main translocation pathways, the Sec, the SRP and the 
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Tat, commonly used for periplasmic protein production in E. coli, the Sec pathway being the major 
gateway for protein secretion (Fu et al., 2005). 
The great differences observed between different signal peptides, in terms of protein production 
kinetics, had a strong effect on growth and viability. Fu et al. (2005) described growth arrest and 
cell death induced by the “saturated translocation” of a secretory exoglucanase when the 
conversion of pre-mature to mature exoglucanase was unable to match the production levels. 
Similarly, results obtained when DsbA was used as a leader sequence to favour the translocation 
of the scFv163R4, a high production of the recombinant protein was detected 6 h post-induction, 
even in the presence of glucose (Figures 4.10). The high level of protein production was also 
accompanied by growth arrest, loss of cell viability and cell lysis with and without glucose 
repression (Figure 4.8 and 4.11). The high levels of production of the precursor form of the 
scFv163R4-A could have saturated the translocation channel or could be the result of SRP 
depletion. Since SRP mediates the translocation of inner membrane proteins, whereas the 
majority of secretory and outer membrane proteins are translocated by the SecB-dependent 
pathway, its depletion may also have a strong negative effect on protein homeostasis in the entire 
bacterial envelope resulting in cell lysis and death (Zhang et al., 2012). 
In contrast, the PelB signal peptide favoured a lower production of the antibody fragment and a 
lower final yield (Figure 4.10), but showed a healthier growth profile, with minimum loss of cell 
viability upon induction with and without glucose repression (Figure 4.8 and 4.11). Nonetheless, 
PelB favoured the translocation of the protein to the periplasm, and only the sequence 
corresponding to the mature protein was detected in whole cell lysates obtained from cultures 
overexpressing either the scFv163R4-A and or the scFv163R4-A::β-lactamase when analysed by 




4.3.3 β-lactamase as a reporter protein for periplasmic RPP 
The effect of different signal peptides on cell growth and cell viability was simple to evaluate, but 
whether the protein was successfully being translocated to the periplasmic space was still hard to 
identify. N-terminal sequencing can provide with the definitive result by determining whether the 
leader sequence is still present, however, this is an expensive test that cannot be applied for 
screening of a large number of samples. The fusion of recombinant proteins by the C-terminus to 
β-lactamase can be used instead, to give a more detailed insight of the localisation of the 
recombinant protein as well as its possible use for high-throughput screening experiments. 
With this tool in hand, it was easier to establish a link between growth, cell viability, protein 
production and the amount of protein being translocated to the periplasm, determining that some 
signal peptides allowed a high and rapid production of recombinant protein but entailed a 
deleterious effect on growth and cell viability, such as DsbA and Bla signal peptides (Figures 4.15 
to 4.18). This effect was independent of the translocation pathway being targeted, SRP pathway 
for DsbA and the Sec pathway for Bla, suggesting that even when SRP depletion may have a strong 
effect on bacterial physiology, cell death was probably caused by the rapid production of the 
scFv163R4-A::β-lactamase. This result suggests a strong relationship between not only the 
amount of protein being produced but also the kinetics of protein production and how the 
saturation of the translocation pathways may affect cell physiology (Fu et al., 2005). 
The effect on cell physiology was so severe, that no colonies were obtained, independently of the 
concentration of ampicillin, when high concentrations of inducer were present in M-H agar plates 
(Figure 4.19) for cultures carrying the DsbA and Bla signal peptides. This was not the result of 
insufficient production of scFv163R4-A::β-lactamase to confer protection to ampicillin, but the 
low cell fitness and growth impairment caused by the production and translocation of the 
scFv163R4-A::β-lactamase. Colonies were only obtained after a 10-fold decrease of the arabinose 
concentration, and a reduction in the cultivation temperature from 30 °C to 25 °C (Figure 4.20), 
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used to slow down the protein synthesis rate. The quick and high levels of protein produced early 
after induction favoured by DsbA and Bla signal peptides was confirmed by the quantification of 
the relative β-lactamase activity (Figure 4.21), and correlates with the results observed by SDS-
PAGE and western blot (Figures 4.17 and 4.18). 
In contrast, when the translocation of the scFv163R4-A::β-lactamase was directed by the STII 
signal peptide, high accumulation of the protein can be observed after 24 hours of growth (Figure 
4.17) but no growth arrest or cell lysis was observed (Figure 4.15 A). A decrease in the CFU was 
observed upon induction, but the loss of cell culturability was less severe than when DsbA and Bla 
signal peptides were used (Figure 4.15 B). A similar profile was observed when PelB was used as 
a signal peptide, showing a slightly lower protein production (Figure 4.17), but better cell 
culturability (Figure 4.15 B). Both signal peptides were able to produce enough protein in the 
periplasmic space to allow the growth of colonies in the presence of high concentrations of 
ampicillin at both cultivation temperatures and concentrations of arabinose evaluated  (Figures 
4.19 and 4.20).The production of functional scFv163R4-A::β-lactamase was also confirmed by 
enzymatic assay, where the relative β-lactamase activity increased over the time after induction, 
reaching the highest levels after 24 hours of growth, with the STII samples showing slightly higher 
β-lactamase activity than PelB (Figure 4.21). 
 
4.4 Conclusions and future work 
The selection of the optimal signal peptide for periplasmic protein production should not be 
evaluated solely on the basis of the levels of protein production but also considering growth and 
cell viability as key for the development of a successful production process. As high induction and 
rapid accumulation of recombinant proteins may lead to growth arrest, signal peptides that favour 
a gradual increase in protein production over time may result in a better growth and cell viability. 
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This is essential for the development of high-cell-density fermentation processes, since protein 
production can be maintained for a longer period of time.  
There is no general rule selecting a signal peptide that guarantees successful translocation of the 
protein to the periplasm. Several signal peptides need to be evaluated in a trial-and-error 
approach, an often costly and time-consuming process (Choi et al., 2004). The development of a 
high-throughput screening would not only help to evaluate the different signal peptides available 
from nature but also the rapid assessment of signal peptide libraries, containing millions of signal 
peptide variations. Signal peptide libraries, either generated by chemical synthesis or 
mutagenesis, may massively expand the catalogue of leader sequences or provide variations of 
the existing ones with improved properties. Therefore, the development of a screening assay for 
the evaluation of signal peptide libraries would be a desirable accomplishment, but to date no 
reporter assays have been developed (Mansell et al., 2010). As β-lactamase has proven to be a 
great tool as a reporter protein to evaluate production and activity of proteins in the periplasmic 
space, its use expands the future possibilities for the screening and evaluation of the production 



















E. coli is quickly gaining status as a reliable host organism for periplasmic protein expression. 
However, despite the recent advances, periplasmic expression of recombinant proteins is a still a 
significant challenge. A better understanding of periplasmic translocation pathways has 
accelerated the development of new screening and applications in this field, specially, the 
understanding of signal peptides that facilitate the translocation of recombinant proteins to the 
periplasm (Low et al., 2013). In addition, optimisation of the conditions for periplasmic protein 
production is often a costly, tedious and time-consuming process. For this reason, systematic 
studies are essential to determine the relationship between cell physiology, cultivation conditions 
and the cell production capability (Rodriguez-Carmona et al., 2012). 
Signal peptides direct the translocation of recombinant proteins to their site of function, such as 
the periplasm, the outer membrane or the culture medium; the selection of the optimal signal 
peptide is essential for the successful production of proteins in the periplasm. Several studies have 
expanded the knowledge regarding the structure of signal peptides, and it is well known that 
signal peptide sequences are often constituted by a short positively charged n-region, followed by 
a non-polar hydrophobic core and a neutral polar region, which is found immediately preceding 
the cleavage site (Heggeset et al., 2013). A more detailed description of the structure of the signal 
peptide can be found in Chapter 1, Section 1.3.2.1. However, even when the structure of signal 
peptide has been described and the production of disulphide bonded-proteins in the periplasm 
has been established, no reporter assays have yet been developed to evaluate protein 
translocation (Mansell et al., 2010). 
In the last decades, directed evolution has emerged as a powerful method that mimics the process 
of natural selection for altering the properties of proteins (Heggeset et al., 2013). In directed 
evolution experiments, mutations are introduced at random positions of a target DNA sequence, 
generating large and diverse libraries. Selection strategies or high-throughput screening are 
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required to select and identify those clones containing mutations that improve the desired 
property (Hanson-Manful and Patrick, 2013). As in directed evolution experiments for selection 
of proteins, signal peptide sequences can be evolved by random mutagenesis, which allows the 
creation of signal peptide libraries which can be evaluated by selection of clones with improved 
translocation properties and screening of individual variants which exert a higher translocation 
activity. 
With the aim to evaluate the translocation of scFv163R4-A to the periplasmic space, a protein 
fusion was generated where a signal peptide was fused to the N-terminus of the protein of interest, 
scFv163R4-A, and the mature TEM-1 β-lactamase (Bla) sequence was fused to the C-terminus of 
the scFv163R4-A. The use of β-lactamase as a reporter protein allows selection using β-lactam 
antibiotics and the quantification of the production and translocation of the fusion protein to the 
periplasmic space by enzymatic assay. 
The steps involved in the development of β-lactamase screening for periplasmic protein 
production are depicted in Figure 5.1. Initially, signal peptide libraries were generated by error-
prone PCR or by chemical synthesis of variants of the PelB signal peptide sequence (1). Signal 
peptide libraries were introduced by seamless cloning into a plasmid vector containing the gene 
coding for the scFv163R4-A::β-lactamase, under the control of the arabinose promoter (2). 
Plasmid libraries were transformed in E. coli (3) and clones containing a variant of the signal 
peptide which allowed the translocation of the scFv163R4-A::β-lactamase to the periplasm were 
selected on ampicillin-supplemented agar plates (4). This step allowed the selection and isolation 
of only those clones containing signal peptide sequences, which allowed the production of the 
fusion protein in the periplasm. Subsequently, clones selected at high concentrations of ampicillin 
were individually screened using the β-lactamase enzymatic assay, allowing the relative 











Figure 5.1. Diagram of the β-lactamase screening for periplasmic protein production.   The 
development of the β-lactamase screening comprises seven main stages: (1) generation of signal 
peptide libraries, either by error-prone PCR or chemical synthesis of oligonucleotide libraries, 
both containing random mutations in the signal peptide sequence. (2)  Seamless cloning of signal 
peptide libraries using type IIs restriction enzymes, containing the sequence coding for the 
protein of interest fused to the reporter protein β-lactamase, under the control of the arabinose 
promoter. (3) Introduction of the plasmid DNA into E. coli, amplification of the vector containing 
the signal peptide libraries and generation of research cell banks containing the signal peptide 
libraries. (4) Selection of clones containing signal peptides favouring the translocation of the 
protein of interest fused to β-lactamase. The production of the protein of interest fused to β-
lactamase in the periplasmic space confers E. coli cells resistance to β-lactam antibiotics, such as 
ampicillin, allowing the selection of only those clones containing signal peptides which allowed 
the production and translocation of the fusion protein to the periplasm. (5) Screening of positive 
clones and relative quantification of the β-lactamase activity of host cells. Clones showing a high 
β-lactamase activity were selected to be further evaluated for periplasmic protein production by 
shake-flask growth experiments and fed-batch fermentation. (6) Evaluation of highly productive 
clones, containing signal peptide (SP) sequences with a higher production of the recombinant 
protein in the periplasm than the wild type signal peptide sequence. (7) Evaluation of selected 
clones by high cell density fermentation for the production of the protein of interest (POI) fused 
to the reporter protein β-lactamase in the periplasmic space. Subsequently, evaluation of 
selected clones by high cell density fermentation for the production of recombinant protein of 
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After the initial selection of ampicillin-resistant clones, the β-lactamase screening allowed the 
selection of clones containing mutant signal peptides with a higher β-lactamase activity than the 
PelB wild type signal peptide, and theoretically, the selection of clones with a higher production 
of the fusion protein in the periplasmic space. The detection of β-lactamase activity was used not 
just as measurement of translocation of the protein to the periplasmic space, but as an indication 
of correct folding and disulphide-bond formation, based on the assumption that if the scFv163R4-
A was correctly folded, β-lactamase should be correctly folded as well. Overall, the β-lactamase 
screening assay was developed as a screening tool, helping to find mutations, which favoured a 
higher translocation of the protein to the periplasm, without compromising cell physiology and 
viability. More important, this approach allows the rapid screening of a large number of signal 
peptide mutants for the production of therapeutic proteins containing disulphide bonds, 
facilitating the development of high productivity fermentation processes. 
 
5.2 Results 
5.2.1 Generation of signal peptide libraries 
The most important step for the successful generation of a large and diverse DNA library is the 
selection of the mutagenesis strategy, which will depend on the type of DNA library to be 
generated and the desired degree of complexity. In addition, the efficiency of the subsequent 
cloning steps also limits the size and complexity of the library to be generated. At present, there 
are several methods that allow the introduction of random mutations in a DNA sequence, such as 
the use of XL1-red cells or degenerate oligonucleotides (Chusacultanachai and Yuthavong, 2004). 
However, error-prone PCR seems to be the optimal choice for the introduction of completely 
random mutations in a given sequence, allowing the generation of a highly diverse signal peptide 




Signal peptide libraries were introduced into the expression vector by seamless cloning using type 
IIS restriction endonuclease, which allows the cloning of two or more DNA fragments joined 
precisely, without the addition of unwanted nucleotides between the two DNA fragments. Type 
IIS restriction enzymes are a class of restriction endonucleases that allow the cleavage of DNA 
sequences outside of their non-palindromic asymmetric recognition sites, e.g. SapI, BsaI or FokI. 
Both the plasmid vector and the insert need to contain the restriction recognition sequences, 
which after restriction digestion would be removed, generating compatible cohesive ends 
allowing the seamless cloning of the DNA fragments (Lu, 2005). 
Both different signal peptide libraries, generated by error-prone PCR and by chemical synthesis, 
used PelB signal peptide sequence as a template. This signal peptide was used as a template since 
results previously obtained showed that PelB allowed the production and translocation of the 
scFv163R4-A::β-lactamase to the periplasmic space, maintaining a good growth profile and cell 
viability (Chapter 4, Figures 4.15 to 4.18). In addition, the production of the mature form of the 
scFv163R4-A and the scFv163R4-A::β-lactamase in the periplasm had been confirmed by N-
terminal sequencing (Chapter 4, Sections 4.2.6 and 4.2.9). 
 
Error-prone PCR (Ep-PCR) is one of the most common methods used to introduce random 
mutations into a given DNA sequence, being based in the misincorporation of nucleotides by an 
error-prone DNA polymerase during the synthesis of DNA product (Hanson-Manful and Patrick, 
2013). The GeneMorph II Random Mutagenesis kit, which contains a blend of two different DNA 
polymerases, Mutazyme I polymerase and a mutant Taq DNA polymerase, was used for the 
generation of the error-prone PCR signal peptide library. This enzyme blend allowed an 
equivalent rate of transitions versus transversions, which means a similar mutation rate of A’s 
and T’s versus G’s and C’s was achieved, obtaining a minimal mutation bias (Chusacultanachai and 
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Yuthavong, 2004). The error prone PCR was carried out by the amplification of the PelB signal 
peptide sequence from the plasmid vector pMA-RQ-SapIPelBSapI using the Mut F and Mut R 
primers (Figure 5.2). This plasmid vector contains the PelB signal peptide sequence flanked by 
the restriction recognition sequence of BspQI restriction enzyme, an isoschizomer of SapI. BspQI 
restriction endonuclease was used instead of SapI, due to its improved storage stability and 
digestion efficiency. The Mut F and Mut R primers aligned to the flanking DNA sequences of the 
PelB DNA template, containing the BspQI recognition sites, the first codon (ATG initiation codon) 
and the last codon (GCC codon) of the PelB signal peptide sequence. This enabled the 
misincorporation of nucleotides only in the core sequence of the signal peptide, avoiding 
mutations in the flanking DNA sequences, as required for the seamless cloning of the signal 
peptide into the expression vector. 
In order to achieve a high mutation rate, between 9 to 16 mutations ∙ kb-1, a low amount of DNA, 
0.1 ng, was used as a template. This mutation rate allowed the generation of 1 or 2 mutations in 
the DNA template per error-prone PCR. However, this mutation rate was considered not sufficient 
for the generation of a highly diverse signal peptide library. With the aim to achieve a higher 
number of mutations, sequential error-prone PCRs were carried out by using the product of the 
previous Ep-PCR as a template, increasing the number of mutations in the final DNA product. Four 
sequential Ep-PCR were carried out (Ep-PCR 1, Ep-PCR 2, Ep-PCR 3 and Ep-PCR 4), aiming to 
achieve between 1 and 8 mutations per copy of the signal peptide sequence. A pool containing 
equivalent amounts of each Ep-PCR product was also generated (Ep-PCR 5 pool), containing a 






Figure 5.2. DNA template used for the generation of signal peptide libraries. The PelB 
signal peptide sequence was used as a template for the error-prone PCR. The sequence 
containing the BspQI restriction recognition sequence (yellow) is located flanking the PelB signal 
peptide sequence (grey), used for seamless cloning of the signal peptide mutants into the 
expression vector. The error-prone PCR was carried out by using the Mut forward and reverse 
primers to amplify the DNA template. The GeneMorph II Random Mutagenesis kit was used to 
amplify and introduce random mutations in the PelB signal peptide sequence. Sequential error-
prone PCRs were carried out using the product from the previous PCR as template, with the aim 
of increase the number of mutations in the signal peptide sequence. 
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A second signal peptide library was also chemically synthesised by Twist Biosciences. Twist 
Biosciences owns an innovative silicon-based 9,600 well platform, enabling the parallel 
production of diverse oligonucleotide pools with high accuracy. As part of a Beta program, Twist 
Biosciences generated an oligonucleotide library, which consisted on the generation of 10,000 
oligonucleotides containing between 2 to 4 mutations per oligonucleotide. The PelB signal peptide 
sequence was flanked by the BspQI restriction sites, the same DNA template used the generation 
of the error-prone PCR libraries (Figure 5.2). Once generated, the oligonucleotide pool was made 
double-stranded and amplified to obtain a final concentration of 10 pM. 
 
5.2.2 Construction of the expression vector 
Classic gene cloning techniques often involves the use of restriction digestion and DNA ligation, 
the commonly called cut-and-paste reaction, which was considered the gold standard for cloning 
and DNA modification during the last decades. Nevertheless, this type of cloning requires the 
addition of operational sequences containing the restriction recognition sequence, which 
introduces undesired sequences coding for extra amino acid residues at the DNA junction. This 
addition of extra amino acid residues may affect the activity of recombinant proteins and the 
generation of the recombinant protein containing non-native amino acid sequences (Lu, 2005). 
In contrast, seamless cloning using type IIS restriction endonucleases was used for the generation 
of signal peptide-protein fusions, since it is essential to ensure that no extra sequences are added 
between the signal peptide and the protein of interest. The type IIS restriction enzyme BspQI, an 
isoschizomer of SapI, used for the cloning of the signal peptides into the expression vector, 
recognises a 7 bp non-palindromic recognition sequence, leaving a 3 bp 5’ overhang after 
restriction digestion (Figure 5.2). BspQI recognition sequences were introduced into the 
expression vector (pLBAD2-SapIXbaISapI-scFv163R4-A::β-lactamase) upstream the sequence 
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coding for the scFv163R4-A::β-lactamase (Figure 5.3). Both signal peptides libraries, the error-
prone and the twist libraries, were generated containing the signal peptide sequence flanked by 
the BspQI recognition sequences. This approach allowed the cloning of the signal peptide libraries 
into the expression vector seamlessly, in one single digestion and ligation reaction, allowing a high 
cloning efficiency. This reaction was carried out for the introduction of the Ep-PCR 1, Ep-PCR 2, 
Ep-PCR 3, Ep-PCR 4 and Ep-PCR 5 (pool) products. The same approach was used for the 
introduction of the Twist library into the expression vector. 
 
5.2.3 Transformation, generation of research cell banks and plasmid DNA stock 
Once the ligation reactions were completed, the ligated product was transformed into the 
commercially available ElectroSHOX competent cells by electroporation. Immediately after, cells 
were resuspendended in LB and incubated for at least 1 hour before being transferred to a 1 L 
shake-flask containing 200 mL of LB broth. After 12-18 hours, cells were harvested, lysed, and the 
plasmid DNA extracted, generating a plasmid DNA stock containing the signal peptide libraries 
cloned into the expression vector. ElectroSHOX competent cells were used due to their high 
transformation efficiency of ligated products and the generation of high quality plasmid DNA 
stocks of the expression vector containing the signal peptide libraries. 
The expression vector library was transformed into E. coli BL21-A, used as expression strain. As 
described previously, after 1-hour incubation, the cell suspension was transferred into a 250 mL 
shake-flask and further incubated for 12-18 hours. At this stage, 0.5 mL aliquots of each culture 
were serially diluted for the selection of clones able to grow on ampicillin-supplemented agar 
plates. Only those clones able to produce and translocate the scFv163R4-A::β-lactamase to the 
periplasmic space were able to grow in the presence of ampicillin. The culture was also used for 











Digestion with BspQI 
Figure 5.3. Generation of the Ep-PCR signal peptide library and introduction into the 
expression vector. The error-prone PCR library was generated by amplifying the PelB signal 
peptide from the pMA-RQ-SapIPelBSapI vector by ep-PCR using the Mut F and Mut R primers 
(top right). The DNA insert and the expression vector (pLBAD2-SapIXbaISapIscFv163R4-A::β-
lactamase) were ligated by the compatible cohesive ends generated by BspQI restriction 
digestion (middle). The expression vector contained the signal peptide library, a mutant variant 
of the PelB signal peptide sequence, fused to the sequence coding for the antibody fragment, 
scFv163R4-A, fused to the reporter protein, β-lactamase (bottom). 
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Electroporated cell suspensions were transferred directly to shake-flasks, instead of being 
selected by plating on selective agar, to ensure that the library size was not being diminished with 
each transformation step. Kanamycin was added to all incubation steps to ensure plasmid 
maintenance, avoiding the overgrowth of plasmid-free cells. Plasmid retention was evaluated 
after each step of the cloning process, by plating a small aliquot of the cell suspension onto 
selective and non-selective LB agar and comparing the number of colonies. Overgrowth of 
plasmid-free cells was not observed at any step of the process and the addition of kanamycin 
seemed to be sufficient to impede the overgrowth of E. coli cells, which had not incorporated the 
expression vector. 
 
5.2.4 Selection of signal peptide mutants based on ampicillin resistance 
A small inoculum obtained from the transformed culture was used to inoculate a starter culture, 
grown at 37°C until an OD600 between 1 and 2. Subsequently, cultures were serially diluted to 
obtain a concentration of 104 CFU · mL-1 and plated onto M-H agar containing 0.2% arabinose, 50 
μg · mL-1 of kanamycin, and ampicillin to a final concentration ranging from 3 to 1600 μg · mL-1. 
After 12 - 18 hours incubation at 37 °C, colonies grown on ampicillin-supplemented plates were 
evaluated by β-lactamase enzymatic assay. As it has been previously observed in cultures carrying 
the DsbA and Bla signal peptides, non-healthy cells were unable to grow under “strong induction 
conditions” (Chapter 4, Section 4.2.8), and therefore, a high concentration of inducer (0.2% 
arabinose) and high cultivation temperature (37 °C) were used to minimise the growth of clones 
with low cell viability or severely affected by protein production. 
Generally, visible growth was detected up to a concentration of ampicillin 200 μg · mL-1, and no 
colonies grew at higher concentrations of ampicillin. Colonies grown under induced conditions, 
independently of the addition of ampicillin, showed large differences in terms of morphology 
when compared to colonies grown on the control plates, supplemented only with kanamycin 
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(Figure 5.4). Different colony morphologies were identified on plates supplemented with 
arabinose: larger colonies with either a flat or a raised morphology or small colonies. In addition, 
there seems to be a correlation between the colony morphology and the Ep-PCR product 
contained in the expression vector, as the number of large-size colonies increased with Ep-PCR 
products containing a higher number of mutations.  The different colony morphologies were not 
detected on control plates, supplemented only with kanamycin, showing large-size colonies. A 
more homogenous colony morphology was observed on plates seeded with the control culture 
carrying the PelB wild type signal peptide and no different colony morphologies were observed 
within the same plate.  
In general, the appearance of different colony morphologies seemed to be the result of the high 
induction, and not by the selective pressure generated by the addition of ampicillin. As had been 
observed before, high levels of production of the scFv163R4-A::β-lactamase could produce a 
detrimental effect on cell culturability observed in cultures where the translocation of the 
scFv163R4-A::β-lactamase was directed by the DsbA and Bla signal peptides (Chapter 4, Section 
4.2.8). The same effect was observed during the selection of clones carrying the Twist library. 
 
5.2.5 Selection of clones obtained from EP-PCR library by β-lactamase assay 
Clones selected by their ability to grow on plates supplemented with ampicillin were evaluated 
for β-lactamase activity with the aim to screen for clones containing signal peptides which allowed 
a higher production of scFv163R4-A::β-lactamase compared with the PelB signal peptide. 
Colonies obtained from ampicillin-supplemented agar plates were grown in duplicate in 96-well 
plates. Cultures were grown in terrific broth at 25 °C and induced with 0.02% arabinose, 2 hours 




Error-prone PCR product 5 (pool): PelB-scFv163R4-A::β-lactamase: 
Error-prone PCR product 1: Error-prone PCR product 2: 
Error-prone PCR product 3: Error-prone PCR product 4: 
Figure 5.4. Selection of clones obtained 
from signal peptide libraries. Different 
colony morphologies observed in M-H 
agar plates grown under non-induced 
(left) and induced conditions (right). M-H 
agar plates were supplemented with only 




substrate by continuous measurement of the OD495 before induction (2 h) and after induction (8 
and 24 hours post-inoculation). The initial velocity (slope) was calculated by linear regression, as 
a quantification of the relative β-lactamase activity. 
As part of the β-lactamase screening assay, 200 clones were evaluated for β-lactamase activity, 
divided between five 96-well plates (Libraries A, B, C, D and E) containing 40 clones each. For each 
library, 8 clones were selected corresponding to each Ep-PCR product (Ep-PCR 1, Ep-PCR 2, Ep-
PCR 3, Ep-PCR 4 and Ep-PCR 5). Cultures carrying the empty vector (pLBAD2), the cytoplasmic 
scFv163R4-A::β-lactamase (M) and the wild type PelB signal peptide fused to the scFv163R4-A::β-
lactamase were used as control cultures. The nitrocefin enzymatic assay was carried out on live 
cells. 
As expected, the majority of the clones showed similar levels of β-lactamase activity to PelB signal 
peptide (Figure 5.5). A few clones, such as clones 25 and 34 obtained from Library C, showed 
reduced or no β-lactamase activity. Some clones showed a higher β-lactamase activity than PelB 
wild type, such as clones 26, 31 and 33 (Library C) and clones 27 and 29 (Library D), with a 3-fold 
increase in β-lactamase activity after 24 hours of growth. Some clones, such as 26 and 33 (Library 
C) showed a 4-fold increase in β-lactamase activity in samples obtained 8 hours post-inoculation. 
Unexpectedly, some clones showed higher β-lactamase activity at 8 hours than at 24 hours of 
growth, such as clones 7 and 19 (Library A) and clone 18 (Library B). 
In general terms, there seems to be a correlation between the expected number of mutations in 
the signal peptide sequence and the level of β-lactamase activity observed between different 
clones. As the Ep-PCR 4 is the product of the fourth sequential error-prone PCR, contained a higher 
number of mutations, and overall, a higher number of clones with high β-lactamase activity were 




































































































































































































































































































Figure 5.5. β-lactamase enzymatic assay for the screening of the EP-PCR library. E. coli 
BL21-A clones containing the vector coding for the error-prone PCR library signal peptides fused 
to the scFv163R4-A::β-lactamase were grown at 25 °C and induced with 0.02% arabinose, 2 
hours post-inoculation. Cultures were evaluated for β-lactamase activity by quantification of the 
hydrolysis of the substrate nitrocefin by continuous measurement of the OD495 before (2 h) and 
after induction (8 h and 24 h post-inoculation). All the data was normalised by OD600. The 
average relative β-lactamase activity after 8 hours (green line) and 24 hours (yellow line) of 
growth for the wild type PelB signal peptide fused to the scFv163R4-A::β-lactamase is 
represented. The dotted lines represent ±2 standard deviations. The initial velocity (slope) was 
calculated by linear regression, adapted to obtain an R ≥ 0.9, and compared between the 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.5. (Continuation) 
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5.2.6 Selection of clones obtained from Twist library by β-lactamase assay 
With the aim to compare both signal peptide libraries, all the steps described in the previous 
sections were repeated using the signal peptide library generated by Twist Biosciences. Colonies 
selected from M-H agar plates were grown in duplicate in 96-well plates containing terrific broth 
at 25 °C, and induced with 0.02% arabinose, 2 hours post-inoculation. The relative activity of β-
lactamase was determined using nitrocefin as a substrate by continuous measurement of the 
OD495 before induction (2h) and after induction (8 and 24 hours post-inoculation). 
As with Ep-PCR libraries, 200 clones were evaluated for β-lactamase activity, divided between 5 
different 96-well plates (Libraries A, B, C, D and E) containing 40 clones each. The empty vector 
(pLBAD2), the cytoplasmic scFv163R4-A::β-lactamase and the PelB signal peptide fused to the 
scFv163R4-A::β-lactamase, were used as controls. 
In general terms, a higher number of clones with high β-lactamase activity were detected from 
clones obtained from the Twist library (Figure 5.6), when compared to the Ep-PCR library 
(Figure 5.5). This result was not unexpected, since the Twist library was designed to have a 
similar number of mutations as the Ep-PCR 4, where the highest number of high productive clones 
were detected. Also some clones from the Twist library had higher activity than most active clones 
from the Ep-PCR library (Figure 5.6). A high number of clones showed high levels of β-lactamase 
activity, such as clone 3 and 11 (Library A), clone 4 (Library D) and clones 18, 33, 35 and 39 
(Library E), showing approximately a 5-fold increase over the wild type PelB, in samples obtained 
after 24 hours of growth. Also, a 2.5-fold increase in β-lactamase activity was detected in clones 
15 and 19 (Library A) and clones 13, 24, 27 and 35 (Library D), 24 hours post-inoculation. 
Overall, the β-lactamase activity assay allowed the rapid screening of a large number of clones, 
which by other methods could have been an extremely time-consuming process. A few clones with 







































































































































































































































































































Figure 5.6. β-lactamase enzymatic assay for the screening of the Twist library. E. coli 
BL21-A clones containing the vector coding for the Twist library signal peptides fused to the 
scFv163R4-A::β-lactamase were grown at 25 °C and induced with 0.02% arabinose, 2 hours 
post-inoculation. Cultures were evaluated for β-lactamase activity by quantification of the 
hydrolysis of the substrate nitrocefin by continuous measurement of the OD495 before (2 h) and 
after induction (8 h and 24 h post-inoculation). All the data was normalised by OD600. The 
average relative β-lactamase activity after 8 hours (green line) and 24 hours (yellow line) of 
growth for the wild type PelB signal peptide fused to the scFv163R4-A::β-lactamase is 
represented. The dotted lines represent ±2 standard deviations. The initial velocity (slope) was 
calculated by linear regression, adapted to obtain an R ≥ 0.9, and compared between the 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































concentration of β-lactamase is sufficient to confer resistance to β-lactam antibiotics and grow in 
 ampicillin-supplemented agar plates. In order to evaluate whether the high β-lactamase activity 
exhibited by some of the clones obtained from the Ep-PCR and Twist libraries correlated with the 
production of the scFv163R4-A::β-lactamase; the production of scFv163R4-A::β-lactamase was 
further assessed by shake-flask growth experiments. 
 
5.2.7 Evaluation of clone-to-clone variability 
In order to evaluate whether the different levels of β-lactamase activity observed between clones 
were the result of the mutation diversity of the signal peptide library or the clone-to-clone 
variation, the β-lactamase enzymatic assay was also carried out using the PelB wild type signal 
peptide. E. coli BL21-A was transformed with the vector coding for the PelB-scFv163R4-A::β-
lactamase, transferred to a shake-flask and grown overnight. Cultures were plated on M-H agar 
plates supplemented with ampicillin and 40 colonies were selected to be evaluated by β-lactamase 
enzymatic assay. 
As expected, all the different clones containing the PelB wild type signal peptide showed a similar 
relative β-lactamase activity (Figure 5.7). No substantial differences in the level of β-lactamase 
activity were observed between different clones after 8 hours of growth; however, a higher 
variability in β-lactamase activity was observed after 24 hours of growth. 
Overall, differences in β-lactamase activity between different clones carrying the PelB wild type 
signal peptide were not comparable to differences observed during the screening of the Ep-PCR 
and Twist signal peptides libraries. Hence, confirming that the variability in β-lactamase activity 
observed different clones was the result of the introduction of mutations in the signal peptide 





Figure 5.7. Evaluation of clone-to-clone variability using the wild type PelB signal peptide. 
E. coli BL21-A clones containing the vector coding for the PelB signal peptides coding for 
scFv163R4-A::β-lactamase were grown at 25 °C and induced with 0.02% arabinose, 2 hours 
post-inoculation. Cultures were evaluated for β-lactamase activity by quantification of the 
hydrolysis of the substrate nitrocefin by continuous measurement of the OD495 before (2 h) and 
after induction (8 h and 24 h post-inoculation). All the data was normalised by OD600. The 
average relative β-lactamase activity after 8 hours (green line) and 24 hours (yellow line) of 
growth for the wild type PelB signal peptide fused to the scFv163R4-A::β-lactamase is 
represented. The dotted lines represent ±2 standard deviations. The initial velocity (slope) was 
calculated by linear regression, adapted to obtain an R ≥ 0.9, and compared between the 




































































































































































































































































































5.2.8 Evaluation of clones selected from the Ep-PCR and the Twist libraries for the production of scFv163R4-
A::β-lactamase 
For further clarity, from this point forward clones selected from the Ep-PCR libraries will be 
referred as EP and from the Twist library as T, followed by a letter corresponding to the library 
were they were obtained from and the clone number. For example, a clone selected from the EP-
PCR library C, clone 25, will be referred as clone EP-C25. 
With the aim to evaluate whether the levels of β-lactamase activity detected by enzymatic assay 
were representative of the production of the scFv163R4-A::β-lactamase, a total of 10 clones were 
selected from the error-prone PCR library C, clones 25 to 34, and grown in shake-flasks. Clones 
evaluated included high productive clones, such as clones EP-C26, EP-C31 and EP-C33; clones 
with a similar β-lactamase activity to PelB wild type, as clones EP-C27, EP-C28, EP-C29 and EP-
C30; and clones showing no or low β-lactamase activity, as clones EP-C25, EP-C32 and EP-C34 
(Figure 5.5). 
Cultures were grown at 25 °C and induced with 0.02% arabinose at an OD600 of 0.5. Cultures where 
the translocation of the scFv163R4::β-lactamase was directed by the PelB wild type signal peptide 
were used as a control. Cell culturability was evaluated by serially diluted culture samples being 
plated onto non-selective LB agar. 
A high variability between clones was observed in terms of growth, reaching a final OD600 between 
15 and 25, after 24 hours of growth (Figure 5.8 A). All the clones reached a higher OD600 than the 
control culture (PelB WT), with the exception of clone EP-C31, which reached a final OD600 of 15 
after 24 hours of growth. This clone, EP-C31, also showed a drastic decrease in the number of CFU 
between 9 and 24 hours of growth, reaching 1.5 · 108 CFU · mL-1, in contrast with the control 
















EP-C25 (L) EP-C26 (H) EP-C27 (M) EP-C28 (M) EP-C29 (M) EP-C30 (M)
EP-C31 (H) EP-C32 (L) EP-C33 (H) EP-C34 (L) PelB WT
Figure 5.8. Growth and cell viability of clones selected from EP-PCR. E. coli BL21-A carrying 
the vector coding for the different signal peptides selected from the error-prone PCR library C 
were grown at 25 °C and induced with 0.02% arabinose at an OD600 ≈ 0.5 (blue arrow). The 
OD600 of the culture was measured at intervals post-inoculation (A). Serial dilutions of culture 
samples at 3 h, 9 h and 24 h post-inoculation were plated onto non-selective LB agar to assess 
the cell viability after induction (B). Clones are labelled as high (H), medium (M) and low (L) 
producers depending on the level of β-lactamase activity detected in the enzymatic assay as a 
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In terms of the production of the scFv163R4-A::β-lactamase, results obtained from the shake-flask 
studies correlated with results obtained from the β-lactamase enzymatic assay (Figure 5.9). 
Clones which exhibited high levels of β-lactamase activity, such as clones EP-C26, EP-C31 and EP-
C33, showed a high production of the scFv163R4-A::β-lactamase accounting for ≥ 20% of the total 
cell protein (TCP), after 24 hours of growth (Figure 5.9 A). Clone EP-C29 also showed a high 
production of scFv163R4-A::β-lactamase, accounting for 24% of the total cell protein. This result 
was unexpected, since this clone had not been identified as a high producer during the enzymatic 
assay (Figure 5.9 C). Clones EP-C27 and EP-C30 showed a similar level of protein production as 
PelB, accounting for 15% and 12% of TCP, respectively, 24 hours post-inoculation (Figure 5.9 A). 
Low accumulation of scFv163R4-A::β-lactamase was observed in samples obtained from clones 
EP-C25, EP-C32 and EP-C34, accounting for ≤ 2% of TCP protein corresponding to the scFv163R4-
A::β-lactamase, correlating with the results obtained from the enzymatic assay. 
A low concentration of scFv163R4-A::β-lactamase was detected in the periplasmic fraction. The 
fusion protein was found to be accumulated mainly in the spheroplast protein fraction for all the 
clones evaluated, independently of the production level of each clone (Figure 5.9 B). 
In general terms, no correlation was obtained between growth, cell viability and protein 
production between clones selected from the EP-PCR library C. The level of production of the 
scFv163R4-A::β-lactamase observed during shake-flask experiments generally correlated with 
the levels of activity detected by the β-lactamase enzymatic assay. 
As growth experiments only included signal peptides selected from the Ep-PCR library C, the 
shake-flask screening was expanded to include high productive clones selected from the Twist 
signal peptide libraries. In contrast with the previous shake-flask growth experiment, only high 
productive clones were selected from the Twist library, and a total of five clones, corresponding 
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Figure 5.9. Production of scFv163R4-A::β-lactamase of clones selected from the Ep-PCR. 
SDS-PAGE gels showing the accumulation of scFv163R4-A::β-lactamase (black arrow) from 
whole cell lysates. Samples were obtained before (3 h) and after induction (9 and 24 hours post-
inoculation) (A). The periplasm (P) and spheroplast (Sp) protein fractions were obtained by 
modified cold osmotic shock from samples after 9 hours of growth (B). Samples obtained from 
cultures carrying the empty vector (-ve) after 24 hours of growth were used as a control. The 
quantity of the scFv163R4-A is expressed as percentage of whole cell protein (A) and the ratio 
of protein accumulated in the periplasm and spheroplast protein fractions (B) are expressed as 
percentage at the bottom of the gel. The relative β-lactamase activity of each clone evaluated is 
represented as a guidance (C). 
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results obtained by the β-lactamase enzymatic assay. As in the previous shake-flask experiment, 
cultures were grown at 25 °C and induced with 0.02% arabinose at an OD600 of 0.5. Cultures 
carrying the PelB wild type signal peptide were used as a control.  
In terms of growth, differences were observed between different clones selected from the Twist 
library. Clones T-A11, T-A19 and T-B2 showed a similar growth profile as the control culture (PelB 
WT), reaching a final OD600 between 11 and 13, after 24 hours of growth (Figure 5.10 A). In 
contrast, clones T-D4 and T-E18 showed signs of growth arrest, reaching an OD600 of 3 and 6, 24 
hours post-inoculation. Nevertheless, growth variability was lower than in clones selected from 
the Ep-PCR, especially between 3 and 9 hours post-inoculation (Figure 5.8 A). Loss of cell 
culturability was observed in cultures corresponding to clones T-D4 and T-E18, showing a 
decrease in CFU between 9 and 24 of growth (Figure 5.10 B). A lower cell culturability was also 
observed for clones T-A19 and T-B2 when compared to PelB WT, after 24 hours of growth. 
In terms of protein production, all the clones evaluated during this experiment showed higher or 
similar production of the scFv163R4::β-lactamase than the PelB wild type signal peptide, 
accounting for 11% to 19% of the total cell protein (Figure 5.11 A). However, the scFv163R4::β-
lactamase protein yields were lower than  for high producer clones selected from the Ep-PCR 
signal peptide library, as EP-C26, EP-C29, EP-C31 and EP-C33 (Figure 5.9), even though β-
lactamase activities of Twist library clones were higher than Ep-PCR clones. 
A high accumulation of the fusion protein in the periplasm was detected in samples obtained from 
clones T-A11, T-A19 and T-B2, from 35% to 40% of the total scFv163R4::β-lactamase, after 9 
hours of growth (Figure 5.11 B). Low concentration of scFv163R4::β-lactamase was detected in 
periplasmic protein samples obtained from clones T-D4 and T-E18, which did not correlate with 
results obtained from the β-lactamase enzymatic assay. The high levels of β-lactamase activity 
exhibited by these two clones could be the result of cell lysis, as growth arrest and low cell viability 




Figure 5.10. Growth and cell viability of clones selected from Twist library. E. coli BL21-A 
carrying the vector coding for the different signal peptides selected from the Twist libraries 
were grown at 25 °C and induced with 0.02% arabinose at an OD600 ≈ 0.5 (blue arrow). The 
OD600 of the culture was measured at intervals post-inoculation (A). Serial dilutions of culture 
samples at 3 h, 9 h and 24 h post-inoculation were plated onto non-selective LB agar to assess 
the cell viability after induction (B). Clones are labelled as high (H), medium (M) and low (L) 
producers depending on the level of β-lactamase activity detected in the enzymatic assay as a 
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Figure 5.11. Production of scFv163R4-A::β-lactamase of clones selected from the Twist 
library. SDS-PAGE gels showing the accumulation of scFv163R4-A::β-lactamase (black arrow) 
from whole cell lysates. Samples were obtained before (3 h) and after induction (9 and 24 hours 
post-inoculation) (A). The periplasm (P) and spheroplast (Sp) protein fractions were obtained 
by cold osmotic shock from samples after 9 hours of growth (B). Samples obtained from cultures 
carrying the empty vector (-ve) after 24 hours of growth were used as a control. The quantity of 
the scFv163R4-A is expressed as percentage of whole cell protein (A) and the ratio of protein 
accumulated in the periplasm and spheroplast protein fractions (B) are expressed as percentage 
at the bottom of the gel. The relative β-lactamase activity quantified for each clone evaluated is 
represented as a guidance (C). 
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In general, higher production of the scFv163R4-A::β-lactamase was detected in clones obtained 
from the Ep-PCR signal peptide library than in the Twist library (Figure 5.12). Nevertheless, 
clones T-A11, T-A19 and T-B2 showed an enhanced production of the scFv163R4-A::β-lactamase 
in the periplasmic space (Figure 5.11 B). In general, clones EP-C26, EP-C33, from the Ep-PCR 
libraries, and T-A11, T-A19 and T-B2, from the Twist libraries, showed the most promising results 
in terms of growth, cell viability and production of the scFv163R4-A::β-lactamase. These clones 
showed a higher production of scFv163R4-A::β-lactamase when compared with the PelB wild 
type after 24 of growth, without compromising growth and cell viability (Figure 5.12). Therefore, 
further experiments would be required to evaluate if any of these clones showed an enhanced 
production of periplasmic scFv163R4-A β-lactamase when compared with the PelB signal peptide.   
Overall, the correlation between the results obtained from the enzymatic assay and the shake-
flask growth experiments validates the use of β-lactamase enzymatic assay as a high-throughput 
screening method, allowing the screening of a large number of clones and the selection of those 
with improved β-lactamase activity. However, growth studies are still required to evaluate the 
effect of the production of the scFv163R4-A::β-lactamase on growth and cell viability, since high 
levels of production and translocation of recombinant proteins to the periplasm may result in 
growth arrest and cell lysis. In addition, high levels of β-lactamase activity could be the result of 
the release of cytoplasmic β-lactamase caused by cell lysis, leading to misleading results from the 
enzymatic assay. In addition, further evaluations would be required to understand the 
relationship between the mutations introduced in the signal peptide sequence and the 
physiological and protein production differences observed between different clones. 
 
With the main objective to expand the knowledge regarding the structure of the signal peptide 


































































































































3 h 9 h 24 h
Figure 5.12. Evaluation of the production of scFv163R4-A::β-lactamase. Production of the 
scFv163R4-A::β-lactamase in cultures grown at 25 °C, induced with 0.02% arabinose at an OD600 
of 0.5. The production of the scFv163R4-A::β-lactamase is represented as a percentage of the 
total cell protein (TCP) obtained after 3, 9 and 24 hours of growth. The production of PelB-
scFv163R4-A::β-lactamase, used as control culture, after 9 (orange dotted line) and 24 hours of 
growth (grey dotted line) is represented as a guidance. Data shown here are single values 
obtained by quantifying the accumulation of the scFv163R4-A::β-lactamase in whole cell lysates 




plasmid DNA samples corresponding to 10 clones obtained from Ep-PCR signal peptide libraries 
(EP-C25, EP-C26, EP-C27, EP-C28, EP-C29, EP-C30, EP-C31, EP-C32, EP-C33 and EP-C34) and 5 
clones obtained from the Twist libraries (T-A11, T-A19, T-B2, T-D4 and T-E18), were sequenced. 
Alignments of the DNA and protein sequences obtained from clones selected from the error-prone 
PCR can be found in the Figure 5.13 and from the Twist library in the Figure 5.14. In general, a 
high variability within the number of mutations was found in sequences obtained from the error-
prone PCR, with sequences containing only 1 mutation to sequences with up to 10 mutations 
(Figure 5.13). DNA sequencing results showed that two clones with a low or non-detectable β-
lactamase activity (Figure 5.5), EP-C25 and EP-C34, had insertions or deletions, which altered the 
open reading frame (ORF). EP-C25 presented an insertion which introduced a stop codon at the 
end of the signal peptide sequence, which could have resulted in the generation of a truncated 
protein, whereas EP-C34 showed an alteration in the ORF which could have led to generation of a 
cytoplasmic version of the scFv163R4-A::β-lactamase. The methionine located at -2 position of 
the signal peptide could act as an initiation codon, generating a cytoplasmic form of the 
scFv163R4-A::β-lactamase containing the last two amino acids of the signal peptide, an extra 
methionine and alanine residues at position +1 and +2. The alteration of the ORF of the EP-C25 
and EP-C34 could explain the low level of β-lactamase activity and production of the scFv163R4-
A::β-lactamase showed by these clones (Figures 5.5 and 5.12). In general, clones with a similar 
level of β-lactamase activity (Figures 5.5 and 5.6) and protein production level (Figures 5.12) 
as the wild type PelB signal peptide showed a small number of mutations, including silent 
mutations, which introduced changes in the codon usage but not in the amino acid sequence, such 
as EP-C28 and EP-C30 (Figures 5.13). 
The hydrophobicity of the signal peptides was evaluated by calculating the grand average of 








CLUSTAL O (1.2.3) multiple sequence alignment: DNA sequence 
 
PelB wild type         ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGG CC 
EP-C25 (L)             ATGAAATACCTGCTGCCGACCCCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGG CCTGAAGAGCGGTACCCTCTGGGCC 
EP-C26 (H)             ATGAAATACCCGCTGTCGACCGCTGCTGCTCGTCTGCTGCTCCTCGCTGCCAAGCCGGCAATGG CC 
EP-C27 (M)             ATGAAATACCTGCTGCCGACAGATGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGG CC 
EP-C28 (M)             ATGAAATATCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGG CC 
EP-C29 (M)             ATGAAATACCTACTGCCGAGCGCTGCTGCTGGTCAGCTGCTCCTCGCTGCCCAGCCGGTGATGG CC 
EP-C30 (M)             ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTCCTGCTCCTCGCTGCCCAGCCGGCGATGG CC 
EP-C31 (H)             ATGAAATACCTGCTACTGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGG CC 
EP-C32 (L)             ATGAAATACCTGCTGCCGACCGTTCCGCCAGGCCTGCTGCTCCTCCTTGCCCAGCCGGC-ATGGGCC 
EP-C33 (H)             ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCACACTGCCCAGCAGGCGATGG CC 
EP-C34 (L)             ATGAAATACCTGCTGTCGACCGATGCTGCTG-TCTGCTGCTCCTCGCTGCCCAGCCGGCGATGG CC 
                       ******** *  **   **    * *  *    *  ******* *  **** *** **  **** ** 
 
 
CLUSTAL O (1.2.3) multiple sequence alignment         GRAVY  Amino acid changes 
 
PelB wild type   MKYLLPTAAAGLLLLAAQPAMA   1.19   - 
EP-C25 (L)   MKYLLPTAAAGLLLLAAQPAMA   1.19   0 
EP-C26 (H)      MKYPLSTAAARLLLLAAKPAMA   0.78   4 
EP-C27 (M)      MKYLLPTDAAGLLLLAAQPAMA   0.95   1 
EP-C28 (M)      MKYLLPTAAAGLLLLAAQPAMA   1.19   0 
EP-C29 (M)      MKYLLPSAAAGQLLLAAQPVMA   0.96   2 
EP-C30 (M)      MKYLLPTAAAGLLLLAAQPAMA   1.19   0 
EP-C31 (H)      MKYLLLTAAAGLLLLAAQPAMA   1.44   1 
EP-C32 (L)      MKYLLPTVPPGLLLLLAQPAWA   0.96   4 
EP-C33 (H)      MKYLLPTAAAGLLLHTAQQAMA   0.67   3 
EP-C34 (L)      --------------------MA    --   - 










Figure 5.13. Alignment of mutant signal peptides obtained from the Ep-PCR libraries. Alignment of DNA sequence and amino acid 
sequence of signal peptides obtained from the error-prone PCR library C and evaluated by shake-flask experiments. Amino acid colour code: 
polar positive (light blue), polar negative (red), polar neutral or hydrophilic (green), non-polar or hydrophobic (yellow) and special 








CLUSTAL O (1.2.3) multiple sequence alignment: DNA sequence 
 
PelB wild type          ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGGCC 
T-A11 (H)      ATGTTATACCTGACAAGGACCGCTATAGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGGCC 
T-A19 (H)      ATGAAATACCTGCTGAAGACCGCTTTTGCTGGTCTGCTGATCCTCGCTGCCCCCCCGGCGATGGCC 
T-B2  (H)      ATGAAATACCTGCTGCGGACCGCTGCTGCTGCACTTCTGCTCCTCGCTGCCCAGCCGGCGATGGCC 
T-D4  (H)      ATGAAATACCTGCTGATGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCTGGGTAGCGATGGCC 
T-E18 (H)      ATGAAATACCTGCTGCAAACCGCTGCTGCTTATCTGCTACTCCTCGCTGCCCAGCCGATTATGGCC 




CLUSTAL O (1.2.3) multiple sequence alignment         GRAVY  Amino acid changes 
 
PelB wild type  MKYLLPTAAAGLLLLAAQPAMA   1.19   - 
T-A11 (H)      MLYLTRTAIAGLLLLAAQPAMA   1.33   4 
T-A19 (H)      MKYLLKTAFAGLLILAAPPAMA   1.25   4 
T-B2  (H)      MKYLLRTAAAALLLLAAQPAMA   1.16   2 
T-D4  (H)      MKYLLMTAAAGLLLLAAWVAMA   1.73   3 
T-E18 (H)      MKYLLQTAAAYLLLLAAQPIMA   1.19   3 
               * **  ** * ** ***   ** 
 
Figure 5.14. Alignment of mutant signal peptides obtained from the Twist libraries. Alignment of DNA sequence and amino acid sequence 
of signal peptides obtained from the Twist library and evaluated by shake-flask experiments. Amino acid colour code: polar positive (light blue), 
polar negative (red), polar neutral or hydrophilic (green), non-polar or hydrophobic (yellow) and special conformation (dark blue for proline 




important role in protein translocation. It has been reported that highly hydrophobic signal 
peptides have a higher affinity for the translocation machinery (Izard et al., 1996). Nevertheless, 
highly hydrophobic signal peptides, as T-D4, with a GRAVY score of 1.73 (Figure 5.14), did not 
correlate with high levels of accumulation of the scFv163R4-A::β-lactamase in the periplasm 
(Figure 5.11 C). On the other hand, several signal peptides showed lower hydrophobicity than 
PelB wild type (average hydrophobicity of 1.19), obtaining hydrophobicity score lower than 1, 
such as EP-C26, EP-C27, EP-C29 and EP-C33 (Figure 5.13). None of these signal peptides showed 
a high concentration of protein in the periplasm either. This example helps to illustrate how 
difficult is to elucidate which mutations within the signal peptide sequence caused the high 
variability between clones observed in terms of growth, cell viability and protein production. 
In general terms, it has been proved to be difficult to identify which mutations favour a higher 
production and translocation of the scFv163R4-A::β-lactamase based on results obtained from the 
β-lactamase enzymatic assay, shake-flask experiments and the DNA sequencing results. As for 
example, a certain mutation in the N-terminus may have a negative effect, which could be 
alleviated by a second mutation that increases the average hydrophobicity of the signal peptide 
(Izard and Kendall, 1994). This could mask the effect of each independent mutation, hampering 
the understanding of relationship between the signal peptide mutations and the production of the 
precursor or the mature form of the protein and its effect on cell physiology. Further studies will 
be required with the aim to understand the effect of different individual mutations on the 
production and translocation of recombinant proteins to the periplasmic space. 
 
5.2.9 Fed-batch fermentation of clones selected from the Ep-PCR and Twist libraries for the production of 
scFv163R4-A::β-lactamase  (early induction)  
As some mutant signal peptides selected from the error-prone and Twist signal peptide libraries 
showed a higher level of production of the scFv163R4-A::β-lactamase than the wild type signal 
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peptide, the next step was the evaluation by fed-batch fermentation. For this purpose, the Ambr® 
250 modular, a benchtop bioreactor system that allows performing up to 8 parallel fermentations, 
was used for evaluation of the clones selected by the β-lactamase screening assay. As a proof-of-
concept, 5 clones with the best performance in terms of growth, cell viability and production of 
the scFv163R4-A::β-lactamase were selected to be evaluated by fed-batch fermentation: EP-C26, 
EP-C33, T-A11, T-A19 and T-B2. The PelB wild type signal peptide fused to the scFv163R4-A::β-
lactamase was used as control. 
Fed-batch fermentations were carried out at 250 mL scale and cultures were grown in 150 mL of 
the semi-defined culture medium obtained from Want et al. (2009). The feed solution, composed 
of glycerol and magnesium sulphate, was started 10 hours post-inoculation following an 
exponential feeding profile to achieve a specific growth rate of 0.1 h-1. Cultures were grown were 
at 25 °C and induced with 0.02% arabinose at an OD600 of 0.5. The dissolved oxygen was 
maintained at 20% by continuous increments of the stirrer speed and pure oxygen was added 
when required. The pH was kept at 7.0 by the addition of 1 M NH4OH or 1 M HCl. 
In terms of growth, only two of the clones, EP-C26 and EP-C33 were able to grow to an OD600 above 
12 during fed-batch fermentation, reaching a final OD600 of 94 and 82, after 48 hours of growth 
(Figure 5.15 A). Clones T-A11, T-A19, T-B2 and the control culture (PelB WT) showed signs of 
growth arrest after 12 hours of growth, reaching a final OD600 lower than 10, after 48 hours. A 
similar profile was observed in terms of cell viability, where a decrease in the CFU was observed 
12 hours post-inoculation, for clones T-A11, T-A19, T-B2 and the control culture, PelB WT (Figure 
5.15 B). In contrast, clones EP-C26 and EP-C33 showed a continuous increase in the CFU during 
through the course of the fed-batch fermentation without loss of cell culturability.  
The production of the scFv163R4-A::β-lactamase was evaluated for EP-C26 and EP-C33 and 
showed a high concentration of the recombinant protein in the spheroplast protein fraction (Data 






































EP-C26 EP-C33 T-A11 T-A19 T-B2 PelB WT
Figure 5.15. Fed-batch fermentation for the production of scFv163R4-A::β-lactamase 
induced at low cell density. E. coli BL21-A carrying the vector coding for the different signal 
peptides selected from the error-prone PCR and Twist signal peptide libraries fused to the 
scFv163R4-A::β-lactamase were grown at 25 °C and induced with 0.02% arabinose at an OD600 
of 0.5 (dotted line). The feed was started after 10 hours of growth (blue arrow). The OD600 of the 
culture was measured at intervals post-inoculation (A). Serial dilutions of culture samples at 
intervals post-inoculation were plated onto non-selective LB agar to assess the cell viability after 






fraction, correlating with results previously obtained from shake-flask experiments (Figure 5.9 
B). The superior growth and cell culturability observed for clones EP-C26 and EP-C33 could be 
the result of the accumulation of the scFv163R4-A::β-lactamase in inclusion bodies, which helped 
to minimise the metabolic burden imposed to the host cells. The possible overload of the SecB-
dependent translocation pathway could had been the cause of the growth arrest and cell lysis 
observed for clones T-A11, T-A19 and T-B2 and the control culture PelB WT. Nevertheless, this 
result led to the conclusion than the growth conditions for the production of the scFv163R4-A::β-
lactamase were not optimal, as the control culture carrying the PelB wild type signal peptide was 
not able to grow by fed-batch fermentation. The cultivation conditions need to be optimised, 
aiming to avoid the possible overload the SEC translocation pathway and favour the production 
of the scFv163R4-A::β-lactamase in the periplasmic space. 
 
5.2.10 Fed-batch fermentation of clones selected from the Ep-PCR and Twist libraries for the production of 
scFv163R4-A::β-lactamase  (late induction)  
With the aim to develop a fermentation protocol which allows the evaluation of growth and 
production scFv163R4-A::β-lactamase from clones selected from the error-prone PCR and the 
Twist libraries, a late induction protocol was evaluated. Fed-batch fermentations were carried out 
as described previously, but the induction point was shifted to a target OD600 of 70-80, to allow 
the separation of the biomass and protein production stages. The cultivation temperature was 30 
°C, and upon induction, shifted to 25°C, to favour a slower protein synthesis rate, avoiding the 
overload of the translocation machinery. The feed solution was started 10 hours post-inoculation, 
and adjusted based on growth (OD600) after 16 hours of inoculation, following an exponential 
feeding profile to achieve a specific growth rate of 0.1 h-1. 
In general, the modification of the cultivation conditions had a positive effect in terms of growth 
and all the clones showed a similar growth profile, reaching a final OD600 ranging between 140 
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and 160, after 28 hours of growth (Figure 5.16 A). Loss of cell culturability in samples taken post-
induction was observed (Figure 5.16 B); however, the loss of colony forming units was not as 
severe as in the previous fermentation (Figure 5.15 B). 
However, the high biomass obtained at the end of the fermentation did not correlate with a high 
production of the scFv163R4-A::β-lactamase (Figure 5.17 A). The accumulation of scFv163R4-
A::β-lactamase was lower in samples taken post-induction when compared with results obtained 
during shake-flask experiments (Table 5.1). Clones EP-C26 and EP-C33 showed a production of 
the scFv163R4-A::β-lactamase, accounting for 7% and 9% of total cell protein (TCP), after 26 
hours of growth. An even lower accumulation was detected 28 hours post-inoculation, possibly as 
a result of plasmid loss, proteolysis or protein degradation. The concentration of scFv163R4-A::β-
lactamase was higher in samples obtained from clones T-A11 and T-B2 after 28 hours of growth, 
reaching a 9% of TCP (Figure 5.17 A). Samples obtained from clone T-A19 showed a similar 
production of the scFv163R4-A::β-lactamase, accounting for 7% of TCP, to the control culture 
carrying the PelB signal peptide.  
No accumulation of the protein in the periplasm was observed from samples obtained from clones 
EP-C26 and EP-C33 (Figure 5.17 B). Nevertheless, the large molecular weight of the scFv163R4-
A::β-lactamase (≈60 kDa) could impede the extraction of the protein, and as some protein can be 
found accumulated in the spheroplast protein fraction. In contrast, samples obtained from clones 
T-A11, T-A19 and T-B2 and the wild type PelB signal peptide showed a high concentration of the 
scFv163R4-A::β-lactamase in the periplasmic fraction, accounting for 35% to 44% of the total 
scFv163R4-A::β-lactamase produced. 
A summary of data obtained from shake-flask experiments (section 5.2.8) and fed-batch 
fermentation experiments (section 5.2.10) in terms of scFv163R4-A:: β-lactamase can be found 





Figure 5.16. Fed-batch fermentation for the production of scFv163R4-A::β-lactamase. E. 
coli BL21-A carrying the vector coding for the different signal peptides selected from the error-
prone PCR and Twist signal peptide libraries fused to the scFv163R4-A::β-lactamase were grown 
at 30 °C, and upon induction at 25 °C. Cultures were induced with 0.02% arabinose at an OD600 ≈ 
70 – 80 (dotted line). The feed was started after 10 hours of growth (blue arrow). The OD600 of 
the culture was measured at intervals post-inoculation (A). Serial dilutions of culture samples at 
intervals post-inoculation were plated onto non-selective LB agar to assess the cell viability after 
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Figure 5.17. Production of scFv163R4-A::β-lactamase by fed-batch fermentation. SDS-PAGE 
gels showing the accumulation of scFv163R4-A::β-lactamase (black arrow) from whole cell 
lysates obtained from cultures grown at 30 °C, and upon induction at 25 °C. Cultures were induced 
with 0.02% arabinose at an OD600 ≈ 70 – 80. Samples were obtained before (20 h) and after 
induction (24, 26 and 28 hours post-inoculation) (A). The periplasm (P) and spheroplast (Sp) 
protein fractions were obtained by modified cold osmotic shock from samples obtained 28 hours 
post-inoculation (B). Samples obtained from cultures carrying the scFv163R4-A::β-lactamase 
produced in the cytoplasm (M) after 24 hours of growth were used as a control. The quantity of 
the scFv163R4-A is expressed as percentage of whole cell protein (A) and the ratio of protein 
accumulated in the periplasm and spheroplast protein fractions (B) are expressed as percentage 







Table 5.1. Comparison of data obtained from shake-flask and fed-batch fermentation experiments at harvest in terms of production of 
scFv163R4-A::β-lactamase. 
 Shake-flask data Fed-batch fermentation data 
Clone name EP-C26 EP-C33 T-A11 T-A19 T-B2 PelB wt EP-C26 EP-C33 T-A11 T-A19 T-B2 PelB wt 
Growth temperature 25 °C 30 °C → 25 °C 
Inducer concentration 0.02% 0.02% 
Induction time OD600 ≈ 0.5 OD600 ≈ 70-80 
Cultivation time 24 h 28 h 
Final OD600 21.7 24.4 12 12.6 11.2 12 153.2 153.2 141.2 146.8 152.8 155 
scFv163R-A::Bla as % of  
TCP 
22% 24% 16% 13% 14% 12.3% 4.4% 2.2% 9% 7.2% 9.3% 7% 
% of periplasmic 
scFv163R-A::Bla 
7% 7% 38% 40% 35% 10% 0% 0% 36% 44% 38% 42% 
% of spheroplast 
scFv163R-A::Bla 
93% 93% 62% 60% 65% 90% 100% 100% 64% 56% 62% 58% 
Total scFv163R-A::Bla  
(g ∙ L-1) 
1.15[1] 1.42[1] 0.46[1] 0.39[1] 0.38[1] 0.36[1] 1.6[1] 0.8[1] 3.1[1] 2.5[1] 3.4[1] 2.6[1] 
Periplasmic  
scFv163R-A::Bla (g ∙ L-1) 
0.08[2] 0.1[2] 0.17[2] 0.16[2] 0.13[2] 0.04[2] 0[2] 0[2] 1.12[2] 1.1[2] 1.29[2] 1.09[2] 
Spheroplast  
scFv163R-A::Bla (g ∙ L-1) 
1.07[3] 1.32[3] 0.29[3] 0.23[3] 0.25[3] 0.32[3] 1.6[3] 0.8[3] 1.98[3] 1.4[3] 2.11[3] 1.51[3] 
 
[1] Estimated from DCW assuming 1 OD600=0.4 g ∙ L-1 and % of scFv163R4-A::Bla of total cell protein assuming protein comprises 60% E. coli dry 
cell weight (g ∙ L-1) (based on 50-61% estimates from Valgepea et al. (2013)). 
[2] Estimated from DCW and % of periplasmic scFv163R4-A::Bla or [3] % of spheroplast scFv163R4-A::Bla of total cell protein calculated from the 
estimated total yield of scFv163R4-A::Bla (g ∙ L-1).  
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lactamase from total cell protein was obtained from SDS-PAGE and quantified by densitometry. 
The scFv163R4-A::β-lactamase yields are estimated, shown here to illustrate the comparison 
between the data obtained from shake-flask and fermentation experiments. 
In general terms, the production level of scFv163R4-A::β-lactamase was not comparable between 
shake-flask and fermentation experiments (Table 5.1). In shake-flask experiments, the 
production of the scFv163R4-A::β-lactamase for clones EP-C26 and EP-C33 was over 20% of the 
total cell protein, comparing with less than 5% obtained by fed-batch fermentation. The 
accumulation of the scFv163R4-A::β-lactamase was higher for clones EP-C26 and EP-C33 between 
24 and 26 hours of growth reaching between 9% and 10% of TCP (Figure 5.17), but only data 
obtained at the harvest was included in Table 5.1. The difference in protein production between 
shake-flask and fermentation experiments was lower in clones T-A11, T-A19 and T-B2, with over 
12% of TCP corresponding to scFv163R4-A::β-lactamase in samples obtained from shake-flask 
experiments and less than 10% in samples obtained from fermentation experiments. Similarly, 
results obtained from the control culture carrying the PelB signal peptide showed almost a 2-fold 
reduction in the total production of scFv163R4-A::β-lactamase. In terms of the concentration of 
scFv163R4-A::β-lactamase in the periplasmic and spheroplast fractions, results obtained from 
shake-flask and fed-batch fermentation had a higher degree of similarity. 
Overall, large differences between the total scFv163R4-A::β-lactamase yields obtained from 
shake-flask experiments and fed-batch fermentation were observed. Nevertheless, it is important 
to highlight the differences in the induction point, induction at an OD600 ≈ 0.5 for shake-flask 
experiments and OD600 ≈ 70-80 for fed-batch fermentation, which could have a great impact in 
recombinant protein production. The “production window” varied between shake-flasks, with an 
induction window of approximately 20 hours, and fed-batch fermentation, where cultures were 
induced for a period of 12 hours after induction. Also, differences in the growth profile and final 
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OD600, a maximum final OD600 of 25 for shake-flasks and 155 for fed-batch fermentations, could 
affect protein production. 
In general terms, the late induction favoured the growth of all the bioreactor cultures reaching a 
high cell density (Figure 5.15 and 5.16). However, the low production of the scFv163R4-A::β-
lactamase suggested that further optimisation of the fermentations conditions will be required 
with the aim to improve the yield of scFv163R4-A::β-lactamase. 
 
5.2.11 Fed-batch fermentation of clones selected from the Ep-PCR and Twist libraries for the production of 
scFv163R4-A 
With the aim to evaluate whether the signal peptides selected from the EP-PCR and Twist libraries 
could show an improvement in the production of the scFv163R4-A, the reporter protein, β-
lactamase, was removed from the vector. Fed-batch fermentations were carried out using the 
same conditions described in Section 5.2.10. The feed was started 14 hours post-inoculation, 
upon depletion of glycerol in the batch medium (determined by a DO spike) following an 
exponential feeding profile to achieve a specific growth rate of 0.1 h-1. 
As observed in the previous fermentation, all the clones showed an excellent growth profile and 
the production window was extended to 12 hours post-induction to favour the production of 
scFv163R4-A. Cultures reached a final OD600 ranging from 155 to 186, after 30 hours of growth 
(Figure 5.18 A). No loss of cell viability was observed in samples obtained post-induction, but the 
number of CFU did not increase with the increment of cell biomass (Figure 5.18 B). 
As in the previous fermentation, the production of the scFv163R4-A was lower than expected and 
did not correlate with the production levels observed in shake-flask experiments (Figure 5.19). 
The low concentration of the scFv163R4-A did not allow an accurate quantification and the 






































EP-C26 EP-C33 T-A11 T-A19 T-B2 PelB WT
Figure 5.18. Fed-batch fermentation for the production of scFv163R4-A. E. coli BL21-A 
carrying the vector coding for the different signal peptides selected from the error-prone PCR 
and Twist signal peptide libraries fused to the scFv163R4-A were grown at 30 °C, and upon 
induction at 25 °C. Cultures were induced with 0.02% arabinose at an OD600 ≈ 70 - 80 (dotted 
line).  The feed was started after 14 hours of growth (blue arrow). The OD600 of the culture was 
measured at intervals post-inoculation (A). Serial dilutions of culture samples at intervals post-
inoculation were plated onto non-selective LB agar to assess the cell viability after induction (B). 
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Figure 5.19. Production of scFv163R4-A by fed-batch fermentation. SDS-PAGE gels showing the accumulation of the precursor (p) and 
mature form (m) of the scFv163R4-A from whole cell lysates and culture medium samples (*) obtained from cultures induced with 0.02% 
arabinose at an OD600 ≈ 70 - 80. Samples were obtained before (18 h) and after induction (22, 26 and 30 h post-inoculation) (A). The periplasm 
(P) and spheroplast (Sp) protein fractions were obtained by modified cold osmotic shock from samples obtained 30 hours post-inoculation (B). 
The scFv163R4-A was detected by western blot using an anti-myc antibody. 
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The precursor form of the scFv163R4-A was detected in samples obtained from EP-C26, being 
only detected in the samples corresponding to whole cell lysates or the spheroplast protein 
fraction (Figure 5.19 B). The two forms of the protein, the precursor and the mature, could be 
identified in samples obtained from clone EP-C33. In samples obtained from EP-C33, a high 
accumulation of the precursor form of the scFv163R4-A was observed in samples taken 22 hours 
post-inoculation and the ratio between the precursor and the mature form of the scFv163R4-A 
seems to shift to higher accumulation of the mature form of the scFv163R4-A over the course of 
the fermentation (Figure 5.19 A). The mature form of the protein was only detected in the 
periplasmic protein fraction (Figure 5.19 B) and culture medium (Figure 5.19 A).  The high 
accumulation of the precursor form of the scFv163R4-A correlates with the results obtained from 
initial fermentation experiments, when under early induction conditions, only clones EP-C26 and 
EP-C33 were able to grow by fed-batch fermentation (Figure 5.15). 
The production of the scFv163R4-A was also detected in whole cell lysates obtained from clones 
T-A11, T-A19 and T-B2 and the control culture carrying the PelB signal peptide (Figure 5.19 A). 
The mature form of the scFv163R4-A was the predominantly observed, as confirmed by western 
blot, being detected in samples corresponding to the whole cell lysates, periplasmic protein 
fraction and the culture medium (Figure 5.19 B). Only traces of the scFv163R4-A were detected 
in the spheroplast protein fraction, probably as the result of residual periplasmic content present 
in the spheroplast fraction. 
The scFv163R4-A was detected in samples obtained from the culture medium (Figure 5.19 A). 
Since E. coli does not naturally secrete recombinant proteins to the culture medium, the release 
of the scFv163R4-A into the culture medium could be the result of outer membrane damage and 




In general terms, it seems that signal peptides obtained from clones T-A11, T-A19 and T-B2 
allowed the translocation of the protein to the periplasmic space. The optimisation of the 
fermentation process allowed high cell densities (OD600 ≥ 150) to be achieved and the extension 
of the “production window” to 12 hours, with no detrimental effect on cell viability. However, the 
production of scFv163R4-A seems to be lower than observed in shake-flask experiments (Figure 
5.9 and 5.11), being not possible to quantify the production of the scFv163R4-A from SDS-PAGE 
gels, confirming the production of the antibody fragment by western blot. It is important to 
highlight the difference in the molecular weight between the scFv163R-A::β-lactamase (≈60 kDa) 
and the scFv163R4-A (≈30 kDa), which could explain the differences in the protein yields obtained 
by fed-batch fermentation. The smaller size of the scFv163R4-A also facilitates its translocation to 
the periplasm, and its extraction by osmotic shock. Further fermentation optimisation would be 
required to achieve a higher protein production without comprising cell viability. 
 
5.2.12 Improved fermentation conditions for the production scFv163R4-A 
It was considered that a higher concentration of arabinose may be required to induce the 
production of the scFv163R4-A at higher cell densities, since the number of arabinose molecules 
per cell would be lower than for shake-flask cultures induced at lower cell densities. A 10-fold 
higher concentration of arabinose, 0.2%, than in previous experiments was used to induce the 
culture at an OD600 ≥ 70, with the aim of increasing the production of scFv163R4-A without having 
a deleterious effect on growth and cell viability. Fed-batch fermentations were carried out as 
described in previous sections and the feed was started 14 hours post-inoculation following an 
exponential feeding profile to achieve a specific growth rate of 0.1 h-1. 
In terms of growth, even when a concentration of arabinose of 0.2% was used to induce the 
production of the scFv163R4-A, no signs of growth arrest were observed and the cultures reached 




Figure 5.20. Fed-batch fermentation for the production of scFv163R4-A induced with 
0.2% arabinose. E. coli BL21-A carrying the vector coding for the different signal peptides 
selected from the error-prone PCR and Twist signal peptide libraries fused to the scFv163R4-A 
were grown at 30 °C, and upon induction at 25 °C. Cultures were induced with 0.02% arabinose 
at an OD600 ≈ 70 - 80 (dotted line).  The OD600 of the culture was measured at intervals post-
inoculation (A). Serial dilutions of culture samples at intervals post-inoculation were plated onto 
non-selective LB agar to assess the cell viability after induction (B). Data shown are single values 





































EP-C26 EP-C33 T-A11 T-A19 T-B2 PelB WT
B) 
Biomass production Protein production 
248 
  
a decrease in the CFU was observed after 26 hours of growth, which recovered at the end of the 
fermentation reaching between 1 and 2.5 · 1011 CFU · mL-1 (Figure 5.20 B). 
The higher concentration of arabinose used to induce protein expression favoured the production 
of the scFv163R4-A for all the cultures evaluated by fed-batch fermentation. As in previous 
fermentations, only the precursor form of the scFv163R4-A was detected in samples obtained 
from clones EP-C26 and EP-C33, accumulated in the spheroplast protein fraction (Figures 5.21 
and 5.22). Clones T-A11 and T-B2 showed a high level of production of the scFv163R4-A in 
samples corresponding to whole cell lysates after 30 hours of growth, accounting for 4% to 5% of 
the total cell protein (Figure 5.21). Clone T-A19 showed a similar level of production of the 
scFv163R4-A to PelB wild type, accounting for at least 3% of the TCP in whole cell lysates, after 
30 hours of growth. A high concentration of the scFv163R4-A was observed in the culture medium 
samples obtained from clones T-A11, T-A19, T-B2 and PelB-scFv163R4-A, accounting for at least 
6% of the protein content in the culture medium. 
A high concentration of the scFv163R4-A was detected in the periplasmic protein fraction 
obtained from clones T-A11, T-A19, T-B2 and PelB wild type, accounting for 24% to 30% of the 
total scFv163R4-A produced; being the second most abundant protein in the periplasm (Figure 
5.22). However, the protein was detected mainly in the culture medium, accounting for 43% to 
52% of the total scFv163R4-A produced. A low concentration of scFv163R4-A was detected in the 
spheroplast protein fraction. 
Non-specific periplasmic protein release had been reported during the production of antibody 
fragments, typically when PelB signal peptide is used to direct the translocation to the periplasm 
(Georgiou and Segatori, 2005). Therefore, it is not surprising to observe the scFv163R4-A being 
released to the medium when a high level of protein is detected in the periplasmic space. The high 
accumulation of recombinant proteins may exceed the maximum capacity of the periplasm, 
favouring the leakage of the periplasmic proteins to the culture medium (Newton et al., 2016). 
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Figure 5.21. Production of scFv163R4-A by fed-batch fermentation induced with 0.2% 
arabinose. SDS-PAGE gels showing the accumulation of the precursor (p) and mature (m) 
form of the scFv163R4-A from whole cell lysates and culture medium samples obtained from 
cultures induced with 0.2% arabinose at an OD600 ≈ 70 - 80. Samples were obtained before (18 
h) and after induction (26 and 30 h post-inoculation). Samples obtained from cultures carrying 
the empty vector (-ve) and cultures producing the cytoplasmic scFv163R4-A (M) after 24 
hours of growth were used as a control. The quantity of the scFv163R4-A is expressed as 
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Figure 5.22. Production of scFv163R4-A in the periplasm, spheroplast and culture 
medium. SDS-PAGE gels showing the accumulation of the precursor (p) and mature (m) form 
of the scFv163R4-A from periplasm (P), spheroplast (Sp) and culture medium (C) samples 
obtained from cultures induced with 0.2% arabinose at an OD600 ≈ 70 – 80, after 30 hours of 
growth. Samples obtained from cultures carrying the empty vector (-ve) and cultures producing 
the cytoplasmic scFv163R4-A (M) after 24 hours of growth were used as a control. The western 
blot was developed using a mouse anti-myc antibody. The ratio of scFv163R4-A accumulated in 




Overall, it seems that mutations introduced in the signal peptides of clones EP-C26 and EP-C33 
diminished the translocation ability of the signal peptide, as slow or no processing of the 
scFv163R4-A was observed, the protein mainly being accumulated as precursor in the 
spheroplast fraction. In contrast, mutations introduced in the signal peptide sequence of clones T-
A11, T-A19 and T-B2 allowed the translocation of the scFv163R4-A in the periplasm, and only the 
mature form of the protein was detected in protein samples. The production of mature 
scFv163R4-A of clones T-A11, T-A19 and T-B2 was slightly better or similar to production levels 
observed with the PelB wild type signal peptide. 
In general terms, the optimisation of the fermentation conditions, late induction protocol in 
combination with a higher concentration of inducer, favoured the production of the scFv163R4-
A. However, the production of the scFv163R4-A in the periplasm does not necessarily correlate 
with the production of properly folded and active product, and therefore, it would be required to 
evaluate the binding activity of the scFv163R4-A. 
 
5.2.13 Purification of scFv163R4-A 
As reference material was required for quantification and the development of an activity assay, 
the scFv163R4-A obtained from a culture carrying the PelB signal peptide was purified by Nickel-
affinity chromatography. A culture medium sample obtained from a fed-batch fermentation 
carried out under identical conditions as those described in section 5.2.12 was used as starting 
material for the purification process, as only the mature form of the scFv163R4-A was detected in 
this sample. Clarified culture medium was loaded onto a HisTrap FF column. The HisTrap FF 
column was washed by using a PBS pH 7.2 buffer containing 40 mM imidazole and the scFv163R4-
A was eluted by using a PBS pH 7.2 buffer containing 100 mM imidazole (Figure 5.23). The final 
concentration of the purified scFv163R4-A material was 0.1 mg · mL-1, determined by 
















             L       FT       W1    W2     E1     E2  
Figure 5.23. Purification of scFv163R4-A from PelB-scFv163R4-A. SDS-PAGE gel showing the 
clarified culture medium loaded (L) into the HisTrap FF column, the flow-through (FT) from the 
column, the material obtained after the washing steps (W1, W2) and the eluted material (E1 and 
E2). The scFv163R4-A was eluted in a PBS pH 7.2 buffer containing 100 mM imidazole (E1). A 
second elution with PBS pH 7.2 buffer containing 500 mM imidazole (E2). 
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5.2.14 Evaluation of the activity of scFv163R4-A by “sandwich” ELISA 
The primary function of an antibody fragment is the recognition of the target molecule that it was 
designed to bind, and the scFv163R4-A was selected for its ability to recognise and bind the 
product of the lacZ gene, the protein β-galactosidase (Martineau et al., 1998). A “sandwich” ELISA 
was developed to evaluate the binding properties of the scFv163R4-A produced by fed-batch 
fermentation. This assay was used an indication of activity, and does not provide information with 
regards to the folding or the formation of disulphide bonds. The cell extracts, corresponding to 
the periplasmic, spheroplast and culture medium protein fractions, obtained from fed-batch 
fermentation experiments described in section 5.2.12, were evaluated for activity with the aim 
to compare the quantity of scFv163R4-A and its activity (Figure 5.24 A). The concentration of 
scFv163R4-A in each protein fraction was also quantified by densitometry from SDS-PAGE gels 
(Figure 5.24 B). The purified scFv163R4-A (Figure 5.23) was used as a reference material. 
Nevertheless, it is important to highlight that densitometry data could result in an overestimation 
of the protein yields and is shown here to aid the comparison between total concentration of 
scFv163R-A produced and the concentration of active scFv163R4-A. 
As expected, low levels of active scFv163R4-A were detected in samples obtained from fed-batch 
fermentations carrying the signal peptide corresponding to clones EP-C26 and EP-C33 (Figure 
5.24 A). The scFv163R4-A was mainly detected in the spheroplasts (Figure 5.24 B), correlating 
with results previously obtained by SDS-PAGE and western blot (Figures 5.20 to 5.22). A low 
concentration of scFv163R4-A in the spheroplast protein fraction was able to bind the β-
galactosidase, 0.17 and 0.04 g · L-1, when compared with the estimated concentration of 
scFv163R4-A quantified by densitometry, 0.57 and 0.27 g · L-1, corresponding to clones EP-C26 
and EP-C33 respectively (Figure 5.24). The total yield of active scFv163R4-A produced by fed-
batch fermentation of clones EP-C26 and EP-C33 was 0.244 g · L-1 and 0.193 g · L-1, respectively 




Figure 5.24. Quantification of scFv163R4-A and detection of anti-β-galactosidase activity 
of scFv163R4-A. The binding activity of scFv163R4-A present in the periplasmic, spheroplast 
and culture medium protein fractions, produced by fed-batch fermentation from clones obtained 
from the error-prone PCR and Twist signal peptide libraries. The binding activity was detected 
by ELISA using an anti-myc antibody HRP-conjugated (A). Estimation of the concentration of 
scFv163R4-A in the periplasmic, spheroplast and culture medium protein samples by 
densitometry (B). Data are shown are mean values from ELISA experiments and single values 
for the quantification of scFv163R4-A, error bars are ±1 standard deviation.   
EP-C26 EP-C33 T-A11 T-A19 T-B2 PelB WT
Periplasm 0.137 0.288 1.435 0.730 2.501 1.281
Spheroplast 0.566 0.273 0.811 0.506 1.436 0.901
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Spheroplast 0.173 0.043 0.036 0.028 0.032 0.026





































Clones T-A11, T-A19, T-B2 and PelB WT showed a higher binding activity of the protein, mainly 
detected in samples corresponding to the periplasmic protein fraction or the culture medium 
(Figure 5.24 A). Results obtained from the ELISA showed that clones T-A11 and T-B2 produced 
high concentrations of active scFv163R4-A, with 0.645 and 0.654 g · L-1 corresponding to 
periplasmic fraction, and 0.149 and 0.172 g · L-1 corresponding to the culture medium. Samples 
obtained from clone T-A19 showed a lower scFv163R4-A binding activity, similar to the culture 
carrying the PelB WT, and the total yield of active scFv163R4-A produced for clones T-A19 and 
PelB WT was 0.41 g · L-1 and 0.56 g · L-1, respectively (Figure 5.24 A). In addition, the 
concentration of scFv163R4-A in the spheroplast did not correlate with high levels of active 
protein, as the absence of disulphide bonds could have a negative effect on activity and stability 
of the scFv163R4-A. This could also explain the low concentration of active scFv163R4-A in 
samples obtained from clones EP-C26 and EP-C33, as the protein was mainly accumulated as a 
precursor in the cytoplasmic space. 
In general, results obtained from the ELISA binding assay are approximated, helping to quantify 
the scFv163R4-A produced with antigen recognition and binding properties. The highest yield of 
active scFv163R4-A was found to be produced by clones T-A11 and T-B2, which yielded almost 1 
g · L-1 of active scFv163R4-A, mainly detected in the periplasmic protein fraction and culture 
medium. The enhanced production of mature and active scFv163R4-A of clones T-A11 and T-B2 
when compared to PelB wild type signal peptide confirms the success in the development of the 
β-lactamase screening and in the optimisation of the fermentation conditions for the production 
of the scFv163R4-A. 
 
5.3 Discussion 
In E. coli, more than 90% of the proteins translocated across the cytoplasmic membrane are 
targeted to the SecYEG translocon, either via the SecB-dependent pathway or the SRP-mediated 
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translocation pathways. The majority of translocated proteins can be found in the periplasmic 
space or associated with the inner or outer membranes, and only a small number of proteins, 
mostly virulence factors, are secreted to the culture medium (Georgiou and Segatori, 2005). For 
recombinant protein production, the production of the proteins targeting the periplasm or the 
culture medium is often desirable, since it allows the generation of post-translational 
modifications, such as disulphide bonds, which are essential for the stability of antibody 
fragments. 
With the aim to develop a screening assay, β-lactamase was used as a reporter assay to facilitate 
the screening of signal peptides generated by random mutagenesis. In order to evaluate the 
possibilities of this screening assay, a model protein, the scFv163R4-A, was introduced between 
the N-terminal signal peptide and C-terminal marker protein, β-lactamase (Figure 5.1). The 
resistance to β-lactam antibiotics was used a selectable phenotype for periplasmic protein 
production, allowing the high-throughput screening of signal sequences obtained from 
mutagenized signal peptide libraries, by directly screening for antibiotic resistance levels of E. coli 
colonies (Mansell et al., 2010). 
 
5.3.1 High-throughput screening of clones by evaluation of β-lactamase activity 
The selection of β-lactamase as a reporter protein was based on the essential requirement of this 
protein to be localised in the periplasmic space to confer protection against β-lactam antibiotics 
(McCann et al., 2007). Therefore, the fusion of a given protein to β-lactamase could be used to 
identify which signal peptides allowed the translocation of the recombinant protein to the 
periplasmic space by the selection of β-lactam-resistant colonies, as opposed to a more time-
consuming screening approach. This approach has been previously exploited in other bacteria, 
such as Mycobacterium tuberculosis, where the TEM 1-β-lactamase was used as a model protein 
for protein export. McCann (2007), showed how a truncated version of β-lactamase, lacking the 
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signal peptide, yielded no colonies on agar containing carbenicillin, confirming that periplasmic 
localisation of β-lactamase was essential to confer antibiotic resistance. Nevertheless, cytoplasmic 
β-lactamase can show a certain degree of enzymatic activity (Chapter 4, Figure 4.21), but it does 
not confer resistance to β-lactam antibiotics, as observed by MIC experiments, where cultures 
carrying a vector coding for β-lactamase or the scFv163R4-A::β-lactamase without the signal 
peptide, were unable to grow at the lowest concentration of ampicillin evaluated, 3 μg · mL-1 
(Chapter 4, Figures 4.19 and 4.20). 
It has been reported that the selection of colonies expressing a protein of interest fused to β-
lactamase based on its resistance to ampicillin could be used as an indication of the translocation 
of the fusion protein to the periplasmic space (Mansell et al., 2010). Therefore, once the 
mutagenized signal peptide libraries were introduced in the expression vector (Figure 5.3), 
ampicillin selection was used to favour the enrichment and selection of only those colonies able 
to produce the scFv163R4-A::β-lactamase in the periplasmic space . In addition, the availability of 
enzymatic assays, as the nitrocefin assay, allowed the screening of colonies expressing the 
scFv163R4-A::β-lactamase based on the quantification of the different levels of β-lactamase 
activity detected in clones containing different mutant signal peptides (Figures 5.5 and 5.6). 
A high variability in β-lactamase activity was observed between clones, possibly as the result of 
different levels of translocation favoured by each mutant signal peptide (Figures 5.5 and 5.6), 
since these differences in β-lactamase activity were not observed in different clones carrying the 
PelB wild type signal peptide (Figure 5.7). Unfortunately, cytoplasmic expression of the 
scFv163R4-A::β-lactamase could also result in β-lactamase activity, since the reporter protein 
exhibits activity when localised in the cytoplasmic space (Chapter 4, Figure 4.21). Cell lysis 
induced during the resuspension of cells in the assay buffer could also release scFv163R4-A::β-
lactamase produced in the cytoplasm, resulting in a false positive result. 
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5.3.2 Evaluation of selected signal peptides for periplasmic protein production 
The structure of the signal peptide plays an important role in the secretion of proteins to the 
periplasmic space, and extensive studies have been carried out to understand its structure. There 
are three main distinct regions in the structure of a signal peptide: the N-terminal region 
constituted by at least two positively charged amino acids, such as lysine and arginine; the central 
hydrophobic core composed by highly uncharged hydrophobic residues, such as leucine or 
alanine; and the hydrophilic cleavage region  formed by amino acid residues with neutral small 
side-chains at position −1 and −3, often preceded by an helix-breaker amino acid residues, such 
as proline or a glycine (Jonet et al., 2012; Izard and Kendall, 1994).  
The presence of highly hydrophobic amino acids is considered the signature of signal peptides 
and the disruption of this region with charged residues may prevent protein secretion (Izard and 
Kendall, 1994). Rusch et al. (1994) showed how the increase in the hydrophobicity of the signal 
peptide favoured a higher translocation and processing rate of alkaline phosphatase (PhoA), by 
replacing the core region of the PhoA signal peptide with different combinations of leucine and 
alanine residues. However, the use of highly hydrophobic core sequences, constituted only by 
bulky hydrophobic residues as leucine, could compete and inhibit the transport of other host 
proteins (Rusch et al., 1994). A similar result was observed in clone T-D4, with a GRAVY score of 
1.73 (Figure 5.14), this highly hydrophobic signal peptide showed the highest β-lactamase 
activity detected during the β-lactamase screening (Figure 5.6). However, impaired growth and 
low cell viability was observed in cultures grown under induced conditions during shake-flask 
experiments (Figure 5.10). This could be the result of the high affinity of this signal peptide for 
the Sec translocation machinery outcompeting host proteins required for cell growth (Rusch et 
al., 1994). In contrast, when Rusch et al. (1994) replaced the core region of the PhoA signal peptide 
solely with alanine residues, generating signal peptides with low average hydrophobicity, resulted 
in slow or no processing of into the mature form of alkaline phosphatase. It was therefore not 
surprising that the two signal peptides with the lowest average hydrophobicity (Figure 5.13), 
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clones EP-C26 and EP-C33, showed none or very slow processing of the scFv163R4-A, being 
accumulated as a precursor protein in the spheroplasts (Figure 5.19). 
The generation of mutant signal peptides allowed the evaluation of the impact of different 
mutations in the translocation efficiency of recombinant proteins. Nevertheless, there is a 
requirement of a balance of the physicochemical properties in combination of the chosen 
secretory protein for the design and selection of the optimal signal peptide, as the negative effects 
of the replacement of a feature may be alleviated by the improvement of another (Izard and 
Kendall, 1994). This effect could mask the effect of each independent mutation, being difficult to 
understand the relationship between specific mutations within the signal peptide sequence and 
its effect on growth, cell physiology and protein production.  
 
5.3.3 Development of fermentation strategies for periplasmic protein production 
Nowadays, the fed-batch fermentation technique dominates the industry for the production of 
recombinant proteins. The development of fermentation protocols to achieve an optimal growth 
profile that favours high production rates is often desired during high cell density fermentation. 
Induction at lower OD600 is often preferable, as it has been associated with high protein production 
and cell viability through the course of the fermentation (Sevastsyanovich et al., 2009; Wyre and 
Overton, 2014). However, during the production of the fusion scFv163R4-A::β-lactamase, growth 
arrest and low cell culturability was observed for all the clones carrying a signal peptide which 
allowed the translocation of the protein to the periplasmic space when induced at low cell 
densities (Figure 5.15). Cultures showed signs of growth arrest early after induction, even under 
“stress minimisation conditions”, such as low concentration of inducer, 0.02% arabinose, in 
combination with a low cultivation temperature, 25 °C. 
Many RPP protocols often separate the biomass generation and the recombinant protein stages 
by inducing protein production at high cell density, which is often carried out when the induction 
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of protein production could induce stress in the host organism. The separation of the biomass 
generation and protein production stages often helps to reduce the metabolic burden caused by 
the high cellular requirements demanded for both biomass and protein production. The length of 
the induction period, commonly known as production window, is determined by the amount of 
time that the cells can produce the recombinant protein without a negative impact on cell viability 
(Overton and Wyre, 2014). 
Induction at high-cell-densities, at an OD600 ≥ 70, was evaluated for the production of the 
scFv163R4-A::β-lactamase. The separation of the biomass and protein production stages allowed 
also the use of different cultivation temperatures during each stage; cultures were grown at 30 °C 
to an OD600 ≥ 70, and upon induction, the temperature was reduced to 25 °C. This approach 
favoured the rapid growth under non-induced conditions and the decrease in the temperature 
during protein production, with the aim to decrease the protein synthesis rate and favour the 
translocation of the protein to the periplasmic space. Following this protocol, all the cultures 
reached a high cell density, with a final OD600 ≥ 140 after 28 hours of growth (Figure 5.16). 
Unfortunately, the yield of antibody fragment was lower than expected, but showing a high 
accumulation of the scFv163R4-A::β-lactamase in the periplasm for clones T-A11,T-A19 and T-B2 
(Figure 5.17). 
With the aim to understand whether the behaviour observed from the selected mutagenic signal 
peptides and evaluate if the production scFv163R4-A::β-lactamase could be used as an indication 
of the production of the scFv163R4-A, the sequence coding for the reporter protein, β-lactamase, 
was removed from the expression vector. Cultures expressing the scFv163R4-A reached a high-
cell-density, with an OD600 ranging from 155 to 186 after 30 hours of growth (Figure 5.18 A), with 
a minimal loss of cell viability after protein production induction (Figure 5.18 B). In addition, the 
production window was extended to 12 hours during this process, considering the maximum 
induction time period before the culture showed signs of growth arrest, loss of cell viability and 
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cell lysis. Unfortunately, low levels of production of the scFv163R4-A were observed (Figure 
5.19), mainly accumulated as mature scFv163R4-A in the periplasm, with the exception of 
samples obtained from clones EP-C26 and EP-C33, where the protein was primarily accumulated 
as a precursor in the spheroplast protein fraction. In general, no major discrepancies were 
obtained in terms of growth profile, cell culturability and protein production were observed 
during fed-batch fermentations carried out for the production of the scFv163R4-A::β-lactamase 
(Figures 5.16 and 5.17) and the scFv163R4-A (Figures 5.18 and 5.19). Therefore, the fusion of 
recombinant proteins to the reporter protein β-lactamase, could be used for high-throughput 
screening of signal peptides for the production of recombinant proteins in the periplasmic space. 
As large differences had been previously observed in the production levels of the scFv163R4-A::β-
lactamase between shake-flask and fed-batch fermentation experiments (Table 5.1), it was 
considered that a concentration of arabinose of 0.02% could be not sufficient to induce the 
production of the scFv163R4-A at high cell densities. This effect was also observed by Wilms et al. 
(2001) that described how a 20-fold increase in the concentration of rhamnose was required for 
the induction of the production of carbomylase at high cell densities, considering that the amount 
of rhamnose present in the culture medium could be limiting for the induction of rhaBAD 
promoter. As the concentration of arabinose used could be not enough for the induction of the 
araBAD promoter when induced at an OD600 ≥ 70, a 10-fold increase in the concentration of 
arabinose was evaluated for the production of the scFv163R4-A. Cultures reached a high cell 
density, with an OD600 ≥ 140 after 30 hours of growth (Figure 5.20 A), and the concentration of 
the scFv163R4-A produced was higher (Figure 5.21) than in previous fermentations induced 
with 0.02% arabinose (Figure 5.19). The mature form of the scFv163R4-A was detected in the 
periplasmic fraction of clones T-A11, T-A19, T-B2 and the PelB wild type (Figure 5.22). Only the 
accumulation of the precursor form of the scFv163R4-A was detected in samples obtained from 
EP-C26 and EP-C33. In addition, a high concentration of antibody fragment was found in the 
culture medium of samples obtained from T-A11, T-A19, T-B2 and PelB wild type (Figure 5.21).  
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Since E. coli naturally does not secrete proteins into the culture medium, extracellular secretion 
could be correlated with non-specific leakage and cell lysis, resulting from the pressure build-up 
in the periplasmic space (Jonet et al., 2012). The capacity of the periplasm is limited, and it has 
been reported leakage of Fab fragments when its accumulation exceeds 6% of the volume of the 
periplasm (Newton et al., 2016). In addition, scanning electron microscopy (SEM) obtained by 
Newton and collaborators (2016) during the production of antibody fragments by fed-batch 
fermentation, showed mostly large intact cells in pre-induction samples, which turned into a 
mixture of swollen cells, empty shells of lysed cells and some still healthy cells at late post-
induction stage. 
The activity of the scFv163R4-A produced by fed-batch fermentation was confirmed by ELISA, 
aiming to evaluate the antigen-binding activity of the scFv163R4-A produced by the different 
signal peptides selected from the β-lactamase screening. In general, high levels of activity were 
detected in samples obtained from clones T-A11, T-A19 and T-B2 (Figure 5.24), mainly 
corresponding to the scFv163R4-A in the periplasm and the culture medium protein samples. The 
bulk of the mature scFv163R-A was localised in these two protein fractions, correlating with the 
results observed by SDS-PAGE and western blot (Figures 5.21 and 5.22). The highest yields of 
active scFv163R4-A were obtained with the signal peptide obtained from clones T-A11 and T-B2, 
with a yield of almost 1 g · L-1 of active scFv163R4-A produced by fermentation, which 
outperformed when compared with the control culture carrying the PelB signal peptide. 
 
5.4 Conclusions and future work 
The development of a screening assay using β-lactamase as a reporter protein was proven to be 
an excellent tool, to allow the rapid selection of signal peptides obtained from large signal peptide 
libraries. Signal peptide libraries were obtained by random mutagenesis of the PelB signal 
peptide, a commonly used signal peptide for the secretion of antibody fragments. Mutant signal 
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peptides were easily and rapidly screened by their ability to confer resistance to ampicillin, being 
the level of production of the scFv163R4-A::β-lactamase relatively quantified by the β-lactamase 
enzymatic assay. Results obtained from the screening assay showed that signal peptides can be 
improved by the introduction of mutations in the sequence and optimised for the efficient 
production and translocation of recombinant protein into E. coli’s periplasmic space. The genetic 
approach used to develop the signal peptide libraries could be applied to any other wild type 
signal peptide sequence, improving the translocation efficiency of signal peptides already 




















6.1.1 Development of approaches for cytoplasmic recombinant protein production 
The optimisation of the fermentation conditions for the production of certain recombinant protein 
therapeutics remains a challenge for the biotechnology industry. Strong promoters to achieve 
high expression and protein production levels are often used during the development of processes 
for RPP, however, the underlying effects on the host physiology are often unseen. This approach 
frequently fails, as plasmid loss, accumulation of misfolded products and even cell lysis, often 
leads to the concomitant reduction in the final protein yield. Good growth and cell viability profiles 
are as important as high protein expression; one must not underestimate how these factors affect 
RPP for the development of a successful production process. 
“Stress-minimisation” conditions aim to reduce the metabolic burden imposed on the host 
organism during RPP, maximise plasmid retention and reduce protein synthesis rate to enhance 
protein folding and minimise inclusion body formation. Several fermentation conditions, 
including culture medium, inducer concentration, induction point and cultivation temperature 
were evaluated by shake-flask experiments, resulting in the accumulation of a soluble and active 
rhTNFα. A fully cGMP compliant fermentation process was developed, which achieved a final 
OD600 of 111 and yielded 5.35 g ∙ L-1 of rhTNFα, of which 70% was accumulated as a soluble 
product. 
The evaluation of the cultivation conditions was carried following a trial-and-error approach, a 
labour-intensive process which only allows the screening of small number of variables (Holmes 
et al., 2009). In addition, the one-factor-at-a-time method used for the optimisation of the 
fermentation conditions for the production of rhTNFα, only allowed the screening of one single 
variable at the time, assuming all variables are independent. This simplistic approach does not 
allow the identification of interactions between different variables, and often fails to identify the 
true optimal conditions for RPP (Islam et al., 2007). An alternative approach could be the use of 
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Design of Experiments (DoE), where statistical and modelling tools are used to explore the 
optimal production conditions with the minimum number of experiments, helping to more rapidly 
determine the relationship between multiple screened variables for maximum soluble protein 
yield (Hsu et al., 2016). The implementation of DoE approaches with high-throughput 
fermentation equipment, such as the Ambr250, could facilitate the development of fermentation 
processes. 
 
6.1.2 Development of approaches for periplasmic recombinant protein production 
Results obtained using scFv163R4-A as a model protein showed the importance of balancing the 
protein synthesis rate with the translocation machinery capability. Several approaches were 
evaluated, such as the modulation of activity of the arabinose promoter by catabolite repression 
or the optimisation of the cultivation conditions, to achieve the fine-tuning between protein 
synthesis and periplasmic translocation. Also, different signal peptides were evaluated including 
STII, PelB, Bla (SecB-dependent pathway) and DsbA (SRP-mediated pathway). Even though all of 
them resulted in the production of periplasmic scFv163R4-A, great differences were observed in 
terms of growth, cell viability and protein production kinetics. Signal peptides allowing a high and 
rapid production and translocation of scFv163R4-A often resulted in the overload of translocation 
pathways, leading to growth arrest and cell lysis. Signal peptides which allowed a slower 
production showed no detrimental effect on the host organism, which could potentially result in 
higher yields at fermentation scale. 
The use of β-lactamase protein fusions helped to elucidate the subcellular localisation of the 
scFv163R4-A, as results obtained from SDS-PAGE and western blot were often inconclusive. The 
use of β-lactamase as a reporter protein was found to be key during the screening of mutant signal 




6.1.3 β-lactamase screening assay as a high-throughput screening tool for periplasmic recombinant protein 
production 
The work presented in this thesis included: (1) the generation of two mutant signal peptide 
libraries, one generated by error-prone PCR and the other chemically synthesised by Twist 
Biosciences, both using the PelB signal peptide as template. (2) A cloning method based on type 
IIs restriction endonucleases developed to allow seamless cloning of the signal peptide libraries. 
(3) A screening method based on the use of β-lactamase as a reporter protein, for the selection of 
clones carrying mutant signal peptides with enhanced translocation activity of the model protein. 
(4) The selection of mutant signal peptides with higher expression than the wild type signal 
peptide. (5) The optimisation of the fermentation conditions for the production of the model 
protein, scFv163R4-A, in the periplasm. The enhanced production of mature and active 
scFv163R4-A of clones T-A11 and T-B2, when compared to PelB wild type signal peptide, 
confirmed the success in the development of the β-lactamase screening. Both clones yielded 
almost 1 g ∙ L-1 of mature and active scFv163R4-A, achieving a 1.5-fold increase over the wild type. 
Overall, the β-lactamase screening assay was proven to be a promising tool for the selection of the 
optimal signal peptide for the production of recombinant proteins in the periplasm. 
 
Limitations of β-lactamase screening assay 
Results obtained from the β-lactamase screening showed promising results, however, two mutant 
signal peptides with no or reduced production of the protein in periplasm were selected during 
the screening, EP-C26 and EP-C33. Firstly, only a minimal amount of periplasmic β-lactamase is 
required to allow the growth in ampicillin-supplemented plates, which resulted in the overgrowth 
of these two clones. Secondly, it is unclear if nitrocefin could be able to diffuse through the 
cytoplasmic membrane, resulting in the misleading detection of high levels of cytoplasmic 
scFv163R4-A::β-lactamase, as periplasmic β-lactamase activity. In addition, cell lysis caused 
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during the cell resuspension could lead to the release of cytoplasmic fusion protein. To avoid this 
outcome, the methodology employed during the development of the β-lactamase screening should 
be reviewed and further optimised. Clone selection needs to be carried out under stringent 
conditions, to favour the selection of only those clones able to grown at highest ampicillin 
concentrations, and therefore, with enhanced translocation of the fusion protein to the periplasm. 
In addition, the β-lactamase screening is limited in the number of clones that can be evaluated 
(100 clones/week). A higher throughput could be achieved by using a fluorescent β-lactamase 
substrate in combination with fluorescent-activated cell sorting (FACS), potentially resulting in 
rapid screening and selection of a larger number of clones. 
  
6.2 Future work 
6.2.1 Improvement of arabinose-inducible expression systems 
The tight repression of arabinose inducible expression systems has shown to be critical, allowing 
cell growth to high cell densities with minimal protein expression under non-induced conditions. 
However, further development is required to achieve a dose-dependent induction, in contrast 
with the “all-or-nothing” induction effect observed with the arabinose expression system. This can 
be achieved by engineering of host strain targeting the arabinose transport system, resulting in a 
more homogenous cell induction if the arabinose uptake is catalysed by arabinose independent 
transporters from a constitutive promoter or an arabinose-independent inducible promoter 
(Khlebnikov et al., 2000). 
 
6.2.2 Optimisation of the fermentation conditions for RPP 
Flow cytometry enables single cell analysis allowing the study of bacterial populations during 
high-cell-density fermentation, being an essential tool for bioprocessing monitoring. A few 
269 
  
fluorescent dyes are available to evaluate cell physiological state, including the evaluation of 
membrane polarisation and permeability, enzyme and efflux pump activity (Silva et al., 2012). 
Two dyes are routinely used for the assessment of cell viability during fermentation, bis-oxonol 
(BOX) and propidium iodide (PI), revealing the proportion of healthy, damaged and dead cells 
(Hewitt and Nebe-Von-Caron, 2001), valuable information for the determination of the optimal 
conditions for the production of recombinant proteins, such induction point and harvest time. 
As certain periplasmic extraction methods, such as osmotic shock, are not practical at large scale, 
other methods such as periplasmic protein release methods derived from a temperature increase 
(45 °C to 95 °C) for a variable length of time (12 hours to seconds) are the most credible alternative 
at industrial scale (Weir and Bailey, 1997). However, the release of the periplasmic content is 
highly variable and dependent on the cell metabolic state. Flow cytometry could be used to 
evaluate damaged cells with the depolarised cytoplasmic membrane, to determine the optimal 
conditions for the release of periplasmic proteins to the culture medium. 
 
6.2.3 Optimisation of β-lactamase screening assay for periplasmic protein production 
Initial experiments carried out with the STII, DsbA, PelB and Bla signal peptides offered an insight 
of which signal peptide could be the optimal for the production of the scFv163R4-A. This 
screening resulted in the selection of PelB, which allowed a lower production of scFv163R4-A 
when compared with other signal peptides, but without entailing a negative effect on cell growth 
and cell viability. This was an essential requirement for the development of a fermentation 
production process, being the signal peptide used as a template for the generation of mutant signal 
peptides, aiming to select mutant versions showing an enhancement in the production of 
periplasmic scFv163R4-A. 
Nevertheless, the preliminary evaluation was limited to three SEC signal peptides and one SRP 
signal peptide. A larger number of signal peptides targeting both pathways needs to be evaluated 
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to expand our knowledge regarding periplasmic protein production. In addition, PelB may not be 
the optimal signal peptide for the production of other recombinant proteins, as proteins which 
fold too quickly in the cytoplasm may fail to be translocated by the SEC pathway. A different signal 
peptide library could be generated with a second signal peptide targeting the SRP-mediated 
translocation pathway, which could expand the capabilities of the β-lactamase screening assay to 
a broader range of recombinant proteins. 
In general terms, the β-lactamase screening assay showed promising results for the screening of 
a large number of signal peptide libraries in a rapid and cost-effective manner. Nevertheless, 
results obtained from the β-lactamase screening assay were limited to one single model protein, 
being an essential requirement to validate the screening assay with a broad range of different 
model proteins. 
Future work could also include the generation of a signal peptide database containing all the 
mutations introduced in the signal peptide sequence and their effect on growth and cell viability, 
as well as its impact on protein productivity and translocation to the periplasmic space. This 
would help to expand the knowledge regarding the structure of the signal peptide. 
 
Development of a “toolbox” for the production of disulphide bonded recombinant proteins 
Results included in this PhD thesis could be directly applied to the production of disulphide 
bonded protein by the biotechnology industry. A suggested approach for the production and 
optimisation of production conditions for a target protein is detailed in Figure 6.1. Briefly, this 
approach includes an initial screening using wild type signal peptides targeting both the SecB-
dependent and the SRP-mediated pathway, and if this approach fails, the evaluation using β-













b) Evaluation using β-lactamase screening assay: 
 
- Mutant signal peptide library targeting the SEC 
translocation pathway (e.g. PelB) 
- Mutant signal peptide library targeting the SRP 
translocation pathway (e.g. DsbA) 
a) Evaluation using wild type signal peptides: 
 
- Signal peptides targeting the SEC translocation pathway: 
e.g. STII, PelB, Bla, OmpA 
- Signal peptides targeting the SRP translocation pathway: 
       e.g. DsbA, TolB, SfmC, TorT 
Optimisation of fermentation 
conditions with selected signal 
peptide 
3. Evaluation of growth, cell 
viability and protein 
productivity 
Final production process 
4. Scale-up and process 
transfer to production scale 




If it fails: 
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targeting the SEC pathway and a second library targeting the SRP-mediated pathway. Successful 
signal peptides would be evaluated for growth, cell viability and protein production. The 
production conditions using the most promising signal peptide could be optimised using a DoE 
approach combined with a screening fermentation system, such as the Ambr250. Once the 
fermentation process has been optimised, it would be transferred to a larger scale, for the 
development of the final production process. This suggested approach helps to illustrate possible 
industrial applications of the work developed in this PhD thesis, and how they could be applied to 
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